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The lymphatic system is essential for the transport of excess fluid, protein, and foreign
materials from interstitial tissues to lymph nodes; for immune surveillance, and to maintain fluid
homeostasis. Dysregulated lymphatics can be attributed to pathological conditions including
tumor metastasis, inflammation, chronic wounds, obesity, blood vascular disorders, and
lymphedema. Of these, lymphedema is the most extreme of lymphatic disorders and is
represented by a spectrum of symptoms ranging from mild, subtle presentation to severe,
disfiguring, overt presentation. Lymphedema is more manageable in the early stages of disease
but severely reduces quality of life with progression. Due to lack of molecular knowledge and
inadequate imaging techniques to safely, rapidly and non-invasively visualize the lymphatics,
lymphedema remains under diagnosed and progresses to the irreversible stage if not diagnosed
early.
Candidate gene studies have identified a myriad of genes responsible for lymphedema,
however, majority of patients do not harbor mutations in these putative genes, indicating many
more unknown genes contribute to the pathology of this disease. In an effort to identify new
polymorphisms that possibly effect lymphatic dysfunction, we combined investigational, noninvasive near-infrared fluorescence lymphatic imaging (NIRFLI) and next generation sequencing
(NGS), to phenotype and genotype human subjects with familial lymphedema. We discovered
that mutations in src homology 2-domain containing 5’-inositol phosphatase-2 (SHIP2), encoded
by INPPL1, are associated with lymphatic abnormalities. SHIP2 is a phosphatidyIinositol (3,4,5)
vi

triphosphate (PIP3) 5’-phosphatase that negatively controls PIP3 levels thereby inhibiting the
PI3K/AKT signaling, a pathway implicated in various lymphatic disorders. Our studies confirm
this inhibitory role of SHIP2 against PI3K/AKT in lymphatic endothelial cells, and identify SHIP2
as a potential regulator of MAPK/ERK signaling, another pathway also recently identified as
important in lymphatic malformations. Pharmacological inhibition of SHIP2 impedes lymphatic
contractility and impairs the normal wound healing processes of lymphangiogenesis and
angiogenesis in mice. These studies suggest that SHIP2 could have a previously unidentified
effector role in lymphatic dysfunction.
In elucidating the roles of SHIP2 in lymphatic dysfunction, the work presented herein
expands our understanding of molecular basis of lymphatic failure which could have clinical
implications affecting populations with lymphatic disorders, including the ever increasing
population of cancer survivors who experience the chronic, disfiguring and incurable
lymphedema.
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CHAPTER 0
ORGANIZATION OF THE DISSERTATION

1

0.1: The Lymphatic System: Role in Many Costly Disorders
The lymphatic system is an extensive network that is widely distributed within the
human body, found in nearly all tissues and organs with the exception of the central
nervous system and bone marrow. The lymphatics run parallel to, yet are intricately
associated with the blood vasculature (Figure 0.1A); however, unlike the blood system,
lymphatic research has lagged behind partly owing to limited methods to safely, rapidly
and non-invasively image lymphatic architecture and function. Mainly responsible for
regulating fluid balance, lipid metabolism and immune cell trafficking, lymphatics are a
double-edged sword that can be either beneficial or disastrous to the immune system
depending on physiological and pathological context. Given their ubiquitous tissue
presentation and paradoxical function, it is not surprising that dysfunctional lymphatics
are associated with a multitude of diseases.
Lymphatic failure or insufficiency manifests in lymphedema, a progressive,
disfiguring and incurable disease, due to either genetic causes (primary lymphedema) or
physical damage (secondary or acquired lymphedema). Moreover, disordered
lymphatics are also associated with inflammation, cancer metastasis, peripheral venous
disease, chronic wounds, hypertension and cardiovascular disease, inflammatory bowel
diseases including colitis and Crohn’s disease, autoimmune diseases such as
rheumatoid arthritis, asthma; obesity and other adipose diseases. Combined, these
disorders, summarized in Figure 0.1B, affect over 150 million U.S patients and present
a huge economic burden to the U.S healthcare system, with current estimates over $250
billion. Therefore the involvement of lymphatics in multiple debilitating pathologies
necessitates the need for understanding molecular mechanisms that belie its function
and dysregulation. Herein, we focus on studying the molecular events associated with
lymphedema with the belief that knowledge of the molecular mechanisms at play in this
2

seemingly rare disease will allow better understanding of more common diseases that
are also associated with the lymphatics.

3

Figure 0.1. The lymphatic system: role in many costly disorders. (A) Schematic
showing the ubiquitous involvement of the lymphatic system in the body with the
direction of lymphatic flow depicted in green and blood flow depicted in red. Shown in
the inset is the intricate association between lymphatic (green, stained with LYVE1
antibody) and blood vessels (red, stained with CD31 antibody) from a mouse ear. (B)
The cost of pathological conditions associated with aberrant lymphatics showing direct
markets in which lymphatics play a primary role in disease causation, progression, and
severity; and indirect markets in which lymphatics does not play a causative role, but
rather a secondary role in disease progression. CMS; Centers for Medicare and
Medicaid Services.
Modified and reproduced with permission from Sevick-Muraca, E.M., Kwon, S., and
Rasmussen, J.C., Emerging lymphatic imaging technologies for mouse and man. J Clin
Invest, 2014. 124(3): p. 905-14. [1].
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Figure 0.1. The lymphatic system: role in many costly disorders

5

0.2: Dissertation organization
The overall strategy employed in this work is threefold: (i) clinical studies that use
non-invasive near infrared fluorescence lymphatic imaging (NIRFLI) to assess lymphatic
phenotypes, (ii) next generation sequencing (NGS) in persons with lymphedema to
identify disease-causing variants and (iii) biological validation of these variants in cell
culture and mouse studies.
This dissertation aims to address two major gaps in lymphatic dysfunction
research: (i) accurate phenotyping in patients with subtle disease and (ii) gene discovery
to identify novel candidates that contribute to lymphatic failure. In Chapter 1, we
introduce the lymphatic system including developmental events that occur during
embryogenesis to give rise to the lymphatic system in a process known as
lymphangiogenesis. In Sections 1.2 and 1.3 we discuss the pathology of lymphedema
including currently known genes responsible for this disease, and current strategies
used in imaging the lymphatics. Section 1.4 we discuss the principles of non-invasive
NIRFLI and why it is a dynamic and superior imaging modality that provides sensitive
lymphatic imaging that can discern varied lymphatic phenotypes even in asymptomatic
patients without overt clinical symptoms, a linchpin in accurate phenotyping of
lymphedema. We present evidence that current candidate genes can only explain one
third of hereditary lymphedema and only one tenth of non-hereditary lymphedema,
underpinning the need for broader, unbiased genetic techniques such as NGS for novel
genetic discoveries.
In Chapter 2, we present our clinical findings that led to our discovery of one
such gene, INPPL1, that encodes src homology 2-domain containing 5’-inositol
phosphatase-2 (SHIP2), identified using this imaging and genetic sequencing approach

6

in two families with lymphedema. Our studies argue that novel gene discovery is only
possible as a result of accurate phenotyping, such as that from NIRFLI.
The experimental studies’ chapters of this dissertation investigate the potential
role of SHIP2 as an effector of lymphatic dysfunction in humans. Thusly, in Chapter 3,
we conduct experimental studies in lymphatic endothelial cells (LECs) to assess
functional and phenotypical response to SHIP2 knockdown and upon overexpression of
SHIP2 mutants, identified in the aforementioned families, in LECs. In Chapter 4, we
further investigate the role of SHIP2 in lymphovascular pathology in mouse studies upon
pharmacological inhibition of SHIP2. Our in vitro and in vivo studies reveal previously
unknown, yet important maintenance roles that SHIP2 plays in lymphatic biology. In
Chapter 5, we summarize our major findings; discuss the clinical impact that this project
will have on the population of cancer survivors who suffer from, and are at risk for
lymphedema; and discuss future strategies that can improve lymphedema diagnosis and
treatment. Experimental methodology employed in this dissertation are outlined in
Chapter 6, and Appendix presents summaries of secondary preclinical, NIRFLI projects
that were published and undertaken during the course of this dissertation project.
Figure 0.2 provides the organization of this dissertation.
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Figure 0.2. Dissertation organization
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CHAPTER 1
LYMPHATIC SYSTEM

9

1.1: Lymphatic Development and Function
1.1.1: Embryonic Development
Origin of the lymphatics: The human body has two vascular systems, namely the
blood (hemivascular) and lymphatic systems. While the existence of the lymphatics has
been known since the 17th century, research in this field has lagged behind that of the
blood system, mainly due to lack of knowledge of the molecular characteristics and
processes that govern the development and maintenance of the lymphatics as well as
the inability to visualize the lymphatics. In 1902, Florence Sabin suggested that during
embryonic development, lymphatic vessels arise from preexisting blood vessels,
specifically the cardinal vein (CV) [2], a hypothesis that has since been proven true [3-6].
Developmentally, the mammalian lymphatic system arises in the following four
sequential steps (Figure 1.1):
(i). Lymphatic specification: Over the last 15 years, key molecular regulators of
lymphatic development have been identified. Among them is the lymphatic endothelial
hyaluronan receptor-1 (LYVE1), the earliest lymphatic marker and the prospero
homeobox transcription factor PROX1, the master regulator of lymphatic endothelial
differentiation [7, 8]. LYVE1 is expressed at embryonic day (E) 9 in a polarized manner
in a portion of venous endothelial cells (VECs or LEC progenitors) within the CV, and
represents the first sign of lymphatic competence. These LYVE1+ LEC progenitors begin
to express PROX1 at E9.5, an event that indicates the beginning of LEC specification
(Figure 1.1A). Expression and activation of PROX1 within LEC progenitors are
regulated by two other transcription factors COUP-TFII and SOX18 [9, 10]. The
expression of vascular endothelial growth factor receptor 3 (VEGFR3), a receptor
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tyrosine kinase (RTK) initially expressed in blood endothelium, becomes restricted to the
LYVE1+/PROX1+ LEC progenitors at E10.5 [11].
(ii). Lymphatic budding: Following their specification, LEC progenitors begin to
bud from the CV into the mesenchyme, a process that requires VEGFR3 signaling in
response to its ligand, VEGFC [12]. While not required for LEC commitment, VEGFC is
necessary for sprouting, migration and maintenance of LEC during embryogenesis. LEC
budding also results in the expression of the transmembrane mucin-type glycoprotein,
podoplanin, at E11 in LEC progenitors that have fully exited the CV. While the molecular
regulation of podoplanin expression in LEC progenitors currently remains unknown [13],
podoplanin is essential for LEC adhesion and migration. VEGFC also binds a nontyrosine kinase coreceptor neuropilin-2 (NRP2), which interacts with VEGFR3 to mediate
LEC sprouting [14]. At this stage, LEC differentiation is progressing with combined LEC
expression as LYVE1+/PROX1+/VEGFR3+/Podoplanin+/NRP2+.
(iii). Lymph sac formation: At E11.5, the primary lymphatic plexus develops into
lymph sacs that give rise to the whole lymphatic vasculature. To achieve this, the
differentiated LECs bud off and migrate in an interconnected manner and assemble into
capillary-like structures which further organize and form lymph sacs (Figure 1.1A).
Separation of the newly forming lymphatic sacs from the blood endothelial is critical at
this juncture to prevent blood flow into the lymphatic vessels. The lymphovenous
separation is achieved by valves (Figure 1.1B). While the majority of PROX1+ LEC
progenitors bud off the CV, a small portion remains and downregulates VEGFR3 and
podoplanin expression, to form lymphovenous valves [13]. Additionally, the lymphocyte
cytosolic protein 2 (SLP76) and kinase protein SYK are necessary for separation of the
lymphatic and blood systems, and mice deficient in any of these signaling factors
develop blood-filled lymphatics [15]. Recent evidence suggests that platelets play an
11

essential role in the lymphovenous separation, and podoplanin activates the platelet
receptor CLEC2 to activate SLP76 and SYK signaling [13, 16, 17].
(iv). Lymphatic maturation and differentiation: As the lymphatic plexus begins to
mature, LECs undergo further differentiation to eventually form three distinctly hierarchal
vessel subtypes of the lymphatic system (Figure 1.2). The initial capillaries comprise of
LECs with high podoplanin expression that secrete the chemokine CCL21 which attract
CCR7+ regulatory T cells (Tregs) and antigen presenting cells (APCs) such as dendritic
cells (DCs). These initial LECs are blind-ended and thin-walled with endothelial junctions
that allow fluid and protein absorption [18]. Precollector lymphatic vessels have
decreased podoplanin expression, sparse pericyte or smooth muscle cell (SMC)
coverage and secrete CCL27 which attracts CCR10+ inflammatory cells upon insult.
However, beyond inflammatory cell recruitment, the functions of precollector vessels are
currently unknown [13, 18]. Collector lymphatic vessels have a complete SMC layer,
basement membrane, and valves. Intrinsic contractility of the SMCs aid in propulsion of
lymph and lymphatic valves prevent retrograde flow or backflow of lymph [19]. As the
lymphatic system lacks a central pumping organ, the collector vessels have a series of
functional pumping units known as lymphangions (Figure 1.3). Collector vessels and
valves develop at approximately E14.5 and E16, respectively, and key in this process is
the forkhead transcription factor FOXC2. Mice deficient in Foxc2 lack lymphatic valves,
with normal initial vessels but later mispatterned lymphatic vasculature indicating the
requirement of FOXC2 in lymphatic maturation [20].
Embryonic development of the lymphatic system is a dynamic process, and while
not all genes, proteins or transcription factors that contribute to this intricate process
have been mentioned above, loss-of-function phenotype of animal models of genes
associated with lymphatic development is summarized in Table 1.1.
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Figure 1.1. Embryonic development of the murine lymphatic system. (A) Sagittal
schematic of developmental events at the cardinal vein (CV), from E9.0 to E11.5. (i)
Expression of transcription factors COUP-TFII and SOX18 by blood ECs in the CV and
intersomitic vessels (ISV). (ii) At E9.5, PROX1 expression is induced by SOX18 and
COUP-TFII, indicating start of LEC specification. (iii) LEC progenitors start to bud from
the CV and ISVs at E10.5, which requires the graded expression of VEGFC in the
surrounding mesenchyme. LECs maintain their VEGFR3 expression and start
expressing podoplanin (PDPN) once outside of the CV. The combined expression of
these genes indicates that lymphatic differentiation is progressing. Transverse
representation of the LEC budding process of PROX1+/PDPN+/VEGFR3+-differentiating
LECs bud from the CV and ISVs at E10.5 is shown as well. (iv) By E11.5, LECs bud off
in an interconnected manner and assemble together to form different lymph sacs, from
which the lymphatic network arises following LEC proliferation and sprouting. (B)
Diagrammatic representation of the lymphovenous valves. A small unique subpopulation
of PROX1+/PDPN-/VEGFR3- LECs do not bud off from the CV and remain to form the
lymphovenous valves at the junction of the jugular and subclavian veins (SCV). Each of
the valve’s two leaflets has two layers of PROX1+ ECs: an inner PROX1+/PDPN+ layer
continuous with the lymph sac and an outer PROX1+/PDPN– layer continuous with the
veins. Left: The region of an E13.5 embryo in which the jugular and subclavian veins join
to form the lymphovenous valves. Right: A frontal view of the boxed region shown at left.
EJV, external jugular vein; IJV, internal jugular vein; LS, lymph sac; LV, lymphovenous
valve; SVC, superior vena cava.
Reproduced with permission from Yang, Y. and Oliver, G., Development of the
mammalian lymphatic vasculature. J Clin Invest, 2014. 124(3): p. 888-97. [13].
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Figure 1.1. Embryonic development of the murine lymphatic system.
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Figure 1.2. Hierarchy of the lymphatic vessels in the dermis. Initial lymphatic
capillaries start as blind sacs (Figure 1.1A). Their LECs form overlapping junctions,
express large amounts of the membrane mucoprotein podoplanin (green), and release
the chemokine CCL21. This attracts CCR7+ immune cells, such as dendritic cells (DCs)
and regulatory T cells (Tregs). The LECs of the precollector lymphatic vessel express
low amounts of podoplanin and high CCL27, which attracts inflammatory CCR10+ T
lymphocytes. The precollector vessels open into the collecting lymphatic vessels that are
podoplanin-low and have lymphatic valves. Pericytes partially cover the precollectors
and completely ensheath collecting vessels.
Reproduced with permission from Kerjaschki, D., The lymphatic vasculature revisited. J
Clin Invest, 2014. 124(3): p. 874-7. [18].
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Figure 1.2. Hierarchy of the lymphatic vessels in the dermis.
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Figure 1.3. Organization of the lymphatic vasculature. Protein-rich interstitial fluid,
collected by the initial lymphatic capillaries (green), is transported by precollector
lymphatic vessels to larger collecting lymphatic vessels onto the lymph nodes for
filtration and immune surveillance. Along the collector vessels are perciytes (red) which
allow (i) lymphatic contraction and, (ii) functional luminal valve subunits known as
lymphangions that prevent backflow of fluid. From the lymph nodes, fluid ultimately
returns to the blood vasculature through the thoracic duct and to the subclavian vein
(blue). Deep lymphatic vessels run along blood arteries and veins.
Reproduced with permission from Alitalo, K., Tammela, T., and Petrova, T.V.,
Lymphangiogenesis in development and human disease. Nature, 2005. 438(7070): p.
946-53. [19].
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Figure 1.3. Organization of the lymphatic vasculature
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Table 1.1. Loss-of-function phenotypes of genes associated with lymphatic vasculature
development. Reproduced with permission from Yang, Y. and Oliver, G., Development
of the mammalian lymphatic vasculature. J Clin Invest, 2014. 124(3): p. 888-97. [13].
Gene

Loss-of-function phenotype in animal models

Related human
vascular disease

Defective LEC progenitor specification
Coup-TFII
Notch1

Prox1

Sox18

Severe subcutaneous edema; embryos lack LECs and lymphatic vasculature due to failure in
LEC progenitor specification
+
Loss of Notch1 results in an increased number of PROX1 LEC progenitors in the veins and
outside the CV with significant lymphatic overgrowth, incomplete separation of veins, and
formation of lymphatics
Severe subcutaneous edema; embryonic lethality at E14.5; embryos lack LECs and lymphatic
vasculature due to failure in LEC progenitor specification; in most genetic backgrounds, Prox1
haploinsufficiency results in defects in LEC fate maintenance, perinatal death with chylothorax,
and chylous ascites; in the NMRI strain, surviving Prox1 heterozygous mice exhibit adult onset
obesity, leaky lymphatics, and lack of lymphovenous valves
Severe subcutaneous edema; embryonic lethal at E14.5; embryos lack LECs and lymphatic
vasculature due to failure in LEC progenitor specification in certain genetic backgrounds

Hypotrichosislymphedematelangiectasia
syndrome

Defective budding of LEC progenitors and lymph sac formation
AM
Calcrl
Ccbe1
Gata2
Nfatc1
PU.1
Ramp2
Tie1

Vegfc
Vegfr3

AM-null embryos die at mid-gestation with interstitial edema and abnormal jugular lymphatics
due to defective LEC proliferation
Severe interstitial edema, embryonic lethal, hypoplastic lymph sacs
Severe subcutaneous edema, budding of LEC progenitors arrested in the CV, lack of lymphatic
vasculature
Hypoplastic lymph sacs and abnormal separation of venous and lymphatic vessels
Enlarged lymph sacs
Hypoplastic lymph sacs, hyperplastic lymphatic vessels
Severe interstitial edema, embryonic lethal, hypoplastic lymph sacs
Reduction in TIE1 levels results in abnormal lymphatic patterning and dilated and disorganized
lymphatics; homozygous null embryos are lethal at E14.5 and exhibit nuchal edema,
hemorrhages, enlarged lymph sacs, dilated lymphatic vessels and impaired lymphatic drainage
Embryonic lethal at E14.5; severe subcutaneous edema, budding of LEC progenitors arrested in
the CV, lack of lymphatic vasculature
Primary receptor for VEGF-C, blood vasculature malfunction in loss of function embryos,
required for survival and migration of LECs

Hennekam
syndrome
Emberger
syndrome

Milroy-like disease
Milroy disease

Defective lymphatic vessel maturation and valve formation
Akt1
Bmp9
Celsr1
Cnb1
Cx37
Cx43
Cx47

Reduced diameter and EC number in lymphatic capillaries; loss of valves in the smaller
collecting lymphatic vessels in the superficial dermal layer of the ear skin
Mutant pups exhibit hyperplastic mesenteric collecting vessels with abnormally high LYVE1
expression, reduction in the number and in the maturation of mesenteric lymphatic valves
Disorganized cell-cell junction, defects in cell reorientation during lymphatic valve formation,
lack of lymphatic valves
Defects in the demarcation of the valve territory
Mutant mice exhibit lymphedema and chylothorax and have defective valve formation in
collecting lymphatics; regulates jugular lymph sacs size
Loss of lymphatic vessels in the diaphragm, absence of lymphatic valves in mesenteric
collecting lymphatic vessels
Expressed in lymphatic valves, currently uncharacterized developmental function
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Primary
lymphedema

Emilin1
Ephrin
B2
Fn1
Foxc2

Defective lymphatic valve structure and lymph flow
Hyperplastic collecting lymphatic vessels, lack of valves, abnormally high level of expression of
LYVE1 in the lymphatic vessels
Defects in the formation and extension of the valve leaflets
Embryonic lethal perinatally; unusual mural cell recruitment on the collecting lymphatic vessels
with abnormal high level of LYVE1 expression, lack of lymphatic valves, and lymph backflow

Integrinα9
Nrp1

Reduced number of valves leads to failure in the formation of the matrix core of the valves
(leaky, lymph backflow)
A mutation in the SEMA3A binding site of NRP1 leads to smaller lymphatic valves and ectopic
SMC coverage on the valve region
Smaller lymphatic valves
Reduced SMC coverage on the collecting lymphatic vessels with abnormally high level of LYVE1
expression, dilated and leaky collecting lymphatic vessels, and reduction in the rate of lymph
flow
Smaller lymphatic valves; ectopic SMC coverage on the valve region; aberrant lymph drainage

Plxna1
Reelin

Sema3a

Lymphedemadistichiasis
syndrome
Congenital
chylothorax

Defective blood and lymphatic vessel separation
Clec2
Fiaf
Plcg2
Pdpn
Rac1
SLP76
Syk

Inactivation of this PDPN receptor results in defects similar to those reported for Pdpn and
SLP76; mutant embryos show blood-filled intestinal and mesenteric lymphatic vessels
Dilated and blood-filled lymphatic vessels in the intestine
Blood-filled lymphatic vessels
Embryonic lethal at birth; lymphedema and dilated and blood-filled lymphatic vessels
Conditional deletion results in embryonic lethality before birth, edema, and blood-filled
lymphatic vessels
Severe subcutaneous edema, peritoneal hemorrhage, and chylous ascites
Severe subcutaneous edema and blood-filled lymphatic vessels.

Defective lymphatic vessel growth
Afadin

Integrinβ1
Nrp2
Ptpn14

Modulates RhoA; severe subcutaneous edema with severe disruption of VE-cadherin–mediated
cell-cell junctions in lymphatic vessels of the skin
Subcutaneous edema, chylous ascites, lymphatic vessel hypoplasia, and mispatterned lymphatic
vessels in the mesentery
Null embryos exhibit subcutaneous edema, defective lymphatic drainage, and mispatterned
collecting lymphatic vessels
Conditional deletion at E12.5 results in subcutaneous edema, hemorrhage, and embryonic
death with dilated subcutaneous lymphatic vessels that appear structurally abnormal,
exhibiting gaps and holes in LEC cell-cell junctions; blood-filled lymphatics show defects in the
separation of the blood and lymphatic vasculatures
Conditional deletion in the ectoderm results in embryonic death before birth, severe
subcutaneous edema, and reduced dermal lymphatic capillary network
Edema and hemorrhages; embryonic lethality; reduced LEC numbers and LEC proliferation;
smaller lymph sacs; complete lack of dermal and mesenteric lymphatic vasculature at E15.5
Absence or severe reduction of small lymphatic vessels and capillaries
Lymphedema; lymphatic hyperplasia; interacts with VEGFR-3

Rasa1

Hyperplasia, dilation, and leakage of lymphatic vessels and chylothorax

Tbx1

Regulates VEGFR3; conditional deletion in ECs results in embryonic edema and postnatal
lethality between 2 and 4 days after birth; mice exhibit chylous ascites and lack of mesenteric
lymphatic vessels
Severe edema; blood-filled lymphatic vessels; reduced lymphatic branching; aberrant lymphatic
vessel network

Ang2
Aspp1
Cxadr

Cx26

TGFBRI
or
TGFBRII
Vezf1

Lymphatic hypervascularization, edema, and hemorrhaging the jugular region of heterozygous
embryos
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Lymphedemachoanal atresia
syndrome
Capillary and
arteriovenous
malformation
DiGeorge
syndrome

1.1.2: Functions of the Lymphatics
Organization of lymphatic vasculature and lymphatic drainage: The main role of
the lymphatic system is to return proteins and fluids back to the blood circulation system
[19]. To achieve this key transport function, interstitial fluids, macromolecules and APCs
are taken up by the blind-ended lymphatic capillaries, transported through the
precollector vessels and to the collector vessels which are ensheathed with SMCs that
aid in contractility. Once within the lymphatic plexus, intravasated fluid is defined as
lymph, which is then filtered through lymph nodes before returning to the blood
circulation via the subclavian vein (Figure 1.3) [19]. The largest lymphatic collector
vessel is the thoracic lymphatic duct which drains lymph collected from all organs for
drainage into the subclavian vein. To propel lymph, intrinsic SMC contractility is aided by
extrinsic contractions from normal respiration, arterial heartbeat, and local skeletal
muscles. In the lymph nodes (LNs), foreign particles taken up by APCs are presented to
lymphocytes for initiation of immune responses, as further discussed below. The
structures of the lymphatics allows for better remodeling of capillaries, which in
lymphatics are thin-walled, lack tight junctions and either lack or have incomplete
basement membrane, and can therefore quickly respond to physical changes within the
local interstitial milieu. Increased interstitial flow and hydrostatic pressure within adjacent
tissue results in pulling of anchoring filaments, which connect lymphatic capillary ECs to
the surrounding stroma, to open the overlapping, zipper-like ECs and allow fluid flow into
the capillaries [21]. As previously mentioned, collector vessels contain valves, which
permit unidirectional lymph flow towards the subclavian vein, a direction that is favored
because of decreased blood pressure and increased tissue osmotic pressure. This
classic role of lymphatics in transport maintains vascular fluid homeostasis, and
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disruption of this process leads to accumulation of proteins and fluid within the interstitial
space, resulting in lymphedema, a chronic and progressive swelling of affected tissues.
Lymphatics in lipid absorption: The intestines are the main sites of lipid
absorption by the lymphatics. Intestinal lymphatic vessels, known as lacteals, within
intestinal villi take up dietary lipids such as chylomicrons for transportation back to the
blood vasculature [22]. Chylomicrons are large lipoproteins structures (200nm-1000nm
diameter) which transport ingested fat and fat-soluble vitamins from the intestine to
peripheral tissues [23]. Chylomicrons are absorbed in a size exclusion manner through
pores within lacteals for subsequent filtration through mesenteric LNs. This chylomicronrich lymph is then transported by the thoracic duct and ultimately to the subclavian vein,
in a similar manner as lymph drained from the lymphatic plexus of peripheral skin.
Chylomicrons give lymph a milky appearance and aberrant lymphatic absorption leads to
accumulation of chylous fluid within intestinal cavity. Mice with heterozygous mutation in
Vegfr3, also known as Chy mice, have lymphedema, abnormal fat accumulation and
accumulation of milky chylous fluid in the abdomen [24]; phenotypes that are also
frequently seen in human lymphedema. Given the role of lymphatics in lipid transport
and that lymphatic vessels and LNs are typically embedded within visceral fat where
they can respond to interstitial changes, it is not surprising that dysfunctional lymphatics
have been implicated in obesity-related diseases such as diabetes, insulin resistance
and hypercholesterolemia [23, 25, 26].
Lymphatics in immune function: The lymphatics are the main component linking
peripheral tissues, the usual site of infection, to the central immune system. Foreign
antigens are carried within lymph by APCs, including DCs and macrophages, to LNs for
presentation to lymphocytes and subsequent mounting of immune responses.
Developmentally, LNs are induced approximately E12.5 when IL-17 and the tumor
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necrosis factor family cytokine, TRANCE, stimulate lymphoid tissue inducer (LTi) cells to
accumulate near LECs and produce lymphotoxin (LT)-α1β2 signals that produce
chemokines, adhesion receptors, and cytokines that attract naïve lymphocytes into the
developing LN [22, 27]. Afferent lymphatic vessels drain lymph from the tissues into the
LNs where antigens are trapped for presentation. Within LNs, B lymphocytes are
localized in follicles while T cells are diffused within the paracortical regions. Upon
antigen presentation, naïve T cells proliferate and differentiate into antigen-specific
effector cells while B cells proliferate and differentiate into antibody-secreting effector
(plasma) cells. These effector cells leave the LNs via efferent lymphatic vessels. As
previously mentioned, lymphatic capillary LECs secrete CCL21, which attracts and
guides CCR7+ DCs and regulatory T cells (Tregs) while precollector vessels LECs
secrete CCL27, which attract inflammatory CCR10+ and neoplastic T cells [18] (Figure
1.2).

Beyond the traditional views that the lymphatics regulate fluid balance, lipid

metabolism, and leukocyte trafficking, recent evidence shows that the lymphatics play
active roles in both innate and adaptive immunity including modulating inflammation,
autoimmune disease and tolerance, pro- and anti-tumor immune responses, and in
transplant rejection [27-30]. For example, the response of CCR7+ Tregs to LEC- and
LN-derived CCL21 activates Tregs to inhibit T effector cell proliferation and accumulation
thus maintaining immune tolerance. Macrophages are chemotactically attracted by LECs
and in turn macrophages contribute to lymphangiogenesis in two major ways: secrete
pro-lymphangiogenic growth factors such as VEGFC in response to inflammation and by
their capacity to transdifferentiate into LECs by incorporating into sprouting lymphatic
vessels [18, 28, 31, 32]. Additionally, LECs express MHC class I and MHC class II
molecules therefore can present antigen for T cell regulation [30, 33]. Collectively, these
physiological and immune modulatory functions of the lymphatics highlight an emerging
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intricate concept that the lymphatics are not just passive conduits but are also active
participants in immune surveillance.
1.1.3: Differentiating blood and lymphatic endothelial cells (BECs and LECs)
While the lymphatic system is an open, linear system without a centralized organ,
the hemivascular (blood) system is a close circulatory system with blood leaving and
returning to the heart. Even though the lymphatics arise from the venous system, there
are structural differences between the lymphatic and blood microvasculature, thus some
molecular differences in the cells that line both endothelia [34]. Blood capillaries, lined by
BECs, are covered by basement membranes and completely surrounded by SMCs [21].
As described above, lymphatic capillaries lack a basement membrane and SMC
coverage. Another key structural difference is that lymphatic capillaries are anchored to
the extracellular matrix (ECM) by filament bundles, which pull LECs open during
increased fluid accumulation and increased pressure to allow flow into the lymphatics. In
comparison to blood vessels, lymphatic vessels have thin walls and wide lumens.
Summarized in Table 1.2 are key structural and functional differences between the
endothelial cells of the blood and lymphatic vascular systems.
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Table 1.2. Comparison of blood vascular endothelial cells (BECs) and lymphatic
endothelial cells (LECs). Reproduced with permission from Choi, I., Lee, S., and Hong,
Y.K., The new era of the lymphatic system: no longer secondary to the blood vascular
system. Cold Spring Harb Perspect Med, 2012. 2(4): p. a006445. [35].
Feature
Constituents

Blood vessels/BEC
Blood, blood cells

Gross
structure
Start/end

Closed, circular

Hierarchical
division
Vessel wall

Arteries, arterioles,
capillaries, venules, veins
Adherens and tight junctions,
continuous basement
membrane, pericytes, or
vascular smooth muscle cells

Development

Cell markers

Vasculogenesis and
angiogenesis
Mesoderm, endothelial
stem/precursor cells from
bone marrow for adults
CD34, CD105/endoglin

Absence

Cartilage, cornea

Functions

Hemostasis, inflammation,
leukocyte trafficking, barrier
function, delivery for oxygen,
nutrients, and tissue wastes

Origin

Lymphatics/LEC
Lymph (interstitial fluid rich in protein,
fat, and lipids, extravasated immune
cells, and large extracellular molecules)
Open, linear

Heart/heart

Heterogeneity Well-established phenotypic
heterogeneity
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Tissue/lymph-vein connection of the
thoracic duct
Capillaries, precollectors, collecting
vessels, thoracic duct, lymph nodes
Overlapping LECs, no tight junctions,
anchoring filaments, discontinuous
basement membrane, few pericytes
(collecting lymphatic vessels have both
continuous membranes and mural
cells)
Lymphangiogenesis (budding from
cardinal vein)
Mesoderm (vein) during development,
lymphatic progenitor cells from bone
marrow for adults
PROX1, LYVE1, VEGFR3, and
podoplanin
Cartilage, brain, bone, spinal cord, and
the retina
Tissue fluid homeostasis, absorption of
large molecules and lipids in the
digestive systems, trafficking of
lymphocytes and antigen-presenting
cells to regional lymph nodes, transport
of degraded extracellular molecules,
cell debris, and lymph fluid
Comparable LEC heterogeneity was
reported. LEC fate is highly plastic in
response to genetic and environmental
stimuli

1.2: Lymphatic Disease and Lymphedema
Lymphatic dysfunction: Deficiency in any aspect of lymphatic transport is the
etiological basis of lymphedema (LE), a chronic progressive swelling of affected tissues.
Abnormal vessel development or damage to lymphatic vessels leads to accumulation of
interstitial fluid, protein and cellular debris, which triggers an inflammatory response
leading to tissue fibrosis, subcutaneous accumulation of fat, impaired immune responses
and susceptibility to infections [19, 36, 37]. Lymphatic vessel damage can also cause
lymph leakage back into interstitial space while damaged lymphatic valves lead to
backflow of lymph and swelling of extremities. LE is a spectrum disease, which while not
life-threatening, severely reduces quality-of-life with no current curative treatments
available.
1.2.1: Lymphedema
Clinical presentation and staging: Peripheral edema (lymphedema) occurs when
capillary and venous (microvascular) filtration rate exceeds lymph drainage for an
extended period of time due to either increased filtration rate and/or lymph flow is
decreased. While the most common site for peripheral edema is subcutaneous tissue,
edema also occurs in the lungs (pulmonary edema), abdominal cavity (chylous ascites)
and other body cavities (synovial, pericardial and pleural effusions) [38]. Clinical
classification of LE is defined by the International Society of Lymphology on a scale of 0III [36].
•

Stage 0, also known as the latency stage, is preclinical disease where there is
underlying impaired lymph transport but without overt edema.

26

•

Stage I (reversible lymphedema) represents the early accumulation of fluid and
when pressed, swollen area leaves a dent (“pitting” edema), which is resolved
with limb elevation.

•

Stage II (spontaneously irreversible lymphedema) shows development of fibrosis,
pitting may or may not occur and limb elevation alone does not reduce swelling.

•

Stage III (lymphostatic elephantiasis) is characterized by non-pitting severe
edema with irreversible tissue damage, severe fibrosis, fat deposits and warty
overgrowths.

These stages are depicted in Figure 1.4.
Early diagnosis at Stage 0 or I improves patient outcome as disease is more
easily managed with appropriate therapies. However, diagnostic tools especially those
that can detect subtle lymphedema before overt clinical presentation are lacking, as will
be discussed later in this chapter.
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Figure 1.4. Clinical staging of lymphedema. Images depicting increasing severity of
lymphedema in the left arm of a patient at Stage 0, Stage I, Stage II and Stage III
following axillary lymph node dissection (ALND) treatment for breast cancer.
Reproduced with permission from Columbia University Department of Surgery
(http://columbiasurgery.org/news/healthpoints/2011_spring/p2.html)
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Figure 1.4. Clinical staging of lymphedema.
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1.2.2: Forms of Lymphedema
Lymphedema is classified based on the cause of lymphatic defect, either intrinsic
or extrinsic factors, as either primary or secondary (acquired), respectively. Primary
lymphedema arises from genetic defects that perturb normal lymphatic development and
while variable in presentation, is further subdivided into three groups depending on age
of onset: congenital lymphedema (at or shortly after birth), praecox (early stage of life,
typically teenage years or early adulthood) and en tarda (after 35 years of age) [38]. On
the other hand, secondary or acquired lymphedema is caused by external stimulus that
damages the lymphatics for example following an infection, trauma or surgery.
Primary lymphedema:
1). Congenital lymphedema accounts for approximately 10-25% of all primary
lymphedema, affecting more females than males [35]. Congenital lymphedema also
manifests more in lower than upper extremities and presents unilaterally as opposed to
bilaterally.

Genetic studies have identified some causal mutations responsible for

congenital lymphedema, with examples provided below.
Milroy’s disease and Milroy-like disease: Heterozygous mutations in VEGFR3, encoded
by FLT4, have been identified in a subgroup of congenital lymphedema known as
Milroy’s disease [39, 40] after initially being linked to the VEGFR3 locus on distal
chromosome 5q [41-43]. Of the mutations reported thus far, all have been in the tyrosine
kinase domain of VEGFR3 and disrupt downstream signaling. While Milroy’s
lymphedema typically exhibits an autosomal dominant inheritance, de novo mutations
have also been identified, thus family history of lymphedema is not required for
diagnosis [44]. Milroy’s disease is often characterized by unilateral lower extremity
lymphedema and a lack of initial lymphatic capillaries (Figure 1.2). Recently, a rare
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mutation in VEGFC, the ligand for VEGFR3 was identified in a Milroy-like lymphedema
patient [45]. As discussed in Section 1.1.2, Chy mice, which have a Vefgr3
heterozygous mutation, develop lymphedema. A second animal model, Chy3 mice, has
a full deletion of the Vegfc gene also develop chylous ascites and lymphedema [46].
2). Lymphedema praecox, also known as Meige’s disease, typically presents
during puberty and exhibits an autosomal dominant pattern of inheritance [47]. Praecox
covers all lymphedema with onset between 1-35 years of age, represents the majority of
primary lymphedema cases (60-80%), and affects females four times more compared to
males [35]. Because primary lymphedema is classified based on age of onset, rather
than genetics, pathophysiology or etiology, there is often confusion between the terms
praecox and Meige’s disease [35]. Thusly, a variety of other anomalies including
vertebral defects, cerebrovascular malformations, developmental defects, hearing loss
and distichiasis (double rows of eyelashes) are seen in praecox [36]. Examples of
praecox lymphedema are as follows:
Lymphedema distichasis (LD) syndrome: The most unique phenotype seen in LD
patients is distichiasis, the presence of a second set of eyelashes at birth, which results
in corneal irritation. LD is an autosomal dominant disorder and mutations in the
transcription factor FOXC2 have been identified in patients [48, 49]. Patients also
develop bilateral lower extremity lymphedema at puberty and while they have normal
number of lymphatic vessels, they exhibit impaired lymphatic drainage due to defective
valves [50]. Mice deficient in Foxc2 also have abnormal lymphatic patterning and
defective valves [20].
Hypotrichosis-lymphedema-telangiectasia (HLTS): This is a rare form of praecox
lymphedema characterized by absence of eyebrows and eyelashes, and presence of
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eye edema and blood vessel dilations [51]. Mutations in the SRY-related transcription
factor, SOX18, which is upstream of PROX1, have been identified in both recessive and
dominant forms of HLTS. Mice deficient in Sox18 are embryonically lethal but mutant
embryos lack lymphatic vasculature and have edema [9].
Hennekam syndrome: This is another rare form of praecox disease characterized
by lymphedema, lymphangiectasia (vessel dilation) and developmental delays.
Lymphedema is typically present at birth and in the face or in the limbs and gradually
progressive, while lymphangiectasias are present in the intestines [52]. Mutations in
collagen and calcium binding EGF-domain 1 (CCBE1) have been identified as causative
for Hennekam syndrome [53]. Zebrafish deficient in ccbe1 show defective embryonic
lymphangiogenesis and lymphatic sprouting from the venous endothelium [54].
3). Lymphedema en tarda manifests after 35 years of age and accounts for
approximately 10% of all primary lymphedema [55-59]. Lymphedema en tarda exhibits
hyperplastic, tortuous vessels which are often dilated and lack functional valves.
Other genes that have been identified to be causal for lymphedema include
ITGA9 that encodes integrin α9 in fetuses with congenital chylothorax [60]; RELN in
congenital lymphedema [61]; GJC2 that encodes connexin 47 in primary and secondary
lymphedema subjects [62]; and HGF and cMET genes that encode hepatocyte growth
factor and its receptor in both primary and secondary lymphedema subjects [63].
Lymphedema can be nonsyndromic (isolated) and also occur in conjunction with other
blood vascular symptoms as part of a syndrome. Table 1.3 summarizes the
lymphedema spectrum that extends from nonsyndromic to syndromic disease,
associated causal genes, mutation type, and pattern of inheritance and phenotypes of
associated animal models, if available.
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Table 1.3. Genes involved in lymphatic anomalies. Reproduced with permission from
Brouillard, P., Boon, L., and Vikkula, M., Genetics of lymphatic anomalies. J Clin Invest,
2014. 124(3): p. 898-904. [44].
Lymphatic anomalies/additional signs

Gene (protein)

Isolated lymphedema
Primary congenital lymphedema/ Nonne-Milroy
FLT4 (VEGFR3)
VEGFC
Milroy-like disease
Syndromic lymphedema
CCBE1
Hennekam lymphangiectasia-lymphedema
syndrome/mental retardation
Lymphedema-distichiasis and yellow nail
FOXC2
syndromes/ptosis
GJC2 (CX47)
Hereditary lymphedema II (Meige disease)
GJA1 (CX43)
Oculodentodigital dysplasia/lymphedema
PTPN14
Choanal atresia/lymphedema
Hypotrichosis-lymphedema-telangiectasia syndrome
SOX18
HGF
Lymphedema-lymphangiectasia
KIF11
MCLMR
Noonan syndrome 1(54% with lymphedema)
PTPN11 (SHP2)
SOS1
Noonan syndrome 1 (63% with lymphedema)
Primary lymphedema, myelodysplasia (Emberger GATA2
syndrome)
IKBKG (NEMO)
OLEDAID
RASA1
CM-AVM/lymphedema
Cholestasis-lymphedema syndrome (Aagenaes
locus in 15q
syndrome)
Syndromic chylothorax/chylous ascites, lymphangiectasia
ITGA9
Fetal chylothorax
Noonan syndrome, cardiofaciocutaneous
KRAS
syndrome/chylothorax
RAF1
Noonan syndrome 1/lymphangiectasia
HRAS
Costello syndrome/chylous ascites, chylothorax
Syndromes with lymphatic malformations
Monosomy X
Turner syndrome/nuchal translucency
Proteus syndrome, Pten hamartoma tumor
PTEN
syndrome
CLOVES, Klipple-Trenaunay-Weber syndrome
PIK3CA
AKT1
Proteus syndrome

Mutation
type

Animal models

Inactivating
LOF

Chy, Flt4
–/–
Chy-3, Vegfc

LOF

fof

LOF

Foxc2

Missense
Missense
LOF
LOF?/D-N
LOF?
LOF
GOF
GOF
LOF

(Gjc2 )
–/–
(Gja1 )
–/–
Ptpn14
–/–
Ragged,(Sox18 )
–/–
(Met )
–/–
(Kif11–/– )
Shp2
–
–/–
(Gata2 )

Hypomorphic
LOF
–

(Ikbkg )
–/– *
Rasa1
–

Missense
GOF

Itga9–/–
Kras

–/–

–/–

–/–

–/–

–/–

AD
AD
–
LOF

(X0 mice)
–/–
(Pten )

GOF
GOF

pα100-KI
–/–
Akt1

MCMLR, microcephaly with or without chorio- retinopathy, lymphedema, or mental
retardation; OLEDAID, X-linked syndrome anhydrotic ectodermal dysplasia with
immunodeficiency, osteopetrosis, and lymphedema; CV-AVM Capillary malformationarteriovenous malformation; Parentheses indicate the absence of lymphatic anomaly,
and bolded text indicates that the model partially mimics the human phenotype.
*Inactivation in adults. AD, autosomal dominant; AR, autosomal recessive; D-N, dominant
negative; GOF, gain of function; KI, knockin; LOF, loss of function; –, not applicable.
Question marks indicate that mutation type and/or inheritance is unclear.
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Secondary lymphedema:
Secondary, or acquired, lymphedema arises when there is damage to the
lymphatics owing to infection, surgery, radiation, compression. Secondary lymphedema
can occur within weeks or decades following lymphatic insult, the cause for this
discrepancy is currently unknown. Examples of secondary lymphedema are as follows:
1). Filariasis: Worldwide, filariasis also known as elephantiasis, is the most
common type of lymphedema affecting more than 120 million people, mostly in the
tropical areas, with highest incidences seen in Africa and Asia [64, 65]. Filariasis is
caused by a parasitic infection by mosquito-borne worm parasites including, Wuchereria
bancrofti, Brugia malayi or Brugia timori, which invade and reproduce within the
lymphatic system. Individuals bitten by an infected mosquito initially do not realize they
have an infection even though lymphatic damage is already in progress. The infection
triggers an inflammatory reaction that results in increased VEGFA, VEGFC and VEGFD
leading to lymphatic vessel hyperplasia, obstruction and eventually blockage of lymph
drainage, resulting in swelling of the extremities [37]. Other complications include tissue
fibrosis, fat accumulation, secondary infections, genital lymphedema and permanent
disability especially with progression to severe elephantiasis. Treatment options for
filariasis include drugs that target the microfilarie larval offspring and those that target
the intracellular bacterial symbiont of filarial parasites.
2). Cancer-related lymphedema (CRL): In the Western world, the most common
cause of secondary lymphedema is due to cancer treatment, which occurs following
lymph node dissection or radiation therapy that damages the lymphatics. CRL is often
seen in breast, melanoma, pelvic, and head and neck cancer survivors. Currently, there
are approximately 3-5 million individuals with lymphedema and these numbers are
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expected to rise as the cancer survivorship increases accordingly. It is estimated that
lymphedema affects ~15-20% of women undergoing breast cancer treatment and ~15%
of all cancer survivors [66, 67]. As discussed in Section 1.2.2, mutations in GJC2, HGF
and cMET genes have been identified in subjects with secondary lymphedema following
breast cancer treatment, and primary lymphedema, which gives further credence to the
hypothesis that there may be a genetic susceptibility for secondary lymphedema [68,
69]. Recently, additional mutations in VEGFR2, VEGFR3 and RORC have also been
identified in breast cancer survivors with lymphedema [70]. As CRL can develop
decades into survivorship, understanding of genetic susceptibility will require prospective
studies and associated molecular studies, some of which are currently underway [71],
which will lead to identification of targeted therapies against CRL.

1.2.3: Lymphedema Diagnosis and Treatment
Diagnosis: Clinical diagnosis of lymphedema is usually done via bedside
observations. Differentiating lymphedema from other forms interstitial edema depends
on other unique sequelae of lymphedema. These physical characteristics include
edema, peau d’orange (orange peel appearance), cutaneous fibrosis and positive
“Stemmer sign” (inability to grasp the skin at base of the digit in the affected extremity)
[72]. Limb measurements such as circumference and/or volumetric analysis, are also
made between the affected and unaffected extremity, typically estimated ≥20%. More
accurate than limb volume analysis are techniques including bioimpedance analysis that
measures differences in edema volume relative to body composition [36]. Additional
confirmation of diagnosis can be done using imaging techniques, which will be
discussed in Section 1.3
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Treatment: Physiotherapeutic interventions are the mainstay of lymphedema
treatment. Complex decongestive physiotherapy (CDPT) involves massage or manual
lymphatic drainage (MLD) and compression garments which aim to increase lymphatic
contractility and flow; reduce accumulated fluid and direct stagnated lymph to functional
lymphatics. However, CDPT techniques have not changed over the last century and
therapy is often expensive, labor-intensive, time consuming and most importantly
depends on patient compliance to be beneficial [36, 72, 73]. Debulking surgical
procedures such as liposuction show initial postoperative success but continuous
compression treatments are still necessary for limb volume maintenance; otherwise
edema can recur at a much more rapid rate and often more severe than initial disease.
All current treatments target lymphedema symptoms, not the underlying causes of
disease, therefore are not curative, and thus there is high risk of recidivism especially in
non-compliant patients. There are no pharmacological therapies currently available for
lymphedema, but pre-clinical studies have shown activation of VEGFR3 by VEGFC as a
promising gene therapy in murine model of primary lymphedema [24]. As lymphedemacausative genetic mutations are still being unraveled, current research efforts focuses on
investigating known gene candidates, determine whether they are efficacious molecular
targets, and if so, it is expected their use in therapy will stimulate regrowth of damaged
and/or nonfunctional lymphatics, and overcome vascular insufficiency in order to
improve or treat lymphedema.
1.3: Lymphatic Imaging
Unlike the blood circulatory system, research into the lymphatic system has often
lagged behind, owing in part to limited imaging modalities that can easily and sensitively
visualize the lymphatics. Angiographic techniques such as magnetic resonance (MR)
and computed tomography (CT) allow for non-invasive visualization of the blood
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vascular system following intravenous (i.v) injections of contrast agents [1]. Early in the
20th century, invasive isolation and cannulation of lymph vessels allowed for the first
structural characterization of the lymphatics but these techniques often led to
dysfunctional lymph transport and are therefore no longer used. Non-invasive methods
are preferred. Lymph is a clear fluid and invisible to the naked eye; therefore the use of
contrast agents is necessary for lymphatic imaging.
Lymphangiography. Angiography refers to the visualization of vessel lumen.
Lymphangiography is the oldest imaging technique for investigating lymphatic
architecture. Administration of an exogenous x-ray or MR contrast agent is done either
directly into cannulated lymphatic vessel or indirectly by intradermal (i.d) injection into
the lymphatic capillary plexus, the entry point for peripheral lymphatics for uptake into
lymphatic vessels. Whether done via direct or indirect methods, an x-ray or MR imaging
system is necessary for the detection of contrast agent transversing through the
lymphatic vessels. Owing to its cumbersome nature and difficulty in cannulating mouse
lymphatic vessels, direct lymphangiography is not performed in animal studies [1].
Indirect MR lymphangiography has recently been used to image lower extremity
lymphedema in cancer survivors with great resolution (Figure 1.5A) [74]. Recent
advances have been made in MR contrast agents such as albumin-binding gadoliniumbased agents, which have enabled visualization of morphological features of lymph
vessel abnormalities [75].
Lymphoscintigraphy. Currently, lymphoscintigraphy is the clinically accepted
modality for imaging lymphedema. Lymphoscintigraphy, also known as isolated
lymphography, involves the i.d injection of a radiolabelled colloid, usually

99m

technecium,

into the affected extremity for uptake, and subsequent imaging of the lymphatics [36]. As
the radiocolloid decays, it releases high energy photons, which exit the tissue and are
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captured by a gamma camera. Within the camera is a sodium iodide crystal plane that
absorbs the released photons and in turn releases an electron and a flash of light is
produced as the electron returns to its ground state. This process is known as
scintillation. Imaging is often performed hours after radiocolloid injection and the
resulting images are often grainy (Figure 1.5B). Lymphatic function can be assessed
which usually includes delayed or lack of radiocolloid uptake, dermal backflow or
infusion, poor visualization of lymphatic vessels and lymph nodes [1, 36].
Lymphoscintigraphy takes approximately 30 minutes for each image to be acquired and
since the subject is exposed to ionizing radiation, repeated imaging sessions are limited.
Additionally, while lymphoscintigraphy is considered the gold standard for diagnosing
and imaging lymphedema, it has limited photon count rate and poor resolution in
comparison to MR lymphangiography. The acquired images are often of poor resolution
thus the extent of lymphatic damage is harder to assess especially during diagnosis.
Fluorescence

microlymphangiography

(FML).

This

technique

employs

intradermal administration of fluorescein isothiocyanate (FITC)-conjugated dextran and
is the first non-invasive fluorescence imaging technique that provides high resolution
images [1]. FML uses video fluorescence microscopy for image capture. However the
inherent spectral properties of a fluorophore like FITC in the visible wavelength only
allows visualization of the initial lymphatic capillaries that are <200µm deep due to
limited light penetration and tissue scattering in humans, although with high resolution
(Figure 1.5C,D). Therefore the use of tissue-penetrating near-infrared (NIR) dyes that
are excited >750nm, such as indocyanine green (ICG), could improve FML techniques.
Near-Infrared Fluorescence Lymphatic Imaging (NIRFLI). This technique
pioneered by our research group, makes use of ICG, a fluorescent dye that has been
approved for human use for intravenous (i.v) administration in hepatic and
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cardiovascular testing and retinal angiography [1]. NIRFLI is also known as ICG
lymphography and is not microscopy-based. Following ICG i.d administration, tissues as
deep as 3-4cm are illuminated with NIR excitation light and ICG fluorescence is collected
using charge-couples device (CCD) cameras. NIRFLI allows visualization of initial
lymphatic capillaries, collecting vessels and lymph nodes (Figure 1.5E, F). However,
FML provides a higher resolution of initial capillaries compared to NIRF imaging. NIRFLI
is discussed further in Section 1.4
Summarized in Table 1.4 are various non-invasive lymphatic imaging techniques used in
mice and man.
Of all these techniques, NIRF lymphatic imaging is the only modality that can
truly assess lymphatic function as images are acquired within milliseconds and lymphatic
pumping assessed in real time. NIRFLI offers a rapid, high resolution, dynamic lymphatic
imaging and currently is the only Food and Drug Administration (FDA)-approved
investigational technique that employs ICG-administration for lymphatic imaging.
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Figure 1.5. Examples of lymphatic imaging techniques. (A) Magnetic resonance
(MR) lymphangiography (indirect) of normal (left) and diseased (right) lymphatic
structure (thin arrows) following administration of gadopentate dimeglumine. Some
enhanced veins are also shown (thick arrows). (B) Lymphoscintigram of lymphatic
drainage in the lower extremities (anterior view) following bipedal administration of
99m

Technicium sulfur colloid. (C and D) Fluorescence microlymphangiography (FML) of

FITC-dextran in initial lymphatic capillaries of medial ankle of human normal control
subject (C) and subject with primary lymphedema (D).(E and F) NIRF imaging of the
lymphatic drainage of an asymptomatic leg (E) and a symptomatic leg (F) following
administration of indocyanine green (ICG). Scale bars: 1 mm (C and D); 1 cm (E and F).
Reproduced with permission from Sevick-Muraca, E.M., Kwon, S., and Rasmussen,
J.C., Emerging lymphatic imaging technologies for mouse and man. J Clin Invest, 2014.
124(3): p. 905-14. [1].

40

Figure 1.5. Examples of lymphatic imaging techniques
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Table 1.4 Summary of imaging modalities for visualizing the lymphatic vasculature in vivo within small and large animals and
humans. Reproduced with permission from Sevick-Muraca, E.M., Kwon, S., and Rasmussen, J.C., Emerging lymphatic imaging
technologies for mouse and man. J Clin Invest, 2014. 124(3): p. 905-14. [1].
Modality

Temporal
Resolution
(acquisition
times)

Spatial
Resolution

Depth
Resolution

Small
Animals

Large
Animals

Humans

Contrast
Agents

Comments

X-ray
lymphangiography
(direct)

ms/exposure;
Requires
surgical
intervention to
cannulate
lymphatic
vessel

<1 mm

Whole
Body

No

Yes

Yes

Oily, iodinated
agents such as
Ethidol and
Lipiodol

Used on a limited
basis due to
incidence of
clinical
complications and
technical skill
required to locate
and cannulate
lymphatic vessel

X-ray
lymphangiography
(indirect)
X-ray Computed
Tomography

ms/exposure

<1 mm

Whole
Body

No

Yes

Yes

>20 sec,
dependent on
region of
interest and
desired
resolution
>2 min,
dependent on
region of
interest and
desired
resolution

1-3 mm

Whole body

Limited

Yes

Yes

Water-soluble
iodinated agents
such as Iotasul
Water-soluble
iodinated agents
such as
Iopamidal

0.1–0.3
mm in mice
1 mm in
human

Whole
Body

Yes

Yes

Yes

MRI
Lymphangiography
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Gadolinium or
iron oxide based
agents;
dendrimer
based
macromolecules

Visualizes lymph
nodes and some
larger lymphatic
vessels

Difficult to resolve
healthy, intact
lymphatic vessels

MRI (non-contrast)

minutes

1 mm

Whole body

No

Yes

Yes

Unknown

Can only resolve
dilated lymphatics
filled with stagnate
lymph

Lymphoscintigraphy

20-60 min

~1 cm

Whole body

No

Yes

Yes

Visualizes large
lymphatic vessels
and nodes only

FML

Video rates

50 µm

200 µm

Yes

Yes

Yes

Radiolabeled
sulfur colloid,
radiolabeled
dextran,
Technitium most
commonly used
isotope
FITC-dextran

NIRF

Typically 50800 ms per
image

~200 µm at
tissue
surface,
resolution
decreases
as depth
increases
due to
photon
scatter
however
larger, and
deeper
vessels are
visualized

Varies with
vessel
diameter;
larger
nodes can
be
visualized
up to 3-4
cm deep

Yes

Yes

Yes
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NIRF dyes;
Qdots; gene
reporters

Visualizes the
initial lymphatics
near the injection
site
Initial lymphatics
as well as
collecting nd
conducting vessels
observed. Active
lymphatic
propulsion
observed in small
and large animals
as well as in
humans;
Photon scattering
limits spatial
resolution, only offlabel use of ICG is
allowed in humans

1.4: NIRF Lymphatic Imaging in Mouse and Man
1.4.1: Principles of fluorescence
Fluorescence is the ability of molecules to absorb and emit light at certain
wavelengths. When a fluorophore is excited at a certain wavelength, it emits light in a
right (red) shifted light, for example ICG is excited at ~780nm and emits at ~830nm.
During fluorescence, energy is lost therefore the emitted light has a longer wavelength
and at a lower energy than the excitation wavelength; the difference between the two
wavelengths is known as Stoke’s shift. The principles of fluorescence are explained by
the Jablonski’s Energy Diagram (Figure 1.6A). The excitation of a fluorophore causes it
to move from the ground state (S0) to a higher, second energy state (S2). From S2, the
fluorophore undergoes internal conversion as it relaxes during a process known as
vibrational relaxation where there is loss of energy but an absence of light emission, and
then falls to the lowest vibrational energy level of the first excited state (S1). From S1,
the fluorophore undergoes more relaxation and falls back to ground state S0 and
emitting fluorescence in the process. The change in energy from S1 to S0 results in the
emission of a unit of energy known as photon. Absorption of a fluorophore and
subsequent fluorescent emission occurs in 1 nanosecond and the fluorophore is excited
again.

In one second there can be as many as 1x108 photons emitted, making

fluorescence a powerful and rapid imaging modality for collection and image formation
[76-79]. This is in contrast to lymphoscintigraphy, the current clinical gold standard that
requires approximately 30 minutes for acquisition of one image.

Optical properties of a fluorophore are based on three characteristics: extinction
coefficient, quantum yield, and lifetime. Extinction coefficient (Є) is the capacity of light
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absorption at a particular wavelength. Therefore a fluorophore with a high extinction
coefficient will absorb more light.

Quantum yield (ф) is a measure of fluorescence

output and defined as a ratio of emitted photons per absorbed photons which is
important in obtaining fluorescence signal, therefore a high quantum yield means the
fluorophore is more efficient. The fluorescence output of a fluorophore, or its
“brightness”, is directly proportional to the product of its extinction coefficient and its
quantum yield. Lifetime (τ) is an intrinsic property of a fluorophore and is the required
time the fluorophore stays in the excited state before returning to the ground state.
Lifetime is independent of experimental conditions such as excitation wavelength,
method of excitation, duration of light exposure, or fluorophore concentration [78, 80].

1.4.2: Near-infrared fluorescence (NIRF) imaging system
Near-infrared (NIR) light lies beyond the visible light on the electromagnetic
spectrum in the ~750-2500nm wavelength range (Figure 1.6B). NIRF imaging requires
four essential elements: (a) excitation light from laser diodes or lasers capable of
penetrating deep tissues and selectively excite contrast agents; (b) NIRF imaging agents
that can be safely administered and sensitively imaged; (c) optical lenses and filters that
can sensitively detect desired fluorescent light while blocking the scattered excitation
light from the tissue; and (d) the detector, usually a charged coupled device (CCD) for
fluorescent light collection [79]. The basic design for the imaging system is outlined in
Figure 1.7.
NIR fluorescence contrast agents should be capable of in situ activation with
tissue-penetrating light. The excitation light must have wavelengths >780nm to avoid
autofluorescence. At wavelengths <780nm, endogenous chromophores are also excited
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therefore increasing the likelihood of high background signal. The contrast agent also
needs to be stable and fluoresce efficiently when excited. At >780nm, tissue penetration
is high therefore excitation of NIRF contrast agents is achieved.
The NIRF imaging process comprises the following: The NIRF contrast agent is
intradermally injected superficially below the skin into the lymphatic capillary plexus from
where it is quickly taken up by the initial lymphatic capillaries. The contrast agent is
excited by tissue penetrating light from a laser diode and in turn emits a fluorescent
signal. The scattered signal from the tissue passes through optical filters that rejects
other wavelengths and collects the emission at 830nm. The collected signal is detected
and amplified by an NIR-sensitive intensifier and collected by the CCD camera and
processed by a computer for visualization of collected images. Typical images are
acquired every 200 milliseconds, which can be sequentially compiled and analyzed
using imaging software such as ImageJ.
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Figure 1.6. Basic principles of fluorescence. (A) Jablonski’s diagram showing the
energy transitions following absorption of a photon that produces fluorescence emission.
Reproduced

with

permission

from

(http://www.piercenet.com/method/fluorescent-

probes). (B) Near infrared (NIR) region of the electromagnetic spectrum is located just
beyond visible light. Reproduced with permission from (http://www.scimed.co.uk/nirspectrometers/).
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Figure 1.6 Basic principles of fluorescence
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Figure 1.7. Near-infrared fluorescence lymphatic imaging (NIRFLI) system.
Schematic of near infrared imaging system used for lymphatic imaging. 785nm laser
diode illumination provides the source for the excitation of the NIRF contrast agent after
intradermal injection of indocyanine green (ICG) in mice (i) or humans (ii). A charged
couple device (CCD) camera captures ICG fluorescence emission at 830nm while filters
reject the scattered light from the tissue. Shown are examples of (i) basic mouse
lymphatic architecture and (ii) human hand of a subject with lymphedema exhibiting
abnormal retrograde lymph flow towards the fingers that can be visualized in computer.
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Figure 1.7 Near-infrared fluorescence lymphatic imaging (NIRFLI) system
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1.4.3: NIRF as a tool for phenotyping human lymphatic disorders in mouse and
man
Fluorescence-based imaging techniques such as FML and NIRF provide the
unique advantage of directly relating human lymphatic phenotypes to mouse models of
lymphatic dysfunction. Currently, there are no fluorescence optical imaging modalities
that are used in the clinic as part of standard-of-care to image the lymphatics. However,
preclinical and clinical studies using ICG-based non-invasive NIRF imaging are
underway. Two examples of the utility of NIRF in associating human and mouse
lymphatic phenotypes are outlined below:
a) Capillary malformation-arterial venous malformations (CM-AVM) and Rasa1
mouse: CV-AVM is a syndromic vascular disorder in which there are enlarged
cutaneous capillaries that increase blood flow near the skin surface. The clinical
presentation of CV-AVM includes lymphedema, chylous ascites, chylothorax,
lymphangiectasia and lymphatic vessel hyperplasia [81]. Genetic mutations in
RASA1 that encodes p120 RasGAP have been identified as responsible for CVAVM [82, 83]. Using NIRF imaging, we identified abnormal lymphatic architecture
and function in a patient with CM-AVM which was similar to that in an inducible
Rasa1 knockout mouse model [84, 85] (Figure 1.8A). In that mouse study, we
confirmed that loss of p120 RasGAP, a negative regulator of the MAPK/ERK
pathway, was directly responsible for aberrant, dysregulated lymphangiogenesis.
b) Primary Lymphedema and Chy mouse: As mentioned previously, mutations in
FLT4, that encodes VEGFR3, have been identified in a portion of subjects with
primary lymphedema. Chy mice have a loss-of-function mutation within the
kinase domain of Vegfr3. Using NIRF imaging, we have characterized the
hypolastic lymphatic phenotype of the Chy mouse, which is strikingly similar to
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subjects with lymphedema who also possesses mutation in VEGFR3 (Figure
1.8B) [1].

Significance: NIRF is a powerful imaging modality that delineates lymphatic
architecture including initial capillaries, vessels and lymph nodes. Furthermore, NIRF is
the only lymphatic imaging modality that can truly assess the lymphatic functions of
contractility and lymph pumping and propulsion. Thus NIRF is a critically useful clinical
tool that can be used in early diagnosis of lymphedema as NIRF can detect underlying
lymphatic architectural and functional abnormalities before the disease progresses to the
irreversible stage when it is also unfortunately, incurable. Assessment of frequency and
velocity of lymph pumping in the collecting and conducting vessels has been performed
in rodent, swine and human studies in normal and disease models which have shown
the utility of near infrared fluorescence as an emerging cutting edge technique of
lymphatic imaging [79, 86-95].
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Figure 1.8. NIRF phenotypes of human disease in mouse and man. (A) The
drainage of ICG from the lower extremity lymphatics into the abdomen in a subject
diagnosed with capillary malformation-arterial venous malformations (CM-AVM)
syndrome, associated with an inactivating mutation in RASA1. (B) The drainage of ICG
into the abdominal cavity of a Rasa1 knockout mouse (Rasa1fl/fl/ubErt2-cre) exhibiting
lymphatic hyperplasia. (C and D) Lymphatic drainage in a wild type (WT) C3H mouse
(C) and a Chy mouse (D) with a Vegfr3 loss-of-function mutation. (E and F) Similar
phenotypes are observed in a normal human foot (E) and the foot of a human subject
with a VEGFR3 mutation with primary lymphedema (F).
Reproduced with permission from Sevick-Muraca, E.M., Kwon, S., and Rasmussen,
J.C., Emerging lymphatic imaging technologies for mouse and man. J Clin Invest, 2014.
124(3): p. 905-14. [1].
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Figure 1.8 NIRF phenotypes of human disease in mouse and man
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1.5 Motivation and rationale of this dissertation
Genetic studies of rare congenital lymphatic disorders provide an opportunity to
identify key molecular mechanisms that may be contributory to more common conditions
and disorders. From candidate gene studies, causal genes including FOXC2, FLT4,
SOX18, CCBE1, GJC2, GATA2, KIF11, PTPN14 and RASA1 (Table 1.3) have thus far
been associated with lymphatic malformations and lymphedema that generally presents
with variable penetrance and expressivity, often late in life. Yet the majority of patients
diagnosed with lymphatic abnormalities do not possess mutations in these genes.
Current estimates show that these putative candidate genes are responsible for only
36% of familial primary lymphedema and only 8% of sporadic lymphedema [96]. This
underscores the need to rapidly identify unknown genes that cause or contribute to
lymphedema. With the advent of unbiased next generation sequencing (NGS) and
associated bioinformatics analyses, key molecular pathways can be discovered in
families harboring rare hereditary lymphatic disorders with as little as four family
members [97], provided accurate phenotyping is performed.
The diagnoses of rare lymphatic disorders are not generally made on the basis of
abnormal lymphatic architecture or function, but rather on the late-stage sequelae of fluid
imbalances, such as irresolvable edema, chylothorax, or chylous ascites. For example,
diagnosis of primary lymphedema is based upon edematous symptoms that appear at
birth (congenital), at puberty (praecox), or late in life, usually following a minor challenge
to the immune system (en tarda). As a consequence of the variable expressivity, the
inaccuracy of phenotyping based upon overt symptoms can limit the association with
genotype and therefore impede discovery of gene variants.

While computed

tomography (CT) or magnetic resonance (MR) lymphangiography can assess lymphatic
abnormalities in symptomatic patients in rare cases, the radiographic procedure is
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contraindicated in asymptomatic subjects owing to procedural risks. The current clinical
gold standard technique of lymphoscintigraphy is commonly used to assess deficiency in
lymph transport, but entails the use of a radioisotope to produce images that have
limited temporal and spatial resolution, and can fail to identify architectural and functional
abnormalities. On the other hand, near infrared fluorescence lymphatic imaging (NIRFLI)
is a rapid, sensitive lymphatic imaging modality with high spatial and temporal resolution
that can discern subtle phenotypes and has been used in clinical studies to assess
human lymphatic phenotypes in normal and diseased subjects. Early detection of
aberrant lymphatic function in asymptomatic patients at Stage 0 or I (Figure 1.4) would
allow early diagnoses and allow for more effective treatment when lymphedema can be
managed much more easily.

The overall objective of my dissertation project has been to uncover gene
variants in persons with lymphatic disease that could point to the molecular basis of
lymphatic failure. We hypothesized that the unique combination of accurate phenotyping
using NIRF imaging with unbiased genotyping using NGS of families that harbor
lymphatic defects would provide new molecular insights to lymphatic disorders, including
lymphedema, a chronic, highly disfiguring and currently incurable disease. Discussed in
Chapter 2 is the discovery one such novel gene, INPPL1, that encodes src homology 2domain containing 5’-inositol phosphatase-2 (SHIP2), that was identified using this
multidisciplinary approach.
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CHAPTER 2
INPPL1 MUTATIONS IDENTIFIED IN FAMILIAL LYMPHEDEMA via
ASSOCIATION OF NIRF LYMPHATIC IMAGING AND WHOLE EXOME
SEQUENCING

Portions of this chapter are based on “Agollah G.D., Gonzalez-Garay M.L, Rasmussen
JC., Tan I-C., Aldrich M.B., Darne C., Fife C.E., Guilliod R., Maus, E.A., King P.D.,
Sevick-Muraca E.M., “Evidence for SH2 domain-containing 5-inositol phosphatase-2
(SHIP2) contributing to a lymphatic dysfunction” PLoS ONE (2014) 9(11): e112548.
doi:10.1371/journal.pone.0112548 [98]. PLOS applies Creative Commons Attribution
License (CCAL) and Open-Access License, wherein no permission is required from
authors or publishers for reprints or reproduction of published works, except proper
citation of original work. Collaborator efforts are outlined in Figure legends, wherever
necessary.
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2.1: Rationale
Pathophysiological processes that exhibit loss of fluid homeostasis, disrupted
lipid absorption and transport, and compromised immune surveillance/response
generally have some abnormal involvement of the lymphatic circulatory system [22].
Discovery of genetic variants responsible for inherited lymphatic abnormalities has been
limited by candidate gene searches and inaccurate phenotyping based upon late-stage,
overt symptomatic presentation.

Recently, we used near-infrared fluorescence

lymphatic imaging (NIRFLI) in investigational studies to (i) characterize normal lymphatic
architecture and function in normal control subjects [79, 99]; (ii) characterize abnormal
lymphatic architecture and function in subjects with lymphatic disorders including
reduced lymphatic contractile function and lymphatic reflux [95]; (iii) detect early
lymphatic abnormalities in a breast cancer survivor asymptomatic for cancer-acquired
lymphedema [92] and (iv) identify abnormal lymphatic architecture and function in a
patient with capillary-malformation arterial venous malformations (CM-AVM) (OMIM:
608354) and Parkes Weber Syndrome (OMIM: 608355) associated with an inactivating
RASA1 mutation which was similar to that in an inducible Rasa1 knockout mouse model
[84, 85].
In this study, we employed NIRF lymphatic imaging to accurately identify
abnormal lymphatic phenotypes in two families with members who were diagnosed with
congenital, praecox, en tarda, and secondary (acquired) lymphedema. In these families,
we sought to discover gene variants, through unbiased whole exome sequencing (NGS)
and analysis of rare single nucleotide polymorphisms (SNPs) with co-segregation
analysis based on NIRFLI phenotyping. Using this approach, mutations in the inositol
polyphosphate phosphatase-like 1 (INPPL1) gene that encodes the src homology 2
domain containing 5’-inositol-phosphatase-2 (SHIP2) were identified in both families.
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2.2: NIRFL imaging subjects within two families with variable lymphedema
phenotypes

2.2.1: NIRF phenotype in first nucleus family
Investigational NIRFLI consists of 0.1 cc intradermal injections of 25µg
indocyanine green (ICG) in saline. Immediately after intradermal administration, ICG is
taken up by functional initial lymphatics and transits through collecting and conducting
lymphatic vessels. Skin is illuminated with dim near-infrared (NIR) light that penetrates
tissues and excites ICG, resulting in near-infrared fluorescence (NIRF) that is collected
with a custom intensified camera system [79, 92, 99] (Figure 1.7). As illustrated in
Figures 2.1B-D healthy lymphatics are typically linear and well-defined, without
lymphatic abnormalities such as dermal backflow, hyperplastic lymphatic capillaries
radiating from injection sites, dilated vessels, or tortuous lymphatics typically observed in
diseased subjects as previously shown in Figures 1.7-1.8. We conducted lower
extremity NIRFLI from a nucleus family of four (Figure 2.1E-2J) harboring two probands,
sisters aged 32 (Subject #2) and 37 (Subject #1) years old at the time of imaging, who
were diagnosed with congenital lymphedema of the lower extremities and with praecox
lymphedema of the left lower extremity, respectively. Their 58 year old father (Subject
#3) had no reports of swelling or any other clinical signs of lymphedema.

NIRFLI

revealed that his lymphatics appeared normal, with the exception of abnormal lymphatic
capillaries radiating from the injection sites on the left foot (Figure 2.1E) and medial calf.
At the time of study, the 59 year old mother (Subject #4) had not been diagnosed but
presented with edema of both ankles, self-reported to initially occur following a minor
sprain on her left ankle at 54 years old thus swelling on her right ankle was
spontaneous. Upon NIRF imaging and medical examination, her clinical diagnosis was
classified as acquired (secondary) lymphedema on the right leg and en tarda
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lymphedema on the left leg. NIRFLI revealed some additional abnormalities including
fluorescent lymphatic capillaries radiating from the injection sites of the left foot (Figure
2.1F), dermal backflow on the medial left ankle (Figure 2.1G) and tortuosity on the right
foot and right medial knee. She also possessed a few varicose veins.

The 37 year old daughter (Subject #1) had been diagnosed with Grade I
unilateral lymphedema praecox at 14 years of age and possessed generally well-defined
lymphatics in the right leg, with the exception of several fluorescent lymphatic capillaries
radiating from the injection sites on the foot with some retrograde flow towards the toes.
Her right “unaffected” shin also exhibited a lymphatic vessel crossing over just below the
knee, indicating abnormality. However, her left edematous foot exhibited dermal
backflow (Figure 2.1H) with fluorescent lymphatic capillaries radiating from the injection
sites on the medial ankle and calf. The 32 year old daughter (Subject #2) had been
diagnosed with Grade II bilateral lower extremity, congenital lymphedema at 1 year of
age. NIRFLI revealed extensive dermal backflow in both legs as shown in the right foot
(Figure 2.1I), the right ankle and the left lateral calf (Figure 2.1J). In summary, the
sister diagnosed with congenital lymphedema (Subject #2) had few, if any, functional
lymphatics resulting in extravascular deposition of ICG. In both subjects, other than
edema and minimal toe fibrosis and skin cellulitis, there were no additional remarkable
clinical signs such as varicose veins, distichiasis, limb hypertrophy, or vascular
malformations.
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Figure 2.1 Aberrant lymphatic phenotype of familial lymphedema imaged with
NIRFLI.

(A) Schematic illustrating the typical location of the intradermal injections

administered in each subject. NIRF images of normal lymphatic vasculature in the (B)
foot, (C) medial ankle, and (D) shin as outlined with the dotted lines. (E-J) Lymphatic
vasculature observed in the nucleus family. The father (Subject #3; unaffected) had welldefined lymphatics in both legs except some lymphatic capillaries radiated from injection
sites on the left foot (arrow) (E). The mother (Subject #4; en tarda in left leg and
acquired lymphedema in right leg) had tortuous, lymphatic capillaries (arrows) radiating
from injection sites in the left foot (F) and an area of dermal backflow (arrow) in the
medial ankle (G). The older daughter (Subject #1; left unilateral lymphedema praecox)
had dermal backflow in the left foot (H). The younger daughter (Subject #2; bilateral
congenital lymphedema) had extensive dermal backflow in both limbs as shown in the
right foot (I) and left lateral calf (J). Injection sites are covered with round adhesive
bandages and/or black vinyl tape to avoid camera oversaturation. Scale bar = 1cm.
(Clinical lymphatic imaging conducted under an FDA-approved study (NCT#00833599:
“Imaging lymphatic function in normal subjects and in persons with lymphatic disorders”)
by Germaine D. Agollah, Drs. John C. Rasmussen, I-Chih Tan, Melissa B. Aldrich and
Chinmay Darne and clinical investigations conducted by Drs. Caroline E. Fife, Renie
Guilliod and Erik A. Maus at Memorial Hermann Hospital Center for Lymphedema
Management).
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Figure 2.1 Aberrant lymphatic phenotype of familial lymphedema imaged with
NIRFLI.
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2.2.2: NIRF phenotype in a second family
In a second family (Figure 2.2A-H), the 73 year old mother (Subject# 17)
presented with severe and disfiguring swelling in her left leg as shown in Figure 2.2A.
NIRFLI revealed extensive dermal backflow throughout her left leg, as shown in Figure
2.2B and 2.2C. While the conducting lymphatics were observed to be intact in the right
leg, fluorescent initial lymphatic capillaries radiated from the injection site on the medial
ankle, as shown in Figure 2.2D. The mother’s 50 year old daughter (Subject #16) also
presented with pronounced edema of her left leg, although less severe than her mother’s
(Figure 2.2E), with NIRFLI evidencing extensive dermal backflow throughout the leg
(Figure 2.2F-H). The lymphatics in her right leg were well-defined, with the exception of
fluorescent lymphatic capillaries which radiated from an injection site on the foot. The
mother self-reported lymphedema onset at 15 years of age during pregnancy, and was
clinically diagnosed at 58 years of age, while the daughter was diagnosed at 46 years of
age.
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Figure 2.2. Abnormal NIRF phenotype in second nucleus family with lymphedema
Shown clockwise from top left are (A) severe swelling in the left leg of mother (Subject
#17) with dermal back flow in the left foot (B) and shin (C). A skin tone color chart is
shown in (A).

Lymphatics in the right leg were better-defined, but abnormalities

including (D) lymphatic capillaries (arrow) radiating from injection sites were observed.
The daughter (Subject #16) presented with less severe swelling in the left leg (E), but
had dermal backflow in the left foot (F) and shin (G). The lymphatics in the right leg
were well-defined, though lymphatic capillaries (arrow) were observed near injection
sites as shown in the right foot (H). Injection sites are covered with round adhesive
bandages and/or black vinyl tape. Scale bar = 1cm. (Clinical lymphatic imaging
conducted under an FDA-approved study (NCT#00833599: “Imaging lymphatic function
in normal subjects and in persons with lymphatic disorders”) by Drs. John C.
Rasmussen, I-Chih Tan, Melissa B. Aldrich and Chinmay Darne and clinical
investigations conducted by Drs. Caroline E. Fife, Renie Guilliod and Erik A. Maus at
Memorial Hermann Hospital Center for Lymphedema Management).
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Figure 2.2. Abnormal NIRF phenotype in second nucleus family with lymphedema
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2.3: Identification of INPPL1 mutations in subjects within two families with
variable lymphedema phenotypes
2.3.1: Current strategies in identifying genes involved in lymphatic anomalies
The conventional approach to find genotypes of Mendelian disorders relies on
interrogating exons (i.e. protein encoding) and adjacent intron regions by polymerase
chain reaction (PCR) amplification techniques such as Sanger sequencing.

This

requires knowledge of target gene(s) or narrowing down the gene candidates to a
manageable number for locus discovery. Following the identification of the FLT4 gene
that encodes VEGFR3; and VEGFC gene that encodes VEGFR3 ligand, VEGFC [11,
100], Ferrell et al., published the first study that identified FLT4 as causal for familial
lymphedema [101]. In that 1998 study, the authors used traditional genetic linkage
analysis, which maps the chromosomal location of disease-causing genes based on the
association of co-inherited genes on the same chromosome during meiosis.
Subsequently, PCR-based Sanger sequencing was carried out to further identify FLT4
mutations in familial lymphedema subjects [102, 103]. Further identification of genes
important in embryonic development (Table 1.1) resulted in linkage analysis and Sanger
sequencing used in identification of mutations in FOXC2, SOX18, CCBE1, GJC2,
GATA2, KIF11, and PTPN14 in subjects with lymphedema. However, majority of
lymphedema patients do not harbor these mutations, and indeed, a recent screening
study found that these genes, most which involve VEGFR3 signaling pathway, explain
only one third of familial and only 8% of sporadic primary lymphedema [96].

For discovery research, whole exome sequencing (WES) provides a method to
sequence all exons (estimated to be ~200,000) to find causal variants without the bias
present in candidate gene studies. In addition, variable penetrance and expressivity of
known causal genes such as FLT4 could suggest the participation of otherwise unknown
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modifier genes. The diploid human genome consists of 6 billion base pairs of which 90
million base pairs encode for proteins. Whole genome sequencing (WGS) accesses the
entire genome including protein encoding regions (or exons) and non-protein encoding
regions (or introns) and represents the most comprehensive approach to human genetic
study. In contrast, mutations in protein encoding portions of the genome, called the
exome, are most likely to cause gain or loss of functions that are responsible for ~95% of
diseases, yet represents only ~2% of the entire genome. Consequently, WES currently
represents the most cost-efficient manner to make new gene discoveries that, as
opposed to WGS, can be translated into pharmacologic strategies.
WES involves probe-specific exon capture of targeted sequences from genomic
DNA, followed by deep sequencing on commercially available next-generation
sequencing platforms, greatly expanding the capacity of traditional targeted sequencing.
Following bioinformatics analysis to identify potential candidate genes, their presence
can be further validated by traditional Sanger sequencing. Furthermore, pathway
analysis can be used to identify key signaling pathways that are affected by these
identified candidate genes. Recently, the use of WES has been proposed as a more
efficient method to identify genetic variants for lymphedema [96, 104].

2.3.2: Identification of T180A SHIP2 mutation in first nucleus family
There were no other siblings in the first nucleus family depicted in Figure 2.1, but
with next generation sequencing (NGS) and cosegregation bioinformatics analyses, as
little as four members are needed to discover new disease causative gene variants [97],
provided accurate phenotyping with NIRFLI could identify affected family members. We
collected blood and extracted DNA from this nucleus family (Subjects #1-4) and
conducted WES. Our results showed both probands from the nucleus family possessed
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a rare, heterozygous, damaging SNP (i.e. likely to alter the normal function of the gene
or the encoded protein) within the alpha-chain of HGF (81359017 Hg19 resulting in C
>A; p.G315V), but not in any other gene previously associated with lymphatic
dysfunction. In their gene candidate studies, Finegold and coworkers [63] found HGF
and cMET mutations in subjects with primary lymphedema, lymphangiectasia, and
breast cancer-related lymphedema (BCRL) subjects that were not polymorphic in control
populations. They concluded that HGF and cMET mutations were likely causal for
primary lymphedema and/or susceptibility genes for acquired lymphedema, an affliction
that impacts an estimated 15% of all cancer survivors [67]. HGF and cMET are both
important for lymphatic vessel formation [105]. Additionally, because Saito et al [106]
showed that HGF gene therapy reduced lymphedema volume in the rat tail lymphedema
model created by lymphatic vessel disruption, we expected the mother in our study to
harbor the HGF gene mutation, making her susceptible to her diagnosed acquired or en
tarda form of lymphedema. However, she lacked the HGF gene variant. Surprisingly,
the asymptomatic father who did not possess an abnormal NIRFLI phenotype had
passed the HGF gene variant to his daughters.

As no other lymphedema-related genes were identified in this family, we
conducted WES bioinformatics analyses to identify rare SNPs which could be likely
causative or could increase susceptibility to lymphedema. Given that HGF could not
explain lymphatic disease in the mother (Subject #4), and the varied penetrance of
lymphedema in this family, we conducted pathway analysis with the goal of identifying
potential HGF-modifier genes that could have been inherited from the mother that
contribute to the probands’ disease. We identified a rare, heterozygous missense
mutation in INPPL1, which encodes SHIP2, in the probands (Subjects #1 and #2) and in
their mother (Subject #4), but not in their father (Subject #3). This SHIP2 mutation
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results in the conversion of threonine 180, located carboxyl to the SH2 domain, to
alanine (p.T180A) (Figure 2.3C). The T180A INPPL1 mutation was validated by Sanger
sequencing (Figure 2.3A), but we did not confirm that mRNAs encoding T180A SHIP2
protein was produced in affected individuals, nor RNAseq since the tissue biopsy
required for RNAseq is well-known to be associated with an increased risk for infection
in lymphedema subjects. While an INPPL1 SNP at 71940154 (C>G; Hg19) resulting in
T180S has been previously reported (rs376749049), our identified SNP at 71940153
(A>G; Hg19) resulting in T180A, has not been reported in SNP databases. The genomic
region that harbors the INPPL1 gene is unique, in particular the area surrounding the
T180A mutation. To verify this mutation was not in an intronic region, we performed a
blast analysis ± 100 bp on each flanking region, and there was a single hit on INPPL1.
NM_001567 is the single transcript for INPPL1 and there are no alternative splice
versions, in addition RNAseq experiments identify the correct exons described in the
gene model. The mutation that we describe in Hg19 chr11:71940153 corresponds to the
codon 180 of exon 5 of SHIP2. This particular region is evolutionary conserved, free of
repeat elements and with no common SNPs reported, consequently we consider
INPPL1 an evolutionary conserved gene with low tolerance for mutations. An overview
of SHIP2 is discussed below in Section 2.4.

2.3.3: Identification of L632I SHIP2 mutation in second nucleus family
In the second family, WES results identified two missense mutations in the
lymphatic receptor, VEGFR3, encoded by FLT4. The mother (Subject# 17) and daughter
(Subject #16) shared a rare and damaging D481E mutation and an H890Q mutation
which is benign and likely a natural variant. Mutations were predicted as either benign or
damaging based on potential functional impact by at least two of three software tools
(See Chapter 6 Materials and Methods for details). It is of note this D481E mutation is
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the first identified VEGFR3 mutation outside the intracellular kinase domain in subjects
with lymphedema. Additionally, we found another rare heterozygous missense SHIP2
mutation in the mother with more severe lymphedema (Figure 2.2A) while the daughter,
who has less severe disease (Figure 2.2E), did not possess the SHIP2 mutation. This
SHIP2 mutation results in the substitution of leucine 632, located in the catalytic domain
of SHIP2, by an isoleucine residue (p.L632I). Both T180A and L632I SHIP2 mutations
were validated by Sanger sequencing (Figure 2.3A-B) and shown in Figure 2.3C are
the location of these mutations within the SHIP2 protein. Table 2.1 shows the summary
of these two SHIP2 mutations and the mutations in lymphatic receptor tyrosine kinases
(RTKs)-related genes, HGF and FLT4.
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Figure 2.3. Validation of whole exome sequencing (WES) by Sanger sequencing
showing chromatograms of SHIP2 SNPs. (A) Family 1 (Subjects #1-4) at position of
interest (highlighted in yellow), both alleles in Subject #3 contain adenosine (A; green
peak) while Subjects #1, #2, and #4 have heterozygous SNPs at the same position, one
containing adenosine (A; green peak) and the 2nd containing guanosine (G; black peak).
This SNP results in amino acid codon change from threonine to alanine at the 180
residue of SHIP2 protein. (B) In Family 2 (Subjects #16 and #17) at position of interest,
the mother (Subject #17) has heterozygous SNP; one containing cytosine (C; blue peak)
and the 2nd containing adenosine (A; green peak). This SNP results in amino acid
codon change from leucine to isoleucine at the 632 residue of SHIP2 protein. The
daughter (Subject #16) does not possess this SNP. Positive (forward) strands shown.
(C) Schematic of the SHIP2 protein indicating its domains with the two identified
mutations at T180A (Family #1) outside the src homology 2 (SH2) domain and L632I
(Family #2) within the catalytic 5’-phosphatase domain. (Dr. Manuel L.Gonzalez-Garay
analyzed whole exome sequencing and bioinformatics data and Germaine D. Agollah
and Otis Hall performed Sanger sequencing validation).
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Figure 2.3 Validation of whole exome sequencing (WES) by Sanger sequencing
showing chromatograms of SHIP2 SNPs
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Table 2.1 List of SHIP2 (INPPL1) mutations and lymphatic-related RTK mutations identified by whole exome sequencing (WES) and
validated by Sanger sequencing showing chromosomal location, nucleotide base change, zygosity and amino acid change.

Nucleus Family #1
Gene

Subject
#1

Subject
#2

Subject
#3

Subject
#4

Chromosome

Location
(Hg 19)

Nucleotide
change

Zygocity

Amino acid
change

INPPL1

Yes

Yes

No

Yes

chr11

71940153

A -> G

Heterozygote

T180A

HGF

Yes

Yes

Yes

No

chr7

81359017

C -> A

Heterozygote

G315V

Nucleus Family #2
Gene

Subject #16

Subject #17

Chromosome

Location
(Hg 19)

Nucleotide
change

Zygocity

Amino acid
change

INPPL1

No

Yes

chr11

72232917

C->A

Heterozygote

L632I

FLT4

Yes

Yes

chr5

180624040

G->T

Heterozygote

D481E

FLT4

Yes

Yes

chr5

180619344

G->C

Heterozygote

H890Q
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2.3.4: Further identification of T180A SHIP2 within extended family
Clinical evaluation of the nucleus family depicted in Figure 2.1 revealed that
there were other extended family members with lymphedema. We therefore further
conducted NIRFLI and/or WES studies on 11 additional maternal family members. Out
of the eleven extended family subjects, excluding the nucleus family, five other subjects
(Subjects #5, 6, 7, 11, and 13) were previously diagnosed with lymphedema (Figure
2.4A). Seven subjects (including nucleus family) were phenotyped with NIRFLI and
genotyped with WES, of which five subjects harbored the T180A SHIP2 mutation, which
was validated by Sanger sequencing. Of those five subjects, four subjects (Subjects
#1,2, 4 and 6) were diagnosed with lymphedema and one subject (Subject #12) was
unaffected but her NIRFLI phenotype revealed vessel tortuosity, small fluorescent
vessels radiating from injection sites, and dilated vessels (Figure 2.4D). Her 30 year old
daughter (Subject #13) was diagnosed with bilateral lower extremity praecox
lymphedema at 13 years and also harbored T180A SHIP2. No clinical information was
available for Subject #13’s father. Subject #6 had swollen ankles and arms with venous
insufficiency, and NIRF imaging revealed dermal backflow in her medial left ankle with
diffuse dye uptake (Figure 2.4B), fluorescent vessels radiating from injection sites on
thighs and limited lymphatic propulsion. The lymphatics of Subject #9 (unaffected) were
mostly well defined but we observed slight tortuosity with fluorescent lymphatic
capillaries radiating from injection site on medial ankle (Figure 2.4C). All 15 subjects
were genotyped with WES, and no other lymphedema-related genes were identified,
however a mutation of a gene encoding a protein within the MAPK/ERK pathway
(MAP3K7) was identified in Subjects# 1, 2, 4, 7, 9, 12 and 13. Out of these seven
subjects with MAP3K7 mutation (Hg19 chr6:91229032; T > C) five of them were
diagnosed with lymphedema (except Subjects #9 and 12) and also harbored the T180A
SHIP2 mutation. The rare MAP3K7 SNP, which results in p.N463S, has been reported in
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SNP databases (rs375179983), but has not yet been associated with any human
disease. The frequency of the MAP3K7 mutation within 6500 exomes is very low
(0.01%) and the resultant protein change is predicted to the functionally damaging by
PolyPhen-2 software. Of the total 15 subjects, 8 subjects were not imaged and thus are
incomplete phenotypes. Out of these eight subjects, four were diagnosed with
lymphedema, of which three have T180A SHIP2. In Subjects #5 and #11, SHIP2 has no
contributory role to their lymphedema but both subjects had later onset of symptoms
(27yrs and 47yrs respectively) and additional lymphatic insults which either exacerbated
(breast cancer surgery in Subject #5) or triggered edema (self-reported >14hour long
flight in Subject #11). Two subjects (#8 and #14) were unaffected by symptoms, yet
harbor the T180A SHIP2 mutation, however, it remains unknown whether these have
any NIRFLI lymphatic phenotype or will encounter symptoms upon an injury, as did
Subject #4. All subjects with lymphedema had lower extremity disease, except Subject
#6 who had both upper and lower extremity lymphedema. There were no other lymphatic
abnormalities such as chylous ascites or chylothorax reported in this family. While we
did not estimate the mutation rate or penetrance of the T180A polymorphism in this
family, 9 of 15 subjects harbored the SHIP2 mutation, and 6 of the 9 subjects diagnosed
with lymphedema. Results of this nucleus and their extended family are summarized in
Table 2.2.
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Figure 2.4. Identification of T180A SHIP2 mutation in familial lymphedema. (A)
Pedigree of the nucleus and extended family showing affected (filled) and unaffected
(open) subjects with lymphedema, phenotyped by NIRF imaging and WES analysis
revealing subjects who harbor T180A SHIP2, G315V HGF and N463S MAP3K7
mutations. NIRF imaging reveals (B) dermal backflow in medial left ankle of Subject #6
(bilateral lymphedema praecox) and also has abnormal lymphatic capillaries on thigh
(not shown). (C) Abnormal lymphatic capillaries radiating from the injection site on the
medial left ankle of Subject #9 which were also observed capillaries on the thigh on this
unaffected subject. (D) Tortuous lymphatics draining the medial left ankle and lymphatic
capillaries radiating from the left medial calf in Subject #12 (unaffected).

All three

subjects appeared to have dilated lymphatics also. (Clinical lymphatic imaging
conducted under an FDA-approved study (NCT#00833599: “Imaging lymphatic function
in normal subjects and in persons with lymphatic disorders”) by Germaine D. Agollah,
Drs. John C. Rasmussen, I-Chih Tan, Melissa B. Aldrich and Chinmay Darne and clinical
investigations conducted by Drs. Caroline E. Fife, Renie Guilliod and Erik A. Maus at
Memorial Hermann Hospital Center for Lymphedema Management. Dr. Manuel
L.Gonzalez-Garay analyzed whole exome sequencing and bioinformatics data and
Germaine D. Agollah and Otis Hall performed Sanger sequencing validation).
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Figure 2.4. Identification of T180A SHIP2 mutation in familial lymphedema
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Table 2.2: Summary of lymphedema diagnosis and T180A SHIP2 status in nucleus (Figure 2.1) and their extended family

Nucleus
Family

Extended
Family

Relation

Subject
#1

INPPL1
p.T180A
Yes

Lymphedema
Diagnosis
Praecox

Onset of
Symptoms
14

Age at
Study
37

NIRF
Phenotype
Abnormal

Proband

Proband

#2

Yes

Congenital

1

32

Abnormal

Father
Mother

#3
#4

No
Yes

Unaffected
en tarda (left)
Acquired (right)

N/A
54

58
59

Normal
Abnormal

Maternal Aunt

#5

No

Praecox

27

58

N/A

Maternal Aunt

#6

Yes

Praecox

8 (legs)
15(hands)

63

Abnormal

Maternal Aunt
Maternal Aunt
Maternal Aunt

#7
#8
#9

Yes
Yes
No

Praecox
Unaffected
Unaffected

20
N/A
N/A

61
50
69

Uncle (by
marriage)
Maternal Male
Cousin
Maternal Aunt
Maternal
Female Cousin
Maternal Uncle
Maternal Uncle

#10

No

Unaffected

N/A
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N/A
N/A
Some
abnormality
N/A

#11

No

en tarda

47

50

N/A

#12
#13

Yes
Yes

Unaffected
Praecox

N/A
13

54
30

Abnormal
N/A

#14
#15

Yes
No

Unaffected
Unaffected

N/A
N/A

48
55

N/A
N/A
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Comments
Diagnosed Grade I left unilateral lower extremity
LE on dorsum of left foot. Minimal fibrosis at base
of toes
Diagnosed Grade II bilateral lower extremity LE
from knees down. Skin cellulitis.
N/A
Diagnosed Grade I right leg; Grade II left leg.
Minor left ankle sprain preceded symptoms on
both legs. Few varicose veins.
Bilateral LE in both legs, ankles and feet. Mild
edema in both arms following breast cancer
bilateral lymph node dissection surgery. Venous
insufficiency
Bilateral LE in both legs, both hands and arms.
Visible enlarged veins and telangiectasia. Venous
insufficiency
Bilateral LE in both legs, feet and toes
N/A
N/A
N/A
Unilateral left foot LE; long >14hr flight preceded
symptoms.
N/A
Mild edema in both legs below the knee.
N/A
N/A

In summary of these clinical studies, the results of WES analysis combined with NIRFLI
phenotyping suggested that T180A and L632I SHIP2 mutations may contribute to but do
not necessarily cause lymphatic dysfunction. Furthermore, these analyses show that in
these families, lymphatic abnormalities are more severe and of earlier onset in
individuals with additional mutations in genes that have been associated with lymphatic
disease previously, such as HGF, FLT4 or within MAPK/ERK signaling pathway [44, 63,
81, 102] suggesting that SHIP2 may be a modifier of lymphatic dysfunction. Based on
these clinical findings as well as previous reports that SHIP2 physically associates with
cMET [107], we investigated a potential function for SHIP2 in lymphatic endothelial cells
(LEC), which will be the focus of Chapter 3.

2.4: Overview of Src Homology 2- domain containing 5’-inositol phosphatase-2
(SHIP2)
2.4.1: Introduction
In response to external stimuli, cellular receptors become activated and recruit
enzymes which generate second messengers. For example phosphatidylinositol-3,4,5triphosphate (PI-3,4,5-P3 or PIP3) is a membrane lipid-derived second messenger that
subsequently recruits pleckstrin homology (PH)-containing signaling molecules, such as
protein kinase B or AKT, to the plasma membrane [108]. Upon activation, AKT
translocates to the cytoplasm to further activate other downstream targets via
phosphorylation. Consequences of this signaling include among others, cell proliferation,
cell survival, and cytoskeletal reorganization. Cellular levels of PI-3,4,5-P3 are controlled
in two ways: positive generation in response to growth factors and other external stimuli;
and negative regulation by phosphoinositide (PI) phosphatase enzymes. Two pathways
degrade PI-3,4,5-P3: (i) phosphatase and tensin homologue (PTEN) that hydrolyzes
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PIP3 at the 3’-position of the inositol ring to produce PI-4,5-P2 and (ii) by 5’-inositol
phosphatases to generate PI-3,4-P2. One such 5’-phosphatase is src homology 2domain containing 5’-inositol phosphatase-2 (SHIP2), the focus of this dissertation.
2.4.2: Structure and functions of SHIP2
Inositol polyphosphate 5’-phosphatase-like protein 1 (INPPL1) on chromosome
11q23 (human), encodes SHIP2, a 142kD protein which contains an amino (N)-terminal
SH2 domain, a central catalytic 5-phosphatase domain, a potential phosphotyrosinebinding (PTB) consensus sequences (NPXY), a proline-rich domain (PRD) and a sterile
alpha motif (SAM) in the carboxy (C)-terminal (Figure 2.3C) [108, 109]. Mouse SHIP2
(on chromosome 7) shares 95% homology with human SHIP2 and 98% with rat SHIP2
(on chromosome 1) [110]. Beyond the catalytic function of SHIP2 which is mediated by
the 5’-phosphatase domain, the other motifs of SHIP2 mediate interactions with various
proteins to effect diverse cellular functions. The SH2 domain of SHIP2 interacts with
p130CAS, src homology and collagen homology (Shc) and the HGF receptor, cMET to
affect cell adhesion, cell scattering and cell spreading in various cellular contexts [107,
111, 112]. Via its PRD domain, SHIP2 interacts with filamin, c-Cbl, c-Cbl-associated
protein (CAP), vinexin and JNK-interacting protein 1 and epidermal growth factor
receptor (EGFR) [113-117]. The SAM domain of SHIP2 interacts with Arap3 and ephrin
A2 (EphA2) receptor while the adaptor protein with a PH and SH2 domain (APS) binds
the 5’-phosphatase domain of SHIP2 and enhances its catalytic activity [108]. These
binding partners of SHIP2 are summarized in Figure 2.5. Recent evidence also shows
that SHIP2 binds protein phosphatase 2A (PP2A), SH3 domain containing Ysc84-like 1
(SH3YL1) and the small GTPase, RhoA, to effect endocytosis, ruffle formation, cell
polarity and migration [118-120].
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In humans SHIP2 is widely expressed, with higher levels in the heart, placenta,
brain and skeletal muscle but SHIP2 shows ubiquitous expression in most tissues in
rodents [108, 110]. In quiescent cells, SHIP2 is in the cytosol and translocates to the
plasma membrane following growth factor stimulation and to membrane ruffles during
cell adhesion [109]. SHIP2 also undergoes tyrosine phosphorylation at its NPXY motif
which contributes to its translocation and likely catalytic phosphatase function [108]. In
all, both its catalytic and scaffolding capabilities allows SHIP2 to exert its influence on
various cellular functions.
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Figure 2.5. Binding partners of SHIP2. The 1258 amino acid protein comprises of a Nterminal SH2 domain, a central catalytic 5-phosphatase domain (5-CAT), a proline-rich
domain (PRD) including NPXY sequences and a C-terminal sterile alpha-motif (SAM)
domain. Also shown are binding partners of SHIP2.
Adapted from Suwa, A., Kurama, T., and Shimokawa, T., SHIP2 and its involvement in
various diseases. Expert Opin Ther Targets, 2010. 14(7): p. 727-37. [108].
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Figure 2.5. Binding partners of SHIP2
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2.4.3: Role of SHIP2 in disease
SHIP2 in insulin signaling and Type 2 diabetes. Perhaps the most well studied
role of SHIP2 in disease is its involvement in insulin signaling. SHIP2 negatively
regulates PI3K-generated PIP3 in response to insulin stimulation and inhibits
phosphorylation of AKT2, which is ultimately important in glucose uptake. Interestingly,
SHIP2 does not regulate insulin-induced phosphorylation of AKT1 [108]. Genetic mouse
models of Ship2 exhibit disordered insulin signaling. In the first reported model by
Clement et al. in which the first 18 exons covering SH2 and 5’-catalytic domains were
left intact and last exons #19-28 deleted, Ship2-/- mice exhibited severe neonatal
hypoglycemia and death within three days, while Ship2+/- mice showed enhanced insulin
sensitivity [121]. However, in this model, a neighboring gene Phox2a was also
inadvertently deleted. A second mouse model by Sleeman et al., addressed this problem
by deleting the first 18 exons and replacing them with a gene reporter while exons 19-28
were left intact [122]. In this second model, Ship2-/- mice were viable with normal glucose
and insulin levels, and interestingly, were resistant to weight gain even on high fat diets
and also exhibited increased metabolic rates. A more recent mouse model by Dubois et
al., in which Ship2 is fully expressed but catalytically inactive, shows that homozygote
mutant mice are viable with defects in lipid metabolism and insulin secretion but with no
effect on glucose tolerance, insulin sensitivity nor insulin-induced Akt activation [123]. On
the other hand, transgenic mice over-expressing Ship2 show reduced insulin-induced
Akt activation, gained more weight with increased insulin levels but normal glucose
levels [124]. Ship2 mutations have been identified in the Type 2 diabetic and
hypertensive rat strain, Goto Kakizaki (GK), while the diabetic mouse strain db/db
exhibits increased Ship2 protein levels [125]. Combined, these studies highlight the
importance of SHIP2 in insulin signaling and in maintenance of glucose metabolism.
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In humans, SHIP2 polymorphisms have been identified in metabolic syndrome,
which is characterized by Type 2 diabetes, hypertension, abdominal obesity, and insulin
resistance [125]. A study of Japanese subjects identified the L632I SHIP2 mutation in
more control subjects than in diabetic subjects, and transfection of mutant L632I-SHIP2
into Chinese hamster ovary cells overexpressing human insulin receptors (CHO-IR)
showed that L632I reduced SHIP2-mediated negative regulation of insulin signaling
leading to the authors’ conclusion that L632I is protective against insulin resistance in
the Japanese population. However, the authors acknowledge that since Japanese Type
2 diabetes genetically differs from both North American and European Caucasians’
disease, therefore the effect of this mutation and of SHIP2 in general, could differ
depending on the studied ethnic group [126]. Nonetheless taken together, these rodent
and human studies highlight the key role that SHIP2 plays in insulin signaling and
obesity.
Role of SHIP2 in cancer. SHIP2 has been controversially implicated in cancer,
suggested to play both proto-oncogenic and tumor-suppressive roles in human and
murine models. As a proto-oncogene, SHIP2 expression has been found to be increased
in breast cancer cell lines and in clinical specimens of breast cancer tissues, non-small
cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC), all of which correlate
with poor prognosis [127-129]. Overexpression of SHIP2 in breast cancer cells
increased their proliferation, while SHIP2 suppression reduced tumor growth and lung
metastases in nude mice [117]. Recently, SHIP2 has been found to be overexpressed in
breast cancer stem cells (BCSCs) with targeted SHIP2 silencing via RNAi and
pharmacological

inhibition

resulting

in

reduced

tumorigenicity,

while

SHIP2

overexpression enhanced epithelial-mesechymal transition (EMT) markers promoting
breast cancer metastasis [130].
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In contrast, SHIP2 has also been shown to have tumor-suppressive effects. As an
inhibitor of PI3K/AKT signaling, a well-established oncogenic pathway that often
increases cell growth, a positive oncogenic role for SHIP2 is understandably
controversial. SHIP2 overexpression in glioblastoma brain cancer cells and in K562
erythroleukemia cells reduced their cell growth and proliferation [131, 132]. Of
importance, miRNA-205 suppresses SHIP2 expression in squamous cell epithelium and
squamous cell carcinoma (SCC) cells express elevated levels of miRNA-205 correlating
with reduced SHIP2 expression and increased AKT phosphorylation [133]. Inhibition of
miRNA-205 induces SHIP2 expression and expectedly decreased AKT phosphorylation.
Since miRNA-205 is upregulated in kidney, bladder and ovarian cancers, but
downregulated in breast and prostate cancers, it is likely that the contradictory role of
SHIP2 as a proto-oncogene and a tumor-suppressor might be explained with expression
of miRNA-205 in these cancers [108, 125].
SHIP2 in neurodegenerative disease and atherosclerosis. Other diseases in
which

SHIP2

plays

a

regulatory

role

are

neurodegenerative

diseases

and

atherosclerosis, both involving the capacity of SHIP2 to suppress PI3K/AKT signaling.
Specifically, SHIP2 inhibits nerve growth factor (NGF)- and insulin growth factor 1
(IGF1)-induced PI3K/AKT activation leading to GSK-3β phosphorylation and activation of
Tau, a microtubule-associated protein which is often hyperphosphorylated in Alzheimer’s
disease [134-137]. In atherosclerosis, SHIP2 inhibits platelet derived growth factor
(PDGF)- and IGF1-induced PI3K/AKT activation leading to apoptosis of vascular smooth
muscle cells (VSMCs), an event that leads to rupture of protective fibrous caps and
deposition of a thrombus, followed by acute myocardial infarction. Additionally, following
binding of the low density lipoprotein (LDL) receptor by apolipoprotein E4 (APOE4),
SHIP2 can be recruited to the intracellular region of the LDL receptor resulting in
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hydrolysis of PIP3 to inhibit AKT activation in umbilical vein endothelial cells, thus
increasing the risk for atherosclerosis [138]. Interestingly, APOE4 is one of the major
genetic risk factors for Alzheimer’s disease, therefore it remains to be seen whether this
novel APOE4-SHIP2 model applies to Alzheimer’s disease as well [108].
In summary, the effects of SHIP2 seem to be context specific by being able to
exert its influence depending on the specific cell and tissue type: for example SHIP2 can
regulate AKT2 but not AKT1 during insulin signaling in skeletal muscle and adipose
cells, and specifically regulate AKT1 signaling in cancer. With the involvement of
PI3K/AKT pathway in various diseases, including lymphatic diseases (Table 1.3), it is
not surprising that SHIP2, a negative regulator of this pathway is also involved in these
pathologies.

2.5: Discussion
We report here two separate families with inherited lymphedema with distinct
heterozygous non-synonymous rare mutations in the INPPL1 gene that encodes the
SHIP2 enzymatic and scaffolding protein. In addition, heterozygous damaging mutations
in the HGF gene that encodes HGF or the FLT4 gene that encodes VEGFR3 were
identified in the two families. Mutations in HGF and FLT4 have been associated with
lymphedema beforehand [63, 102]. Of the two SHIP2 mutations that were identified in
families, one (T180A) is located carboxy terminal to the SH2 domain whereas the other
(L632I) is located within the catalytic domain (Figure 2.3C). Interestingly, individuals in
these families that harbored mutations in both INPPL1 and HGF or INPPL1 and
VEGFR3 showed more severe lymphatic symptoms. Further WES analyses of the
extended family from the first nucleus family identify this T180A SHIP2 mutation in 6
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other subjects, 3 of whom have various diagnoses of lymphedema. This SHIP2 mutation
also overlaps with a mutation of a gene within the MAPK/ERK signaling pathway,
MAP3K7, in 5 individuals with lymphedema. However, while computationally predicted to
be damaging, it remains to be biologically validated whether MAP3K7 specifically has a
cellular functional role in LEC. Nonetheless, our findings implicate SHIP2 as a regulator
of lymphatic function in humans and that inherited mutations in the INPPL1 gene may
act in concert with HGF and VEGFR3, and likely MAP3K7, mutations to exacerbate
lymphatic phenotypes.

High penetrance genes associated with lymphedema, such as VEGFR3, exhibit
the standard, rare Mendelian inheritance pattern in patients with an extreme phenotype.
However, since lymphatic abnormalities most likely arise from the interplay between
several genes and environmental factors as in the case of many other disorders,
lymphedema likely cannot only be attributed to single, high penetrance genes. For the
majority of the more common disorders such as stroke, hypertension, obesity, autism,
schizophrenia, bipolar disorder, etc. a large number of genes are involved with each one
contributing to the disorder. This situation may be expected in non-syndromic primary
lymphedema, since only VEGFC/VEGFR3 axis genes that have been identified as the
sole source of the disorder (Table 1.3), yet 64% of patients with familial history and 92%
of patients with sporadic non-syndromic lymphedema do not harbor these mutations [44,
96]. Inherited heterozygous mutations in SHIP2 together with germline heterozygous
mutations in other lymphatic-regulating genes may be sufficient for the development of
lymphedema. Ideally, as evidenced by the variable phenotypes in our subjects,
screening of families with syndromic lymphatic dysfunction for INPPL1 mutations could
be informative and substantiate the variable penetrance that is normally observed in
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lymphatic disorders. Additonally, as suggested by NIRFLI phenotyping of aberrant
lymphatic architecture and function in asymptomatic subjects, variations in normal
physiologic challenges such as puberty, pregnancy, immune insults, or mechanical injury
could provide physiologic and/or environmental second-hits that could account for the
differences in disease expressivity and age of onset in subjects.

Recently both homozygous and heterozygous mutations in SHIP2 have been
reported in a rare skeletal disorder, opsismodysplasia (OMIM: 258480) in both unrelated
and consanguineous family members [139, 140]. Furthermore, while SHIP2 has been
implicated in obesity, diabetes and insulin resistance in rodents [121-124] and in humans
[126, 141, 142];

and has been suggested to have proto-oncogenic roles in human

breast cancer, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC)
worsening patient outcomes [127-129], and paradoxically, a tumor-suppressive role in
squamous cell carcinoma (SCC) [133], SHIP2 has not been associated with vascular
disorders.

However, PTEN, which similarly to SHIP2, is a negative regulator of

PI3K/AKT signaling, has been implicated in lymphatic malformations specifically
Proteus-like syndrome, exhibiting medium penetrance and loss-of-function phenotype
[143]. Thus, it may be expected, but remains to be tested in genetic mouse models,
whether SHIP2 plays a primary role in lymphangiogenesis and lymphatic vessel
maintenance. To our knowledge, the only previous evidence suggesting a role of SHIP2
in lymphatic biology is a recent transcriptomic microarray study using paired punch
biopsy samples of human lymphedema tissue versus normal samples. In that study,
among ~8400 differentially expressed genes, INPPL1 was found to have reduced
expression in lymphedematous tissue samples suggesting a role for this protein in
lymphatic function [71].
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2.6: Significance
Discovery of variants responsible for inherited lymphatic abnormalities has been
limited by candidate gene searches and inaccurate phenotyping which is often based on
late-stage, overt symptomatic presentation.

We address these two issues by (i)

employing near-infrared fluorescence lymphatic imaging (NIRFLI) to accurately identify
abnormal lymphatic phenotypes in two families, both symptomatic and asymptomatic
members, who were diagnosed with congenital, praecox, en tarda, and secondary
(acquired) lymphedema and (ii) through unbiased whole exome sequencing and analysis
of rare SNPs with co-segregation analysis based on NIRFLI phenotyping, in order to
discover gene variants. Using this approach, mutations in the inositol polyphosphate
phosphatase-like 1(INPPL1) gene that encodes the src homology 2 domain containing
5’-inositol-phosphatase-2 (SHIP2) were identified. These imaging and genetics studies
identify SHIP2 as a potential effector of lymphatic dysfunction in humans. However, the
functional relevance of these INPPL1 mutations requires biological validation in
lymphatic endothelial cell (LEC) culture studies, which is the focus of Chapter 3.
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CHAPTER 3
DISRUPTION OF SHIP2 CONFERS AN IN VITRO LYMPHATIC PHENOTYPE

Portions of this chapter are based on: Agollah G.D., Gonzalez-Garay M.L, , Rasmussen
JC., Tan I-C., Aldrich M.B., Darne C., Fife C.E., Guilliod R., Maus, E.A., King P.D.,
Sevick-Muraca E.M., “Evidence for SH2 domain-containing 5-inositol phosphatase-2
(SHIP2) contributing to a lymphatic dysfunction” PLoS ONE (2014) 9(11): e112548.
doi:10.1371/journal.pone.0112548 [98]. PLOS applies Creative Commons Attribution
License (CCAL) and Open-Access License, wherein no permission is required from
authors or publishers for reprints or reproduction of published works, except proper
citation of original work. Germaine D. Agollah performed all experiments, unless
otherwise noted in figure legends.
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3.1: Rationale
SHIP2 is a phosphatidylinositol (3,4,5) triphosphate (PIP3) 5’-phosphatase that
negatively controls PIP3 levels in cells, thereby inhibiting the phosphatidylinositol-3kinase (PI3K)/AKT signaling pathway. Recently, mutations within the PI3K/AKT pathway
have been implicated in various lymphatic malformations and syndromic conditions that
have a lymphatic involvement. CLOVES syndrome (OMIM: 612918) and KlippelTrenaunay-Weber syndrome (KTWS, OMIM: 149000) are caused by gain-of-function
mutations in PI3KCA, which encodes p110α, a catalytic subunit of PI3K, while AKT1
mutations have been identified in Proteus syndrome (OMIM: 176920) [44, 144, 145]. In
addition, targeted mutations of Pik3r1, Pi3kca and Akt1 genes result in lymphatic
abnormalities including lymphangiectasia, defective lymphatic sprouting and maturation,
lymphatic vessel hypoplasia, and chylous ascites in mice [146-148]. SHIP2 is known to
interact physically with receptor tyrosine kinases (RTKs), focal adhesion proteins,
scaffold proteins, protein phosphatases, and cytoskeletal proteins to regulate cell
proliferation, adhesion, migration, survival, and receptor internalization [108, 117, 149,
150]. Therefore, given the evidence that PI3K/AKT pathway plays a role in lymphatic
malformation, one may hypothesize that SHIP2, a negative regulator of this pathway,
could be involved in lymphatic disorders. Furthermore, as discussed in Chapter 2, with
the identification of SHIP2 mutations in two families with varied diagnoses of
lymphedema, we sought to investigate the functional role of SHIP2 in lymphatic
endothelial cells (LECs).
3.2: Dysregulated HGF- and VEGFC-induced activation of AKT and MAPK in
SHIP2-deficient LEC.
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The role of SHIP2 has been previously evaluated in other cell types but not in
LECs [107, 117, 127]. We confirmed the lymphatic lineage of primary human dermal
lymphatic endothelial cells (HDLECs) and TIME (telomerase-immortalized microvascular
endothelial) cells by flow cytometric analysis of lymphatic-specific podoplanin and panendothelial PECAM1 (CD31) antigen expression (Figure 3.1A). We found that SHIP2
was expressed in HDLECs (Figure 3.1B) and in TIME cells via immunofluorescence.
Transfection

of

HDLECs

and

TIME

cells

with

four

different

SHIP2

siRNA

oligonucleotides resulted in effective knockdown of SHIP2 as revealed by Western
blotting (Figure 3.1C.D), and RT-qPCR (Figure 3.1E).

Subsequent SHIP2 siRNA

transfections were carried out with the pool siRNA oligonucleotide comprising the four
individual siRNA sequences to ensure effective knockdown. (Note: general references to
LECs imply both lymphatic cell lines, HDLECs and TIME cells).
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Figure 3.1 SHIP2 is expressed in lymphatic endothelial cells (LECs) (A)
Confirmation of lymphatic lineage of primary HDLECs (passage 8) and TIME cells
(passage 30) and expression of SHIP2 in HDLECs and TIME cells. Cells were grown to
confluency and stained with pan-endothelial marker anti-human CD31 (top panels) and
lymphatic marker anti-human podoplanin (bottom panels). Antigen markers are depicted
in orange, isotype controls are in blue, and unstained in red. 50,000 events per
experiment, N=3 independent experiments, 3 replicates per experiment. (B) Primary
HDLECs (passage 5) were subjected to (pool) siRNA transfection for 48 hours then
plated in chamber slides. LECs were allowed to adhere, fixed and permeabilized before
staining with anti-human SHIP2 antibody followed by Alexa Fluor 546 antibody (green).
Cells were counterstained with Alexa 488 phalloidin to detect actin (red) and nuclear
stain DRAQ5 (blue). Scale bar = 25µm. (C-D) Western blot analysis of SHIP2
expression upon transfection with four different sequences of SHIP2 siRNA (#1-4 and
pool, see Chapter 6 Materials and Methods for oligonucleotide sequence information) in
HDLEC and TIME cells. Equal loading was determined by Western blotting for actin. (E)
RT-qPCR measurement of SHIP2 mRNA levels in HDLEC and TIME pool SHIP2 siRNA
transfectants normalized to GAPDH expression levels; N=5 independent experiments, 3
replicates per experiment. Control = untransfected cells; Mock = transfection reagents
only; NT = non-targeting control siRNA.
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Figure 3.1 SHIP2 is expressed in lymphatic endothelial cells (LECs)
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Given that the major reported function of SHIP2 is to dampen PI3K/AKT
signaling, and that aberrant PI3K/AKT signaling results in lymphatic dysfunction in both
mouse [146-148] and humans [144, 145] we examined the effect of SHIP2 knockdown
upon HGF- and VEGFC-induced AKT activation in LEC. Activation of AKT in HDLECs
and TIME cells was examined by Western blotting using phospho-specific anti-AKT
antibodies (Figures 3.2 and 3.3). Stimulation of control HDLECs resulted in activation of
AKT with the peak response evident between 10 and 15 minutes and 10 and 30 minutes
after stimulation with HGF and VEGFC, respectively (Figure 3.2A,C and Figure
3.3A,C). After SHIP2 knockdown in HDLECs, the magnitude of AKT activation was
modestly increased in response to HGF and substantially increased in response to
VEGFC, although the kinetics of responses were not altered. Similar results were
obtained in TIME cells after SHIP2 knockdown (Figure 3.2B,C and Figure 3.3B,C)
These data are consistent with a function for SHIP2 as a negative regulator of the
PI3K/AKT signaling pathway in LEC.

Recent studies have also identified mutations within the Ras/MAPK/ERK
signaling network as responsible for lymphatic abnormalities [44, 81, 84, 85, 151, 152].
Given that we identified a mutation in MAP3K7, a Ras/MAPK/ERK-related gene, we also
examined activation of MAPK in SHIP2 knockdown HDLEC using phospho-specific antiERK antibodies. In control HDLEC, HGF and VEGFC both induced activation of ERK
with peak responses occurring at 15 and 10-15 minutes post-stimulation, respectively
(Figure 3.2A,D and Figure 3.3A,D). In SHIP2 knockdown HDLECs, substantial
increases in the magnitude of ERK activation were evident in response to HGF and
VEGFC stimulation. In both cases, activation of ERK occurred earlier and persisted for
longer times after growth factor stimulation than in naïve HDLECs. These results were
replicated in TIME cells in which we observed potent and protracted ERK activation
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upon SHIP2 knockdown in response to both HGF and VEGFC stimulation (Figure
3.2B,D and Figure 3.3B,D). This data implicates SHIP2 as a negative regulator of
MAPK signaling, as well as negative regulator of PI3K/AKT activation in LEC.

97

Figure 3.2 Dysregulated HGF-induced activation of AKT and ERK1/2 in SHIP2deficient LECs. (A) HDLECs and (B) TIME cells were subjected to 48hr SHIP2 siRNA
and stimulated with the HGF for the indicated times. Activation of AKT and ERK was
determined by fluorescent double staining Western blotting of cell lysates with both
phosphospecific antibodies and antibodies to total proteins. Phosphoantibodies were
detected by IRDye680 (red signal) and total antibodies detected by IRDye800 (green
signal) fluorescent secondary antibodies. Quantification of AKT (C) and ERK (D)
activation in HDLECs and TIME cells by mean fluorescence intensity (MFI) and
represented as a ratio of pAKT-S473 to total AKT and pERK1/2 to total ERK1/2,
respectively. SHIP2 knockdown levels shown and COX IV used as loading control.
MW=molecular weight marker.

98

Figure 3.2. Dysregulated HGF-induced activation of AKT and ERK1/2 in SHIP2deficient LECs.
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Figure 3.3 Dysregulated VEGFC-induced activation of AKT and ERK1/2 in SHIP2deficient LECs. (A) HDLECs and (B) TIME cells were subjected to 48hr SHIP2 siRNA
and stimulated with the VEGFC for the indicated times. Activation of AKT and ERK was
determined by fluorescent double staining Western blotting of cell lysates with both
phosphospecific antibodies and antibodies to total proteins. Phosphoantibodies were
detected by IRDye 680 (red signal) and total antibodies detected by IRDye800 (green
signal) fluorescent secondary antibodies. Quantification of AKT (C) and ERK (D)
activation in HDLECs and TIME cells by mean fluorescence intensity (MFI) and
represented as a ratio of pAKT-S473 to total AKT and pERK1/2 to total ERK1/2,
respectively. SHIP2 knockdown levels are shown and COX IV used as loading control.
MW=molecular weight marker.
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Figure 3.3. Dysregulated VEGFC-induced activation of AKT and ERK1/2 in SHIP2deficient LECs.
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3.3: SHIP2 is required for HGF- and VEGFC-induced lymphangiogenesis in vitro.
We next sought to investigate the role of SHIP2 in LEC biology using in vitro
assays of cell proliferation, adhesion, migration, and tubulogenesis that model different
steps in lymphangiogenesis. Given the increases in AKT activation (Figure 3.2 and 3.3),
we expected SHIP2 knockdown to result in increased LEC proliferation. However, we
found reduced LECs proliferation both under basal conditions (1% FBS) and following
HGF or VEGFC stimulation (Figure 3.4A).

SHIP2-deficient LECs also exhibited a

reduced capacity to adhere to extracellular matrix proteins, collagen, and fibronectin
(Figure 3.4B) and showed reduced directed migration in scratch wound assays (Figure
3.4C). The ability of LECs to organize into tube-like structures was assessed using a 3DMatrigel assay. SHIP2 knockdown resulted in significantly less tube formation after HGF
and VEGFC stimulation (Figure 3.4D). However, contrary to the known pro-survival role
of PI3K/AKT, we found increased apoptosis in SHIP2 knockdown LEC induced by
overnight serum starvation or staurosporine treatment (Figure 3.4E). These results were
also obtained in TIME cells in all functional assays (Figure 3.5).

102

Figure 3.4 SHIP2 is required for in vitro lymphangiogenesis in primary HDLECs.
(A) MTS cell proliferation assay in response to growth factor stimulation for 48hrs,
normalized to 1% FBS of non-targeting (NT) siRNA (N=3).(B) Cell adhesion assay of
siRNA-transfected HDLECs onto BSA, collagen and fibronectin and quantification
presented as area fraction of whole images (triplicates per experiment; 5 independent
experiments). (C) Wound scratch cell migration assay of siRNA-transfected HDLEC
immediately after injury, at 24hr and 48 hrs afterward. (D) 3D tube formation networks in
response to growth factors imaged 24hrs post plating. (E) Annexin V apoptosis assay of
siRNA-transfected HDLECs either untreated or following staurosporine treatment,
quantification of total annexin v-positive cell populations and mean intensity of annexinV
and propidium iodide of 3 independent experiments. Data presented as means±SEM.
*p<0.05, ***p<0.001. Scale bar = 50µm. Control = untransfected cells; NT=non-targeting
siRNA.
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Figure 3.4 SHIP2 is required for in vitro lymphangiogenesis in primary HDLECs.
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Figure 3.5 Phenotype of TIME cells upon SHIP2 knockdown. (A) MTS cell
proliferation assay of 24hr-transfected TIME cells in response to 1% FBS over 48 hrs;
N=3. (B) Representative images of cell adhesion assay of siRNA-transfected TIME onto
BSA, collagen and fibronectin. (C) Wound scratch cell migration assay of siRNAtransfected TIME cells immediately after and at 24 and 48hrs after wounding. (D) 3D
tube formation networks in response to growth factors imaged 24hrs post plating. (E)
Annexin V apoptosis assay of siRNA-transfected TIME cells either untreated or following
staurosporine treatment, quantification (N=3) of total annexin v-positive cell populations
and mean intensity of annexinV and propidium iodide. Data presented as means±SEM.
*p<0.05. Scale bar = 50µm. Control = untransfected cells; NT=non-targeting siRNA.
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Figure 3.5 Phenotype of TIME cells upon SHIP2 knockdown.
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Taken together, these data suggest that while SHIP2 is necessary for in vitro
lymphangiogenesis in HDLECs and TIME cells, the cellular phenotypes of reduced
proliferation, adhesion, and migration may be secondary to increased apoptosis.
Furthermore, the observed phenotypes were not as a result of reagent toxicity given that
tube networks were stained with Calcein AM viability fluorescent dye (Figure 3.4D) and
four SHIP2 RNAi with different targeting sequences were tested, including mock and
non-targeting (NT) control transfections, and all four RNAi showed comparable levels of
SHIP2 knockdown (Figure 3.1C,D). Why loss of SHIP2 would lead to increased AKT
activation but increased apoptosis of LECs is unclear but may be explained by still
greater increases in pro-apoptotic ERK activation (see Section 3.10 Discussion).

3.4: SHIP2 is required for cytoskeletal reorganization in LECs
In addition to its catalytic 5’-phosphatase function, a major function of SHIP2 is to
effect cell spreading, motility, and adhesion [117, 120]. We therefore assessed whether
some of the loss-of-function phenotypes we had observed upon SHIP2 knockdown was
due to altered cytoskeletal reorganization. Formation of lamellipodia, which are actin-rich
projections at the leading edge of a mobile cell, was assessed in LECs plated onto
collagen-coated slides for 1 hour. Starved cells (1% FBS) exhibited a spreading
phenotype and reduced actin polymerization, with no obvious morphological differences
observed between control and SHIP2-siRNA transfected LECs (Figure 3.6A). However
following 10 minute VEGFC stimulation, control cells were polarized whereby
lammellipodia localized to front end extending toward the direction of movement (line
arrows) (Figure 3.6B panels i-iii). Control cells also exhibited increased fluorescent
stress fibers indicative of actin polymerization (filled block arrows). On the other hand,
SHIP2-siRNA transfected LECs retained the spreading phenotype, exhibited reduced
actin fibers, while some cells had focal adhesions (open block arrows) and some had
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radial protrusions that resemble peripheral lamellipodia (arrow head) (Figure 3.6B
panels iv-vi). These experiments demonstrate an essential function of SHIP2 in
maintaining intracellular actin organization which is necessary for LEC migration.
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Figure 3.6 SHIP2 is necessary for cytoskeletal reorganization in LECs. Lamellipodia
formation was assessed in LECs that had been subjected to 24 hour SHIP2 siRNA,
starved overnight in 1%FBS, harvested, plated onto collagen-coated slides for 1 hour
and then stimulated for 10 minutes using VEGFC. (A) Under starvation, both control and
siRNA transfectants exhibit spreading phenotype. (B) Cytoskeletal reorganization in
control LECs with lamellipodia formation at the leading edges of motile cells (line arrows)
and bright regions of actin polymerization (filled block arrows) in response to VEGFC
stimulation. Most SHIP2-siRNA transfected LECs have spreading phenotype (B panels
v-vi), focal adhesion contacts (open block arrows) and some cells have peripheral
polarizing lamellipodia (arrow head). Scale bar =20µm.
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Figure 3.6 SHIP2 is necessary for cytoskeletal reorganization in LECs
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3.5: SHIP2 physically interacts with cMET and VEGFR3 in LECs.
SHIP2 interacts physically with cMET in epithelial cells to effect HGF-induced
lammellipodia formation, spreading and spreading [107]. To confirm this interaction in
LECs and investigate whether SHIP2 also interacts with VEGFR3 we used proximity
ligation assays (PLAs) and traditional immunoprecipitation.

PLA allows for in situ

detection and quantification of protein-protein interactions in intact cells, whereby a
fluorescent signal is generated when two PLA probes are present in close proximity
within 30-40nm [153]. Through transfection of FLAG-tagged wild type (WT) SHIP2 into
TIME cells, we confirmed that SHIP2 interacts with endogenous cMET upon HGF
stimulation in PLA assays (Figures 3.7A, C). Additionally, we identified that SHIP2
associates with VEGFR3 following VEGFC stimulation in PLA assays (Figures 3.7B, D).
Physical association between endogenous SHIP2 and cMET or VEGFR3 in response to
growth factor stimulation was confirmed by co-immunoprecipitation (Figure 3.7E).
Negative controls included the omission of one primary antibody during the PLA reaction
(Figure 3.7A). The finding that SHIP2 physically interacts with cMET and VEGFR3 in
LECs further substantiates the notion that SHIP2 mutations contribute to the lymphatic
abnormalities in the studied families. Furthermore, a role for SHIP2 in cMET and
VEGFR3 signaling pathways could provide an explanation for the occurrence of more
serious disease in individuals with mutations in SHIP2 together with mutations in one or
the other of these RTKs.
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Figure 3.7. SHIP2 interacts with cMET and with VEGFR3. Proximity ligation assay
(PLA) depicting interaction of (A) SHIP2-FLAG and cMET and (B) SHIP2-FLAG and
VEGFR3 in Vector- and FLAG-tagged WT SHIP2-transfected TIME cells following (A)
HGF stimulation and (B) VEGFC stimulation and respective quantification of PLA
fluorescence signal (C and D) in 100 cells/experiment (N=3) quantified by ImageJ (NIH).
(E) Co-immunoprecipitation depicting endogenous SHIP2 interacting with cMET and
VEGFR3. Confluent naïve TIME cells were serum-starved overnight and subjected to
HGF and VEGFC stimulation for 15 minutes before harvesting and lysates subjected to
immunoprecipitation with anti-cMET and anti-VEGFR3 antibodies pre-absorbed with
agarose beads. Immunocomplexes were subjected to immunoblotting, blots probed with
anti-SHIP2 antibody, and GAPDH used to determine equal loading in whole cell lysates
pre-IP. (F,G) PLA negative controls (F) SHIP2FLAG-cMET and (G) SHIP2FLAGVEGFR3 interaction whereby a single primary antibody is used, the second primary
antibody is omitted and both PLA probes added. Note lack of red PLA signal. Blue =
DAPI, green = actin and red = PLA fluorescence with each red dot depicting in situ
interaction site. Scale bar = 50µm, bottom right panel.

112

Figure 3.7. SHIP2 interacts with cMET and with VEGFR3
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3.6: Influence of T180A and L632I SHIP2 mutations upon PIP3-directed
phosphatase activity.
Given findings in SHIP2-deficient LECs, we next asked if T180A and L632I
SHIP2 mutations might affect SHIP2 phosphatase activity. The T180A mutation resides
between the SH2 and catalytic domains (Figure 2.3C). Because the entire crystal
structure of the SHIP2 protein has not been solved, we were unable to model the
potential impact of the T180A mutation on intramolecular interactions that could impact
upon catalytic and non-catalytic (scaffolding) activity. In contrast, the L632I mutation lies
within the catalytic domain, the three-dimensional structure of which has been elucidated
[154]. Because recognition and binding of an enzyme to its substrate requires protein
conformational changes which, among other factors, depend on the innate geometrical
flexibility of the protein structure, we used rapid simulation methods [155] to access
flexibility and provide valuable information on protein function [156]. We performed
computational simulations to understand how L632I, could affect the PIP3 substrate
binding site within SHIP2. We used rigidity analysis using FIRST [157] and explored
flexible collective motions using FIRST/FRODA [158, 159] and El Nemo [160] software
in combination [155]. We found that a highly flexible and mobile beta-hairpin loop
(residues 674-683) exists above the substrate binding site and that this flexibility is likely
to affect the binding site geometry. This almost entirely solvent-exposed beta-hairpin
loop region appears to be structured only in a SHIP2 molecule that binds a synthetic lipid
head group surrogate as determined by X-ray crystallography. Molecular modelling and
dynamics studies suggested that this flexible loop might close over the ligand during
binding [154]. Normally L632 is part of a pair of short helices (628-634 and 614-626) that
are positioned above the main body of SHIP2 and L632 anchors the helices to I655 and
W688 on one side, while W673 links the helices to the hairpin loop on the other side.
The constraint network of hydrophobic tether interactions linking L632 through the two
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helices to the hairpin loop is shown in Figure 3.8A. The flexible motion of SHIP2
involves motion of the hairpin loop affecting the binding site and coordinated motion of
the hairpin loop and the two helices (Figure 3.8B). This suggests that this helical region
is a “governor” affecting the flexible dynamics of the hairpin loop and the binding site,
and therefore the L632I mutation affects the constraint network and disrupts the function
of the governor.

To determine the potential impact of T180A and L632I mutations upon catalytic
activity directly, we examined phosphatase activity toward PIP3 in in vitro phosphatase
assays (Figure 3.8C). Following site-directed mutagenesis to generate point mutations
that result in T180A and L632I, FLAG-tagged SHIP2 mutants were transfected in TIME
cells. The WT and mutant SHIP2 proteins were eluted following immunoprecitations
against FLAG antibody and the immunocomplexes subjected to Malachite green in vitro
phosphatase assay against recombinant PIP3. The phosphatase activity of T180A
SHIP2 was unaltered compared to WT SHIP2 in this assay. In contrast, the phosphatase
activity of L632I SHIP2 was increased relative to WT SHIP2. This experimental finding
correlates with the hypothesis suggested by our computational simulations: the
conversion of leucine to isoleucine results in a gain of enzymatic function due to
functional disruption of the helical (governor) region that ordinarily regulates the flexible
hairpin loop and substrate-binding site within SHIP2.
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Figure 3.8. Effect of T180A and L632I SHIP2 mutations on PIP3 catalysis. (A)
Constraint network of hydrophobic tethers indicating location of L632 anchoring I655 and
W688 on one side of the helices while W673 anchors the helices to the beta hairpin
loop. (B) Depiction of flexible modes involving collective motion linking helices, hairpin
loop and binding site of SHIP2 catalytic domain. (C) Malachite green in vitro
phosphatase assay indicates increased phosphate released by L632I SHIP2 suggesting
increased enzymatic activity against recombinant PIP3 substrate. (Collaborator
contributions: Dr. Stephen A. Wells and Prof. Barry V.L. Porter (University of Bath, U.K)
performed computational simulations and data interpretation of flexible motions shown in
Figure 3.8A-B).
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Figure 3.8. Effect of T180A and L632I SHIP2 mutations on PIP3 catalysis
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3.7: Effect of T180A and L632I SHIP2 mutations upon AKT and MAPK activation in
LECs.
We next examined whether T180A and L632I mutations affected the function of
SHIP2 in a cellular context. FLAG-tagged WT SHIP2 and SHIP2 mutants were stably
expressed in TIME cells. As revealed by Western blotting using a FLAG antibody, WT
and mutant SHIP2s were comparably expressed (Figure 3.9A). Consistent with its role
as a negative regulator of PI3K/AKT signaling, over-expression of WT SHIP2 in TIME
cells resulted in reduced HGF- and VEGFC–induced AKT activation compared to TIME
cells that were transfected with vector alone (Figure 3.9B). However, this inhibitory
effect of over-expressed WT SHIP2 upon HGF- and VEGFC–induced AKT activation
was completely abrogated by the T180A and L632I SHIP2 mutations. We also assessed
the effect of over-expressed WT and mutant SHIP2 upon ERK activation in TIME cells.
In agreement with results obtained in SHIP2 knockdown experiments (Figures 3.2 and
3.3), over-expression of WT SHIP2 resulted in reduced HGF- and VEGFC-induced
activation of ERK (Figure 3.9C). However, the T180A mutation abrogated the ability of
over-expressed wild type SHIP2 to inhibit ERK activation in response to both growth
factors. In contrast, the L632I SHIP2 mutation did not affect the ability of over-expressed
WT SHIP2 to inhibit ERK activation in response to HGF and partially inhibited its ability
to dampen ERK activation in response to VEGFC (Figure 3.9C).

3.8: Effect of T180A and L632I mutations upon SHIP2 interaction with cMET and
VEGFR3
To provide insight into how T180A and L632I mutations result in loss of SHIP2 to
inhibit AKT and ERK activation within LECs, we also examined the effect of mutations
upon physical interaction with cMET and VEGFR3. Since T180 is in close proximity to
the SHIP2 SH2 domain that is known to mediate interaction with cMET, we predicted a
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reduced interaction with this RTK. However, as determined in PLA assays, the T180A
mutation did not affect the ability of SHIP2 to bind cMET or VEGFR3 after stimulation of
cells with their respective growth factors (Figure 3.9D and E). In contrast, and somewhat
unexpectedly, the L632I mutation resulted in significantly reduced binding of SHIP2 to
both growth factor receptors after ligand stimulation (Figure 3.9D and E). Reduced
binding of L632I SHIP2 to these RTKs, therefore, could provide an explanation to the
apparent paradox that the L632I mutation results in increased PIP3 phosphatase activity
in vitro but loss of ability to inhibit AKT activation and partial loss of ability to inhibit ERK
activation in transfected LECs. Thus, increased phosphatase activity afforded by the
L632I mutation would be obviated by an impaired ability of SHIP2 to access PIP3
substrate at membrane locations.
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Figure 3.9. Effect of T180A and L632I SHIP2 mutations on signal transduction and
in interaction with cMET and VEGFR3. (A) Western blot analysis depicting expression
of SHIP2 and DYKDDDDK (FLAG) tag epitope in SHIP2 TIME transfectants. COX IV
used to determine equal protein loading. Activation of (B) AKT and (C) ERK was
determined by Western blotting of cell lysates with phosphospecific antibodies. Blots
were reprobed with total AKT and ERK antibodies to demonstrate equal loading. Initial
phosho- and total-antibody reprobes were detected with IRDye680 secondary
antibodies. Proximity ligation assay depicting decreased interaction of L632I-SHIP2 with
(D) cMET and with (E) VEGFR3. Data expressed as % of PLA signal in at least 5
images, presented as mean±SEM *p<0.05 **p<0.01. Blue = DAPI green = actin and red
= PLA fluorescence with each red dot depicting in situ interaction site. MW = molecular
weight marker. Scale bar = 50 µm.
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Figure 3.9. Effect of T180A and L632I SHIP2 mutations on signal transduction and
in interaction with cMET and VEGFR3
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3.9: Influence of T180A and L632I SHIP2 mutations upon LEC functional
responses.
We also examined the effect of T180A and L632I mutations upon LEC functional
responses. As shown previously, SHIP2 knockdown resulted in reduced LEC
proliferation, adhesion, directed migration, tube formation and survival (Figure 3.4 and
3.5). However, in comparison to vector controls, over-expressed WT SHIP2 did not
influence LEC proliferation, directed migration, tube formation or survival, although it did
result in increased LEC adhesion and increased chemotaxis in response to HGF (Figure
3.10). Increased chemotaxis to HGF and adhesion to collagen resulting from overexpression of SHIP2 was reduced by the T180A mutation, consistent with the loss of an
ability of T180A SHIP2 to inhibit activation of AKT and MAPK (Figures 3.9B, C). On the
other hand, the T180A mutation did not reduce the ability of over-expressed SHIP2 to
increase adhesion to fibronectin. L632I SHIP2 transfectants behaved differently from WT
SHIP2 and T180A SHIP2 transfectants in most regards. Thus, compared to WT SHIP2
LEC, L632I SHIP2 transfectants exhibited increased proliferation (Figure 3.10A),
directed migration (Figure 3.10B), tube formation (Figure 3.10D) and survival (Figure
3.10E). They also demonstrated increased chemotaxis to HGF and VEGFC (Figure
3.10C) and increased adhesion to collagen and fibronectin (Figure 3.10C) compared to
control cells, albeit the increases in adhesion were less than those observed in WT
SHIP2 transfectants.

Summarized in Table 3.1 are functional phenotypes of LECs upon SHIP2 siRNA
knockdown and mutant overexpression.
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Figure 3.10 Influence of T180A and L632I SHIP2 mutations upon LEC functional
responses. (A) MTS cell proliferation rate is increased in L632I-SHIP2. (B) WT-SHIP2
exhibits increased chemotaxis compared to Vector (HGF (p<0.05) while chemotaxis
towards VEGFC is N.S compared to Vector. T180A mutant has similar chemotaxis
towards VEGFC and slightly reduced, but not significant, chemotaxis towards HGF, both
compared to WT. L632I mutant has increased chemotaxis toward HGF (N.S) and
VEGFC (p<0.01), both compared to WT. Data are presented as % of area covered by
migrated cells on underside of transwell filters. (C) WT-SHIP2 exhibits increased
adhesion over Vector on BSA, collagen and fibronectin. Both T180A and L632I mutants
have decreased adhesion to collagen compared to WT. T180A mutant exhibits
increased adhesion to fibronectin compared to WT. L632I exhibits decreased adhesion
to BSA and similar adhesion to fibronectin compared to WT. (B) L632I mutant has
increased cell migration and (D) enhanced tube formation. (E) Decreased apoptosis in
L632I-SHIP2 transfectants as assessed by annexin v staining. All comparisons are
between Vector vs. WT; WT vs. T180A and WT vs. L632I. *p<0.05, **p<0.01, ***
p<0.001. Data presented as mean±SEM. Scale bar = 100µm. All experiments at least
N=3.
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Figure 3.10 Influence of T180A and L632I SHIP2 mutations upon LEC functional
responses
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Table 3.1 Summary of functional phenotypes of LEC upon RNAi and mutant expression of SHIP2

siRNA (HDLEC)

siRNA (TIME)

overexpressed
WT SHIP2
Similar to Vector

T180A SHIP2
(Family 1)
Similar to WT

Cell Proliferation

Reduced

Reduced

Cell Adhesion

Reduced

Reduced

Less than WT

Reduced

Increased over
Vector
Increased over
Vector
Increased over
Vector
Similar to Vector

Cell Migration (wound
healing)
Cell Migration (chemotaxis)

Reduced

Reduced

Reduced

Reduced

Tube Formation

Reduced

Apoptosis
Interaction with cMET

Increased
N/A

Increased
N/A

Similar to Vector
Interaction

Interaction with VEGFR3

N/A

N/A

Interaction

Effect on cellular PIP3
levels
Catalysis of recombinant
PIP3
Activation of AKT

Increased over
control
N/A

Increased over
control
N/A

Less than Vector

Similar to WT
Less than WT
(n.s)
Less than WT
(n.s)
Increased over
WT
Similar to WT

Increased activation
over control

Increased over
control

Activation of ERK1/2

Increased and more
sustained over
control

Increased and
more sustained
over control

Reduced
activation over
Vector
Reduced
activation over
Vector
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Catalysis

Less than WT
Less than WT
Less than WT

L632I SHIP2
(Family 2)
Increased over
WT
Increased over
WT
Increased over
WT
Increased over
WT
Increased over
WT
Less than WT
Less than WT
Less than WT

Increased over
WT

Increased over
WT
Increased over
WT
Increased over
WT

Increased over
WT

Increased over
WT

In summary, although the T180A mutation in SHIP2 was found not to affect PIP3
phosphatase activity in vitro (Figure 3.8C), this mutation results in a complete loss-offunction of SHIP2 with regards to activation of AKT and ERK in a cellular context
(Figures 3.9 and 3.10). In contrast, whereas the L632I mutation resulted in increased
PIP3 phosphatase activity in vitro (Figure 3.8C), in a cellular context, the L632I mutant
appears to behave as a partial loss-of-function SHIP2 that is unable to inhibit the
activation of AKT but retains at least some activity as a negative regulator of ERK
activation in HGF and VEGFC induced responses (Figures 3.9 and 3.10). Importantly,
AKT and ERK activation in T180A or L632I transfected cells was not greater than that
observed in vector control cells in response to either growth factor. This indicates that
neither mutants function in a dominant negative capacity to regulate the activation of
AKT and ERK in the respective growth factor induced signaling pathways.

3.10: Discussion
SHIP2 dephosphorylates PI(3,4,5)P3 at the 5’ position of the inositol ring and
thereby is a negative regulator of the PI3K/AKT signaling pathway. To verify this
important role for SHIP2 in lymphatics, we performed SHIP2 knockdown studies in
LECs. These studies confirmed that SHIP2 acts as a negative regulator of HGF- and
VEGFC-induced PI3K/AKT signaling in LECs and further showed an important role for
SHIP2 as a negative regulator of Ras-MAPK/ERK signaling in this cell type. SHIP2 has
the potential to negatively regulate Ras-MAPK/ERK signaling through either catalytic or
non-catalytic mechanisms.

Non-catalytic mechanisms by which SHIP2 may inhibit

MAPK activation are suggested by functional studies of SHIP1, which is homologous to
SHIP2. For example in B cells, SHIP1 negatively regulates MAPK through inhibition of
the binding of a Grb2/SOS Ras guanine nucleotide exchange factor complex to the Shc
adapter protein, which is an event that is necessary for Ras activation [161]. In addition,
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through physical interaction with the p62dok adapter protein, SHIP1 is thought to
promote recruitment of the Ras GTPase-activating protein to membranes that inactivates
Ras [162]. Additionally, over-expression of WT SHIP2 in the CHO cell line resulted in
increased insulin-induced SHIP2/Shc association, reduced Shc/Grb2 association and,
consequently, reduced MAPK activation, suggesting that SHIP2, like SHIP1, competes
with Grb2 for Shc [126]. However our preliminary studies show that these observations
do not extend to SHIP2 in LECs as SHIP2 does not seem to interfere with the Grb2/Shc
complex in LECs (Figure 3.11A). Nonetheless we cannot rule out the possibility that
SHIP2 could non-catalytically inhibit MAPK via the interaction of SHIP2 and protein
phosphatase 2A (PP2A), a serine/threonine phosphatase that dephosphorylates and
inactivates MEK1 and ERK-related kinases [163]. SHIP2 binds PP2A to inhibit epidermal
growth factor receptor (EGFR)-signaling [118]. It is of note that we have recently
identified a PP2A mutation in a separate family with lymphedema. Therefore, it remains
to be validated whether SHIP2/PP2A complex could inhibit MAPK/ERK signaling, or
even PI3K/AKT pathway for that matter given that PP2A can also inactivate AKT [164].
With regards to the catalytic regulation of MAPK by SHIP2, PIP3 could potentially lead to
membrane recruitment of pleckstrin homology (PH) domain-containing proteins, other
than AKT, that subsequently amplify growth factor induced activation of Ras, as reported
previously for antigen receptor signaling in lymphocytes [165]. To this end, our
preliminary results indicate that exogenous PIP3 is capable of activating MAPK in LECs
(Figure 3.11B). To determine the extent to which PI3K and PIP3 are required for HGFand VEGFC-induced MAPK activation in LECs, we further examined the effect of PI3K
inhibition in these two pathways.

PI3K inhibition substantially reduced but did not

completely block HGF- and VEGFC-induced activation of MAPK (Figure 3.11C). While
the exact mechanism needs to be further clarified in future studies, our initial finding is
consistent with the possibility that SHIP2 can use a PIP3-dependent catalytic
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mechanism, either directly or indirectly as a consequence of altered PI3K activity, to
negatively regulate MAPK in LECs.
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Figure 3.11. SHIP2 does not interfere with Shc/Grb2 complex in LEC and PIP3/PI3K
influences MAPK activation in LECs. (A) TIME cells were transfected with WT SHIP2
(overexp SHIP2) or empty vector for 48 hours, serum-starved for 16 hours followed by
HGF or VEGFC stimulation. Total lysates were harvested and subjected to Shc
immunoprecipitation using anti-Shc antibody pre-absorbed with agarose beads.
Immunocomplexes were probed for SHIP2, phosphoTyrosine (pTyr99), Grb2 and Shc
using standard fluorescent immunoblotting techniques. The amount of SHIP2 associated
with Shc was not increased over the amount of Grb2 associated with Shc. (B) Increasing
concentrations of recombinant PI(3,4,5)P3 was delivered into TIME cells using Shuttle
PIP kit (Echelon Biosciences) for 1 hour and cells subsequently lysed and subjected to
immunoblotting against pAKT and pERK1/2 antibodies. (C) PI3K inhibition reduces
HGF- and VEGFC-induced ERK activation in LECs. TIME cells were treated with
LY294002 (PI3K inhibitor) and U0126 (MEK inhibitor) prior to 5 min growth-factor
stimulation. Activation of ERK was determined by Western blotting of cell lysates with
double staining of pERK1/2 antibody (red signal) and total ERK1/2 antibody (green
signal) to demonstrate equal loading. MW = molecular weight marker. N=3.
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Figure 3.11. SHIP2 does not interfere with Shc/Grb2 complex in LEC and PIP3/PI3K
influences MAPK activation in LECs
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SHIP2 knockdown studies in LECs also showed that this phosphatase is
necessary for optimal HGF- and VEGFC-induced proliferation, adhesion, migration, and
tubulogenesis, which are all key processes in lymphangiogenesis. We also find that
SHIP2 is required for cytoskeletal reorganization in LEC for the optimal polymerization of
actin and in lammellipodia formation. As cytoskeletal reorganization is a foremost event
that ultimately affects all our examined phenotypes, it is likely that this scaffolding feature
of SHIP2 is the major contributing factor to the aberrant lymphangiogenic phenotype
exhibited by SHIP2-deficient LEC. Surprisingly, we also found that knockdown of SHIP2
in LECs results in increased apoptosis, despite that PI3K/AKT signaling is recognized to
promote cell survival. While the exact mechanisms responsible for this increased
apoptosis remain to be studied, it is of note that sustained MAPK signaling, itself a
mitogenic pathway, has paradoxically been shown to trigger cell death [166]. In this
regard, the increase in MAPK signaling in SHIP2 knockdown LECs was substantially
greater than the increase in PI3K/AKT signaling (Figure 3.2 and 3.3). Therefore, any
increased

survival

resulting

from

augmented

PI3K/AKT

signaling

may

be

counterbalanced and exceeded by increased apoptosis as a consequence of increased
MAPK signaling.

Mechanisms of ERK-mediated cell death include both intrinsic

apoptosis activation characterized by mitochondrial release of cytochrome c and
activation of caspase-9 and extrinsic apoptosis via activation of caspase-8 [166].
Potentially, increased apoptosis in SHIP2 knockdown cells could account for the
impairment in the other LEC functional parameters that were examined. To confirm this
hypothesis, future studies should evaluate the extent of apoptosis in SHIP2-deficient
LEC treated with MAPK inhibitors. On the other hand, increased MAPK activation in
other cell types has been shown to inhibit cell proliferation and migration directly [167,
168]. Accordingly, future studies are necessary to investigate whether these
mechanisms are at play in the LEC context.
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Of the two SHIP2 mutations that were identified in families, one (T180A) is
located carboxy terminal to the SH2 domain whereas the other (L632I) is located within
the catalytic domain. Molecular modeling studies predicted that the L632I mutation
would affect SHIP2 catalytic activity directed toward PIP3. In line with this prediction,
L632I SHIP2 showed increased phosphatase activity against PIP3 in vitro. Similar
predictions could not be made for the T180A mutation since at the time of this writing,
the entire three-dimensional crystal structure of SHIP2 has not yet been elucidated.
Nonetheless, T180A SHIP2 showed similar levels of PIP3 phosphatase activity as WT
SHIP2 in vitro. However, in transfected LECs, both of these mutations resulted in loss of
an ability of SHIP2 to function as a negative regulator of AKT and MAPK. In contrast to
WT SHIP2, T180A SHIP2 was completely unable to inhibit HGF- and VEGFC-induced
activation of AKT and MAPK. Similarly, L632I SHIP2 was unable to inhibit HGF- and
VEGFC-induced activation of AKT, although retained some activity as an inhibitor of
ERK activation, particularly in response to HGF stimulation. Thus, at least with regards
AKT and MAPK activation, T180A and L632I represent complete and partial loss-offunction SHIP2 mutations respectively. How the T180A mutation affects the inhibitory
function of SHIP2 specifically in vivo is unclear at present but does not appear to relate
to any impaired ability of SHIP2 to interact physically with cMET or VEGFR3. In contrast,
the L632I mutation inhibited an ability of SHIP2 to interact with both receptors.
Therefore, the partial loss-of-function of L632I SHIP2 can be explained on the basis of
impaired SHIP2 localization to PIP3 which resides at membranes. How SHIP2 binds to
VEGFR3 was not determined in this study, but interaction with cMET is known to be
mediated by the SHIP2-SH2 domain [107]. As such, it is unclear how the L632I
mutation, which is located in the catalytic domain, would affect this SH2 domainmediated interaction. By analogy with SHP2 protein tyrosine phosphatase (encoded by
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PTPN11), it is conceivable that L632 is involved in intermolecular interactions between
the catalytic domain and SH2 domain that regulate an ability of the latter to recognize
phosphotyrosine ligands [169, 170]. Further insight into how T180A and L632I mutations
impair SHIP2 activity is likely to come from determination of the crystal structure of the
full length SHIP2 protein. Additionally, while we cannot rule out what impact that
endogenous SHIP2 has in the WT- and mutant overexpressing cells, we used vectortransfectants as a control to account for any experimental differences given that a stable
SHIP2-null lymphatic cell line is not available.

Consistent with the finding that the magnitudes of AKT and MAPK activation in
T180A SHIP2 transfected LECs were comparable to that observed in vector alone
transfected LECs, functional responses of the two LEC types were similar. One
exception was adhesion of LECs to fibronectin that was increased in T180A-SHIP2
transfected LECs to a similar extent as that observed in WT SHIP2 transfected LECs.
This finding could indicate a role for SHIP2 in regulation of adhesion to fibronectin that is
independent of its ability to regulate the activation of AKT and MAPK. The functional
effects of L632I SHIP2 in LECs are more difficult to interpret. Thus, L632I SHIP2
transfected LECs showed increases in all examined LEC responses compared to control
LEC and WT SHIP2 LEC with the exception of adhesion. Therefore, although the L632I
mutation results in partial loss-of-function with respect to inactivation of AKT and MAPK,
with regards to most functional parameters it has the capacity to behave as a gain-offunction mutation. Alterations in the balance between the extent of AKT versus MAPK
activation observed in L632I SHIP2 transfected cells, compared to control and WT
SHIP2 transfected cells, may underlie this apparent gain-of-function. In addition,
unknown effects of the L632I mutation upon AKT- and MAPK-independent functions of
SHIP2 may be a contributing factor.
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Previous studies performed in epithelial cells have shown that SHIP2 binds HGFactivated cMET at Y1356 in the cMET cytoplasmic tail to effect cell scattering and
spreading [107]. Here we show that SHIP2 also interacts with cMET in LECs (Figure
3.7). In addition, we show for the first time that SHIP2 interacts with VEGFR3 in LECs.
cMET is known to couple to the PI3K signaling pathway through direct physical
interaction with PI3K [171]. Similarly, VEGFR3 has recently been shown to trigger the
PI3K pathway through physical interaction with PI3K [172]. Altogether, these studies
reveal strong similarities in the mechanisms by which cMET and VEGFR3 activate and
regulate the PI3K/AKT pathway. The finding that SHIP2 physically interacts with cMET
and VEGFR3 in LECs further substantiates the notion that this SHIP2 mutation
contributes to the lymphatic abnormalities in the studied families. Furthermore, a role for
SHIP2 in cMET and VEGFR3 signaling pathways could provide an explanation for the
occurrence of more serious disease in individuals with mutations in SHIP2 together with
mutations in one or the other of these RTKs. Similar to mutations in HGF and cMET
[63], it is still unclear why the SHIP2 mutations reported herein results in a lymphatic
phenotype, given the relative ubiquitous expression of SHIP2. One possible explanation
could be the rapid physiologic lymphatic responses to external triggers during
developmental and adult lymphangiogenesis [81]. Compared to the blood vasculature,
the lymphatic structure may better facilitate remodeling of capillaries, in which
lymphatics’ are thin-walled, lack tight junctions, and either lack or have incomplete
basement membranes [21]. Another explanation may be the compounding effect of
mutations in SHIP2, RTKs or their ligands, or in other components of PI3K/AKT and
MAPK/ERK pathways, leading to abnormal LEC signal transduction and subsequently to
lymphatic dysfunction.
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3.11: Significance
As part of a clinical study to associate non-syndromic lymphatic phenotypes
characterized by near-infrared fluorescence lymphatic imaging with genotypes found
from unbiased next generation sequencing, we have uncovered two rare mutations in
INPPL1. SHIP2 is a phosphatase that negatively regulates the PI3K/AKT signaling, a
pathway implicated in syndromic human diseases and animal models of lymphatic
dysfunction. With siRNA knockdown, we have shown that SHIP2 is required for the
proliferation, adhesion, cytoskeletal reorganization, migration, tubulogenesis, and
survival of human lymphatic endothelial cells (LECs), and regulates both PI3K/AKT and
MAPK/ERK phosphorylation following stimulation by HGF and VEGFC. When
overexpressed in immortalized LECs, mutant SHIP2 abrogated regulation of PI3K/AKT
and MAPK/ERK pathways, associated with receptors important in lymphatic signaling,
VEGFR3 and cMET, and resulted in impaired, migration, tubulogenesis, chemotaxis,
and adhesion.

These in vitro results contribute to growing evidence that balanced

regulation of PI3K/AKT and MAPK/ERK is required for the development and
maintenance of the lymphatic vasculature. However, further investigation into the role of
SHIP2 in lymphatic pathophysiology requires in vivo studies, which is the focus of
Chapter 4.
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CHAPTER 4
SHIP2 IS REQUIRED FOR NORMAL BLOOD AND LYMPHATIC
VASCULATURE FUNCTION IN MICE

This chapter is based on a manuscript that is currently under peer review, “Agollah G.D.,
Kwon, S., Robinson, H., Sevick-Muraca E.M., “Lymphatic and Vascular Responses to
Pharmacological Inhibition of SH2 domain-containing 5-inositol phosphatase-2 (SHIP2)”.
Germaine D. Agollah performed all experiments, unless otherwise noted in figure
legends.
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4.1: Rationale
Interruption of the lymphatic transport process caused by genetic defects,
physical trauma during surgery, or infection can result in accumulation and stagnation of
interstitial fluid and painful swelling leading to irresolvable edema known as
lymphedema, a disfiguring and incurable condition [173]. Lymphedema can also be
caused by excessive blood capillary filtration that (i) results from venous hypertension
due to occlusion or vascular anomaly and (ii) exceeds the transport capacity of
otherwise functional lymphatics. Thus it may not be surprising that tissue lymphedema
can be part of syndromic disorders wherein the function of the blood vasculature is
compromised, overwhelming the lymphatic system and giving rise to the aberrant
lymphatics.

Given that developmental biology shows that the lymphatic system

embryonically arises from the cardinal vein, it is also not surprising that the two vascular
systems may share key molecular regulators.
specific

molecular

regulators

of

With the identification of lymphatic-

lymphangiogenesis

and

embryonic

lymphatic

development, candidate gene studies have identified mutations in FLT4 (VEGFR3) and
VEGFC as well as other genes which interact with the vascular endothelial growth factor
receptor 3 (VEGFR3)/VEGFC

pathways in which they are associated, as being

responsible for hereditary lymphatic anomalies, including lymphedema (Table 1.3)
However, these putative genes that directly or indirectly involve VEGFR3 signaling are
not causative in the majority of patients with familial primary lymphedema (64%), and an
even higher percentage of those with sporadic lymphedema (92%), thus underscoring
the need for identification of other genes directly responsible for lymphatic dysfunction,
or contributing to edematous symptoms by mediating the permeability of the blood
vasculature [96].
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Recently, in an effort to associate lymphatic phenotypes with genetic causes, we
conducted investigational non-invasive near-infrared fluorescence lymphatic imaging
(NIRFLI) and unbiased gene search using whole exome sequencing (WES) on subjects
with non-syndromic, familial lymphedema. We identified rare mutations in the inositol
polyphosphate phosphatase-like 1 (INPPL1) gene that encodes src homology 2 domain
containing 5’-inositol phosphatase-2 (SHIP2) in nine subjects. Six of these subjects have
varied clinical diagnoses of lymphedema within a large extended family (Figure 2.4;
Table 2.2) while two have subclinical disease as determined from aberrant lymphatic
function detected from NIRFLI. A third subject with the SHIP2 mutation was not imaged
by NIRFLI, therefore their lymphatic phenotype remains unknown. Three of these
subjects exhibited varicose veins, two of whom had venous insufficiency showing visibly
enlarged veins and telangiectasia. When the SHIP2 mutation was combined with a
damaging mutation in hepatic growth factor (HGF), the ligand for the receptor tyrosine
kinase (RTK) cMET, or with a mutation of a gene encoding a protein within the
MAPK/ERK pathway (MAP3K7), family members suffered more severe clinical
diagnoses of lymphedema than those who possessed the SHIP2 mutation alone, while
no lymphatic abnormalities were associated with either the MAP3K7 or HGF mutation
alone, even though mutations in HGF and cMET have been identified as likely causative
for primary and secondary lymphedema in breast-cancer survivors [63]. In a second
family we identified another SHIP2 mutation which was associated with more
exaggerated forms of lymphedema resulting from mutations in FLT4 that encodes
VEGFR3 (Figure 2.2; Table 2.1). As discussed in Chapters 2 and 3, our clinical and
lymphatic endothelial cell (LEC) studies suggest that SHIP2 contributes to, but does not
necessarily cause, lymphedema.
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Herein we further investigate the role of SHIP2 in lymphatic (patho-) physiology
by employing AS1949490, the first discovered small molecule inhibitor of SHIP2 [174].
AS1949490 is a selective inhibitor of phosphatase function of SHIP2 that was recently
identified via high throughput screening. AS1949490 is a competitive inhibitor of both
mouse and human SHIP2, and was shown to increase phosphorylation of AKT, activate
glucose metabolism, suppress gluconeogenesis and improve diabetic-related symptoms
in db/db mice [174, 175].

4.2: Inhibition of SHIP2 via a small molecule inhibitor results in altered in vitro
lymphangiogenic responses.
By employing RNAi, in Chapter 3 we showed that SHIP2 is required for in vitro
lymphangiogenesis in LECs. With the ultimate goal of investigating whether SHIP2
functional inhibition also alters lymphatic responses in vitro, we used AS1949490, a
commercially available pharmacological inhibitor of SHIP2 [174, 175]. We therefore
investigated the effect of AS1949490 on AKT and MAPK activation in HDLECs, to
assess whether it had similar effects as we had previously observed with SHIP2-siRNA.
We observed a dose-dependent, but modest, activation of AKT and ERK in response to
HGF stimulation of HDLECs treated with AS1949490 for 1 hour (Figure 4.1A and 4.1B)
without affecting total SHIP2 protein levels. We next assessed the effect of AS1949490
on HDLEC functional responses. Treatment with AS1949490 for 24 hours resulted in
reduced cell migration as assessed by wound scratch assay (Figure 4.1C) and reduced
tube formation following 6 hours of drug treatment (Figure 4.1D). Taken together, our
data evidences that perturbation of SHIP2, whether through reduced expression via
siRNA (Figure 3.2-3.4) or functional inhibition via pharmacological inhibition of SHIP2,
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results in reduced in vitro HDLEC lymphangiogenic responses and altered PI3K/AKT
and MAPK ERK signaling in HDLEC.
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Figure 4.1. AS1949490 results in altered in vitro lymphangiogenic responses. (A)
AS1949490 results in a dose dependent modest activation of AKT and ERK1/2 in LECs
following 1 hour inhibition followed by 10min HGF stimulation, with no effect on SHIP2
protein levels. Activation of AKT and ERK was determined by fluorescent double staining
Western blotting of cell lysates with both phosphospecific antibodies and antibodies to
total proteins. Phosphoantibodies were detected by IRDye 680 (red signal) and total
antibodies detected by IRDye800 (green signal) fluorescent secondary antibodies. (B)
Quantification of AKT and ERK activation in LECs by mean fluorescence intensity (MFI)
and represented as a ratio of pAKT-S473 to total AKT and pERK1/2 to total ERK1/2,
respectively. (C) Wound scratch cell migration assay of AS1949490-treated LECs
immediately after injury and 24 hrs afterward. (D) 3D tube formation networks of
AS1949490-treated LECs imaged 6 hrs post plating and treatment. Data presented as
means±SEM. *p<0.05, **p<0.01, ***p<0.001. Scale bar = 100µm. N=3. MW=molecular
weight marker.

141

Figure 4.1. AS1949490 results in altered in vitro lymphangiogenic responses
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4.3: AS1949490 suppresses in vivo lymphatic contractile function.
To assess the effect of SHIP2 pharmacological inhibition on in vivo lymphatic
function, we orally administered (per os; p.o) AS1949490 in normal C57BL/6 mice twice
daily for 7 days at 300mg/kg. This chronic administration did not affect mice body weight,
and thus was well tolerated as reported previously [174]. To evaluate changes in
systemic lymphatic architecture and function in AS1949490-treated mice, non-invasive
near infrared fluorescence (NIRF) lymphatic imaging was performed after intradermal
(i.d.) injection of indocyanine green (ICG) in the base of tail (Figure 4.2A, arrow). ICG is
quickly taken up by the lymphatic plexus at the injection site, trafficked to the inguinal
lymph node (ILN; arrow head) and to the axillary lymph node (ALN; block arrow). Each
mouse was imaged twice to establish normal (baseline) lymphatic architecture and
function prior to drug treatment, at Day 3 and Day 7 p.o. Shown in Figure 4.2A are the
overlay of white light and ICG NIRF images of two representative mice over the
treatment period. We did not observe differences in in vivo lymphatic architectural
between the two groups during treatment with AS1949490. In order to assess lymphatic
contractile function, we selected three regions of interest (ROIs) along the fluorescent
collecting vessel between the ILN and ALN. Using ImageJ (NIH), the number of ICGladen lymph bolus contractions was counted between ~5-10 minutes post ICG injection,
and the frequency of lymphatic contractions/minute was determined. The average
propulsion frequency of two baseline imaging sessions in both control and AS1949490treated mice was ~6.3/min (Figure 4.2B). Treatment with AS1949490 resulted in
significantly reduced contractility to approximately ~3.5/min at day 3 p.o, which persisted
to day 7 (T Test analysis p=0.002 Control vs. P.O Day 3; p=0.014 Control vs. P.O Day
7). We also confirmed that the retardation in contractility was not as a result of altered
blood pressure. Furthermore, using Quansys cytokine array kit, we assessed whether
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cytokine expression was affected by AS1949490 treatment. Of the four cytokines
evaluated (interleukin -2 (IL-2), IL-4, IL-6 and tumor necrosis factor-alpha (TNF-α)), we
found significantly increased expression of IL-6 and TNF-α in the skin (Figure 4.2C), and
serum (Figure 4.2D), of AS1949490-treated mice. There were no differences in the
levels of IL-2 and IL-4 of the skin or serum in the two groups (Figure 4.2E-F).
Previously, it was found that certain cytokines, including IL-6 and TNF-α, mediate
lymphatic contractility in response to acute inflammation [176]; thus, our data suggests
that in response to AS1949490, lymphosuppressive cytokines such as IL-6 and TNF-α
are upregulated, possibly resulting in reduced lymphatic propulsion. We also assessed
activation of PI3K/AKT and MAPK/ERK pathways in homogenized skin of AS1949490treated mice and found increased levels of pERK1/2, pAKT, pGSK3β, among others,
indicating the activation of these pathways in response to SHIP2 inhibition which could
contribute to reduced lymphatic function (Figure 4.2G).
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Figure 4.2. Reduced in vivo lymphatic function following AS1949490 treatment. (A)
Overlay of white light and fluorescent (green) images following ICG injection at base of
tail (arrow) and trafficking to inguinal lymph node (ILN; arrowhead) onto the axillary LN
(ALN, block arrow). No significant differences were seen in lymphatic architecture
between control and AS1949490-treated mice over the treatment period. (B)
Significantly reduced in vivo lymphatic contractility at day 3 with AS1949490 treatment
which persists to day 7. N=4 Control, N=6 AS1949490. Data presented as means±SEM.
Upregulation of lymphosuppressive cytokines IL-6 and TNF-α in skin (C) and serum (D),
while no differences were observed in levels of IL-2 and IL-4 (E-F) in AS1949490-treated
mice compared to Controls. (G) Analysis of skin homogenates using PathScan
intracellular signaling array kit (Cell Signal) showing detection of 18 signaling molecules
either phosphorylated or cleaved. (B) *p<0.05, **p<0.01, ***p<0.001 vs Control baseline;
#p<0.05, ##p<0.01, ###p<0.001 vs. Control treatment at respective day; %p<0.05,
%%p<0.01, %%%p<0.001 vs. AS1949490 baseline. (C and D) *p<0.05, **p<0.01,
***p<0.001 vs. Control. (NIRF lymphatic imaging, as shown in Figure 4.2A, performed
with assistance from Dr. SunKuk Kwon).
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Figure 4.2. Reduced in vivo lymphatic function following AS1949490 treatment
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4.4: AS1949490 alters immune cell profiles in lymph nodes.
Given that AS1949490-treated mice had reduced lymphatic function, we next
sought to determine whether the cellular composition in lymph nodes was altered due to
AS1949490 treatment. Smaller lymph nodes were observed in AS1949490-treated mice
in comparison to vehicle control-treated mice (Figure 4.3A). We performed flow
cytometry on single cell suspensions harvested from axillary lymph nodes to analyze
relative percentages of various immune cells as a function of total cells. This analysis
revealed significantly reduced total leukocytes (CD45+) in mice treated with AS1949490
for 7 days, but no difference between control and 3-day treated mice (Figure 4.3B). This
trend

was

also

seen

in

percentages

of

B

cells

(CD45+CD19+),

T

helper

cells(CD45+CD4+), cytotoxic T cells (CD45+CD8+), macrophages (CD45+F4/80+), myeloid
cells (CD45+CD11b+) and presumed neutrophils (CD45+Ly6g/Gr1+CD11b+). Dendritic
cells (CD45+CD11c+) were also reduced in day 7-treated mice, but the difference was
not significant in comparison to either control or day 3. Interestingly, the frequency of
presumed T regulatory cells (CD45+CD4+CD25+) increased ~2-fold at day 3 compared to
control levels, but then significantly decreased ~3 fold below control mice levels. On the
other hand, the percentage of non-leukocytes (CD45-) was significantly increased in day
7 mice in comparison to both control and day 3 mice. In summary, while the effect of
AS1949490 on lymphatic function is evident by Day 3 (Figure 4.2B), immune cell profile
is not altered until 7 days on treatment, and is accompanied by a shift to increased nonleukocyte populations in lymph nodes.
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Figure 4.3 Altered immune cell profile in lymph nodes with prolonged AS1949490
treatment. (A) Smaller axillary LNs were observed in AS1949490 treated mice which
also showed altered immune cell profiles compared to vehicle control and Day 3 treated
mice (B). All data presented as means±SEM . *p<0.05, **p<0.01, ***p<0.001 vs Control;
#p<0.05, ##p<0.01, ###p<0.001 vs AS1949490 PO Day 3. Scale bar = 1mm.
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Figure 4.3. Altered immune cell profile in lymph nodes with prolonged AS1949490 treatment
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4.5: AS1949490 alters wound healing responses in normal mice.
Wound healing is a complex process which requires coordination of
angiogenesis, lymphangiogenesis, and inflammatory cell infiltration among other
mechanisms, for complete tissue repair [177]. Given the anti-lymphangiogenic in vitro
responses we observed following inhibition of SHIP2, we next investigated the effect of
SHIP2 drug inhibition on in vivo lymphangiogenesis. Ear punch biopsy wounds were
generated on normal C57BL/6 mice, and AS1949490 was administered twice daily for 7
days via oral gavage. Whole mount immunofluorescence staining for the lymphatic
endothelial marker, LYVE-1 and blood vessel marker CD31 (also known as PECAM1
and exhibits higher expression in blood vessels) were used to visualize vessels at the
wound edge on day 7 after wounding. Enlarged lymphatic vessels (arrow head)
accompanied by more robust lymphatic sprouting (arrows) were seen in control animals
(Figure 4.4A). In contrast, AS1949490-treated mice exhibited thinner lymphatic vessels
(arrow head) and reduced vessel sprouting (Figure 4.4B). In control mice, we observed
denser CD31-positive networks around the edge of the wound which appeared as
increased CD31 staining at lower magnification (asterix), likely around the granulation
tissue. Higher magnification images showed increased blood vessel density in control
mice as compared to AS1949490-treated mice (arrows). Image analysis of vessels
formed through lymphangiogenesis and angiogenesis carried out using AngioTool
software [178] showed that AS1949490-treated mice had decreased lymphatic and
blood vessel areas (Figure 4.4C and 4.4D, respectively) in comparison to control
animals. Assessment of non-wounded ears following AS1949490 treatment (Figure
4.5A-D) revealed a slight reduction (91495 vs. 93242µm2) in total lymphatic vessel area
of all analyzed animals, which was not statistically significant (Figure 4.5C) but
significantly reduced blood vessel area (Figure 4.5D) compared to control treatment.
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Figure 4.4. AS1949490 alters lymphangiogenic and angiogenic wound healing
responses in normal mice. (A, B) Whole mount staining of the wound edge (white
dashed line) on day 7 after wounding using lymphatic LYVE-1 (green) and blood vessel
CD31 (PECAM1; red) of control-treated (A) and AS1949490-treated (B) mice. Note
denser lymphatic networks with larger vessels (arrow head in LYVE1 inset panels and
lymphatic sprouting (arrows) in control mice compared to AS1949490-treated mice.
Denser blood vessels (asterix) and larger CD31+ vessels (arrows) in control mice
compared

to

AS1949490-treated

mice

(C,

D)

Graphical

representation

of

lymphangiogenesis and angiogenesis analysis. N=7 Control, N=9 AS1949490. Scale
bars = 400µm (top LYVE1 inset panel in A and B); 200µm (large double stained panels,
middle and bottom LYVE1 inset panels and top CD31 inset panels in A and B); 100µm
(middle CD31 inset panels in A and B); 50µm (middle and bottom CD31 inset panels in
A and B).
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Figure 4.4. AS1949490 alters lymphangiogenic and angiogenic wound healing
responses in normal mice
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Figure 4.5 Effect of AS1949490 on lymphatic and blood vessels in unwounded
ears. (A, B) Whole mount staining of contralateral (unwounded) ears on day 7 of
lymphatic LYVE-1 (green) and blood vessel PECAM1 (CD31; red) of control-treated (A)
and AS1949490-treated (B) mice. Difference in lymphatic vessel area is not significant
between the two groups (C) while there is reduced blood vessel networks in
AS1949490-treated mice (D) N=7 Control, N=9 AS1949490. *p<0.05, **p<0.01. Scale
bar = 200µm.
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Figure 4.5. Effect of AS1949490 on lymphatic and blood vessels in unwounded
ears
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The wounds were costained with F4/80 to assess infiltration of macrophages to
the wound bed (Figure 4.6). More macrophages were visualized in the wound edge in
control mice compared to AS1949490-treated mice. Some of the F4/80+ cells colocalized
with CD31+ (arrow head) and with LYVE+ vessels (arrows) in control animals (Figure
4.6A), suggesting that endothelial vessels release chemoattractants of macrophages to
the wound site. Quantification of macrophages in the wound edge shows a ~2-fold
increase in the number of F4/80+ cells in the wound edge in control animals compared to
AS1949490-treated animals (Figure 4.6C). As macrophages respond to VEGFC signals
and in turn themselves become a potent source of VEGFC thus inducing angiogenesis
and lymphangiogenesis [31, 179], it is likely that AS1949490 hinders the initial
production of lymph(angiogenic) growth factors such as VEGFC, leading to reduced
macrophage infiltration at the wound site. In this study, VEGFC was not directly
measured. In summary, chronic administration of AS1949490 significantly reduced
macrophage infiltration, as well as suboptimal lymphangiogenic and angiogenic
responses, all of which result in delayed wound healing in mice (Figure 4.6D).
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Figure 4.6. AS1949490 alters macrophage infiltration during wound healing. (A)
Increased F4/80+ macrophage infiltration at the wound edge of control animals, some of
which colocalize with blood vessels (arrow head) and lymphatic vessels (arrows)
compared to AS1949490-treated mice (B). (C) Macrophage cell counts in 400x images
confirm reduced infiltration in AS1949490-treated mice. N=3 Control, N=3 AS1949490.
(D) ImageJ analysis of area of wound at Day 7 shows smaller wounds in control-treated
mice compared to AS1949490-treated mice. *p<0.05, **p<0.01. Scale bars = 100 (large
panels in A, B) and 25µm (insets in A, B).
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Figure 4.6. AS1949490 alters macrophage infiltration during wound healing
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4.6: AS1949490 alters in vitro angiogenesis and MAPK activation in BEC.
Given the reduced angiogenic response in wound healing in AS1949490-treated
mice, we next assessed whether SHIP2 directly plays a functional role in blood
endothelial cells (BECs). We first confirmed the blood endothelial lineage of human
umbilical vein/vascular endothelium cells (HUVECs) by flow cytometric analysis of
lymphatic-expressing podoplanin and pan-endothelial CD31 antigen expression (Figure
4.7A). We found that SHIP2 was expressed in HUVECs, and transfection with SHIP2
siRNA resulted in effective knockdown as revealed by Western blotting (Figure 4.7B).
The ability of HUVECs to organize into tube-like structures was assessed using a 3DMatrigel angiogenesis assay. SHIP2 knockdown resulted in significantly less tube
formation compared to control HUVECs (Figure 4.7C, D). Activation of AKT in HUVEC
was examined by Western blotting using phospho-specific anti-AKT antibodies (Figure
4.8A). However, HGF-stimulation of control HUVECs showed no response in activation
of AKT up to 60 minutes, a result also seen in SHIP2-siRNA transfectants. These
results were also noted in response to VEGFA stimulation. We examined activation of
MAPK after SHIP2 knockdown in HUVECs using phospho-specific anti-ERK antibodies.
In control HUVECs, HGF induced activation of ERK, with peak responses occurring at
10 minutes, persisting to 15 minutes post-stimulation. In SHIP2 knockdown in HUVECs,
substantial increases in the magnitude of ERK activation were evident in response to
HGF and VEGFA, and similar kinetics were observed, but SHIP2-siRNA treatment
increased ERK activation (Figure 4.8A, C). We also examined whether AS1949490
impacted activation of AKT and MAPK activation in HUVECs, as we had observed with
HDLECs (Figure 4.8B). Similar to results seen with SHIP2-siRNA (Figure 4.8A), 1 hour
SHIP2 inhibition via AS1949490 did not affect AKT activation, yet it significantly
increased HGF-induced ERK activation in a dose-dependent manner. This effect was
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also observed following VEGFA stimulation (Figure 4.8B). Combined, our data suggests
that in HDLECs, SHIP2 exerts its influence via both the PI3K/AKT and MAPK/ERK
pathways; but only via the MAPK/ERK pathway in HUVECs.
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Figure 4.7 SHIP2 is necessary for in vitro angiogenesis in BECS. (A) Blood
endothelial lineage of HUVECs was confirmed using lymphatic-specific marker antihuman podoplanin (left panel) and pan-endothelial marker anti-human CD31 (right
panel). Markers are depicted in orange, isotype controls are in blue and unstained
controls in red. HUVECs are Podoplanin-CD31+. 50,000 events per experiment, N=3. (B)
Western blot analysis of SHIP2 in 3 independent transfections of SHIP2 siRNA in
HUVECs. Equal loading was determined by Western blotting for COX IV. (C) 3D tube
formation networks of SHIP2-siRNA HUVECs imaged 8 hrs post plating and
quantification of percent vessel area (D) shows reduced tubulogenesis in SHIP2 siRNA
transfectants. Cell viability confirmed with Calcein AM staining of tube networks. N=3.
MW=molecular weight marker. Scale bar = 100µm.
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Figure 4.7 SHIP2 is necessary for in vitro angiogenesis in BECs
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Figure 4.8 AS1949490 alters MAPK activation in BECs. (A) HUVECs were subjected
to 48hr SHIP2 siRNA and stimulated with HGF and VEGFA for the indicated times.
Activation of AKT and ERK was determined by fluorescent double staining Western
blotting of cell lysates with both phosphospecific antibodies and antibodies to total
proteins. Phospho-antibodies were detected by IRDye680 (red signal) and total
antibodies detected by IRDye800 (green signal) fluorescent secondary antibodies.
SHIP2 knockdown levels shown and COX IV used as loading control. (B) AS1949490
results in a dose dependent significant activation of ERK1/2 in HUVEC following 1 hour
inhibition and 10min HGF and VEGFA stimulations, with no effect on AKT activation or
SHIP2 protein levels. Quantification of ERK activation by mean fluorescence intensity
(MFI) and represented as a ratio of pERK1/2 to total ERK1/2 following HGF stimulations
of SHIP2 siRNA (C) and AS1949490 treatment (D). Data presented as means±SEM.
*p<0.05, **p<0.01, ***p<0.001. N=3. MW=molecular weight marker. N.S=not significant.
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Figure 4.8. AS1949490 alters MAPK activation in BECs
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4.7: Discussion
Currently, known lymphedema-causing genes explain only one third of all familial
primary lymphedema cases, thus WES techniques are necessary in identifying other
currently unknown genes that contribute to lymphedema [96]. As part of a clinical study
to associate non-syndromic lymphatic phenotypes characterized by NIRFLI with
genotypes found from unbiased NGS, we uncovered SHIP2 mutations in families with
lymphedema (Discussed in Chapter 2 and 3). In that study, in vitro analysis in LECs
showed that mutant SHIP2 abrogated regulation of PI3K/AKT and MAPK/ERK
pathways, resulted in impaired lymphangiogenesis, and SHIP2 associated with VEGFR3
and cMET, two RTKs important in lymphatic development and function. Enhanced ERK
activation was associated with LEC apoptosis, consistent with reports from Cagnol et al.
[166]. Herein, we further examine the potential effector role of SHIP2 in vascular function
in HDLECs and HUVECs using AS1949490, a small molecule inhibitor of SHIP2, and
RNAi transfections. In HDLEC, both AKT and ERK are activated in a dose-dependent
manner in response to growth factor stimulation following AS1949490 treatment, while
only ERK activation was observed in HUVECs (Figure 4.1 and 4.8.) In both HDLECs
and HUVECs, AS1949490 resulted in reduced cell migration and tubulogenesis,
consistent with dysregulated ERK activation which is likely due to apoptosis. These
observations are also extended to effects of SHIP2 siRNA. Interestingly, our finding that
neither HGF nor VEGFA induces AKT activation in HUVECs following SHIP2 knockdown
or pharmacological inhibition, suggests that AKT and ERK have differing functions in
LECs versus BECs, and that SHIP2 can exert its influence distinctly in either endothelial
cell type, further highlighting the complexity of SHIP2 function in different cellular
contexts (see Chapter 2, Section 2.4.3). Our results complement those by Tvorogov et
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al. who showed that VEGFC strongly induces both AKT and ERK activation in LECs, but
only ERK activation in BECs [180].
In this proof-of-concept study, we also showed that treatment with AS1949490
systemically suppressed in vivo lymphatic contractility as early as three days into
treatment, suggesting that SHIP2 inhibition has a significant impact on systemic
lymphatic function. While the exact mechanisms responsible for this AS1949490induced retarded lymphatic contractility are currently unknown, they are likely not due to
vessel dilation, as we observed no significant differences in in vivo lymphatic
architecture as assessed by NIRF imaging.

However, we assessed intracellular

signaling molecules in the skin and found increased expression of pERK1/2, pAKT,
pGSK3β, among others, indicating that AS1949490 also activates PI3K/AKT and
MAPK/ERK signaling in the skin (Figure 4.2E). Moreover, we observed upregulation of
lymphosuppressive cytokines in the skin and serum of AS1949490-treated mice.
Previously it has been shown that during lipopolysaccharide (LPS)-induced acute
inflammation, cytokines such as IL-1β, IL-6 and TNF-α are quickly upregulated within 4
hours, concurrent with stagnation of lymphatic flow. Additionally, local administrations of
these cytokines impede systemic lymphatic function in normal mice in an inducible nitric
oxide synthase (iNOS)-dependent manner [176]. These cytokines could directly impede
lymphatic contractility, or induce LECs, BECs, macrophages, or other stromal cells to
release additional factors that diminish lymphatic function. For example, a previous
study showed that in response to TNF-α and interferon-γ (IFN-γ), macrophages secrete
nitric oxide (NO), which induces mesenteric lymphatic vessel dilation and reduced
contractility [181, 182]. During normal conditions, NO produced by endothelial nitric
oxide synthase (eNOS) in LECs aids in maintenance of lymphatic contractility and NO
produced by iNOS during inflammation overrides the normal eNOS-regulation [183-185];
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thus, it is likely that increased levels of TNF-α lead to increased NO levels and reduced
lymphatic contractility in response to AS1949490. Catalytic inhibition of SHIP2 via
AS1949490 could also directly affect cytokine levels. Previous studies have shown that
SHIP2 and its homologue SHIP1, negatively regulate IgE + antigen-induced cytokine
production in mast cells, and specifically SHIP1 inhibits IL-6 and TNF-α by inhibiting
calcium influx and phosphorylation of ERK [186, 187]. It remains to be elucidated
whether similar mechanisms are at play in LECs and BECs following SHIP2 siRNA or
AS1949490 treatment. Additionally, given that the lymphatics play a key role in immune
response by providing a conduit for antigen presenting cells (APCs) and leukocyte
migration, it may be expected that reduced lymphatic function could result in altered
immune profiles in lymph nodes, and thus altered immune responses. Indeed, we found
a significant decrease in all leukocyte subpopulations in lymph nodes with prolonged
exposure to AS1949490. Our observations of no differences between control-treated
and day 3 AS1949490-treated animals suggests that sustained stagnation of lymph flow
may be required for altered immune cell profiles, and by day 7, the majority of cells in
peripheral lymph nodes are non-leukocytes, which are likely stromal cells. While our
studies ended seven days into treatment, these results raise the possibility of impaired
immune surveillance upon prolonged SHIP2 inhibition.
Wound repair requires a coordinated effort requiring inflammation, granulation
tissue formation, re-epithelization, angiogenesis and lymphangiogenesis [188]. During
wound healing, macrophages are initially recruited by VEGFC secretion, and in turn,
macrophages become the major source of growth factors, including VEGFC, that
accelerate tissue repair [189]. Exogenous administration to wounds has shown that
VEGFC enhances angiogenesis and lymphangiogenesis and accelerates wound healing
[177, 188, 190]. In response to AS1949490, we observed reduced lymphatic and blood
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vessel networks and macrophage infiltration to the wound bed. Given that SHIP2 is
expressed by LECs, BECs, and other cell types that would affect the wound healing
process, we cannot rule out the possibility that vascular changes we observe are directly
reflective of lymphatic and blood vessel function, instead of secondary consequences of
altered SHIP2 function in the different SHIP2-expressing cell types in the wound bed.
Additionally, future studies are needed to assess whether AS1949490 alters local
expression of VEGFR3 and cMET, and whether exogenous administration of HGF and
VEGFC can overcome impaired wound healing in AS1949490-treated animals.

Known for its inhibitory role against PI3K/AKT signaling, a pathway that is often
disordered in diabetes, SHIP2 has recently been investigated as a potential therapeutic
target in Type 2 diabetes via development of small molecule inhibitors [174, 191, 192].
Of the published studies, AS1949490 is the only small-molecule inhibitor showing in vivo
anti-diabetic effects [108, 174, 175]. However, wound healing is impaired in diabetes,
and therefore our studies may suggest that inhibiting SHIP2 could potentially worsen
diabetic wound healing. Strategies that stimulate lymph(angiogenesis) such as
exogenous administration of VEGFC as shown by Saaristo et al. might be more
beneficial in treating diabetic wounds [188]. Nevertheless, recent evidence suggests that
SHIP2 also has a proto-oncogenic role in cancer, and pan-SHIP1 and SHIP2 inhibitors
have been identified to have efficacy in killing multiple myeloma and SHIP2overexpressing breast cancer cells [193]. The most recent Ship2 genetic mouse model
mimics the effect of systemic AS1949490, whereby Ship2 is expressed but catalytically
inactive [123]. As there have been no reported NIRF-detected lymphatic defects in
SHIP2 mouse models [121-123], it remains unknown whether lymphatic phenotypes
would occur in response to inducible catalytic inactivation of Ship2 in LECs. It is of note
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that mouse knockouts of PTEN, which, similarly to SHIP2, is a negative regulator of
PI3K/AKT signaling, do not exhibit lymphatic phenotypes [194-197]. However, PTEN
has been implicated in human lymphatic malformations, specifically Proteus-like
syndrome, exhibiting medium penetrance and loss-of-function phenotypes [143].
4.8: Significance
SHIP2 is a negative regulator of the PI3K/AKT pathway that has been implicated
in syndromes involving lymphatic and blood vascular anomalies and more recently, in
familial cases of non-syndromic lymphedema.

We have shown that a selective,

competitive inhibitor of SHIP2, AS1949490, significantly inhibits tubulogenesis and cell
migration in both lymphatic and blood endothelial cell (LEC and BEC) assays, and
results in enhanced phosphorylation of both AKT and ERK in LECs stimulated by HGF
and VEGFC. In contrast, AS1949490 treatment of BECs has little or no impact on AKT
phosphorylation but a strong dose-dependent ERK phosphorylation when stimulated by
HGF and VEGFA as compared to control cells. These results may be consistent with
the differential AKT driven responses of LECs and BECs recently reported by others.
Furthermore, in animals with ear punch wounds that were administered vehicle as
control and AS1949490 at therapeutic doses used in other studies, we further
demonstrate that AS1949490 reduced in vivo lymphatic contractility assessed by
dynamic NIRF lymphatic imaging, increased levels of serum and skin IL-6 and TNF-α,
depressed the number of leukocytes in lymph nodes, and impaired wound repair
processes of angiogenesis and lymphangiogenesis. Because SHIP2 is investigated as
a therapeutic target against Type 2 diabetes in which patients are at risk for impaired
wound healing, further work is required to understand the role of SHIP2 in the processes
that mediate angiogenesis and lymphangiogenesis.
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CHAPTER 5
CLINICAL SIGNIFICANCE AND FUTURE DIRECTIONS
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While the main roles of the lymphatic circulatory system are to transport excess
fluids and protein from interstitial tissue to lymph nodes for immune surveillance and to
maintain hydrostatic fluid homeostasis, dysregulated lymphatics have been attributed to
diverse pathological conditions including lymphedema, inflammation, tumor metastasis,
and more recently to transplant rejection, cardiovascular disease and obesity [18, 22, 23,
29, 35, 38, 173, 198]. While the existence of the lymphatic system has been known
since the early 20th century, the discoveries of molecular regulators of lymphatic
development have only been identified within the last ~15 years. We are progressively
gaining knowledge of biological mechanisms that underlie aberrant and normal
lymphatic function, including associated genotypes and phenotypes. In this dissertation
project, we have shown that the unique combination of NIRF, an emerging fluorescence
lymphatic imaging modality, to accurately phenotype abnormal, yet asymptomatic
lymphatics, and unbiased NGS techniques, can lead to gene discovery of
polymorphisms that contribute to lymphatic disease.
Herein, in Section 5.1, we will summarize the major findings of this dissertation
and highlight the potential clinical impact that this multidisciplinary project will have on
the ever increasing population of cancer survivors, currently with lymphedema, or at risk
for developing this incurable and highly disfiguring disease. In Section 5.2, we will
discuss both short and long term research efforts that are necessary to address gaps in
this field that are essential to maximize patient benefit. Namely, development of more
stable and brighter dyes than ICG is necessary, which will aid in delineation of lymphatic
architecture, and thus improve diagnosis and phenotypic characterization of subjects
with lymphedema. Additionally, as discoveries of genes that contribute to lymphedema
continue to be made, the simplistic classification of lymphedema that has remained in
place for over 50 years that are based on age of onset rather than pathophysiology,
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need be revised accordingly. Efforts should also be made to treat underlying specific
pathology of lymphedema by development of molecular therapies.
Finally, in Section 5.3, we explore an emerging concept in lymphatic research:
the likely reciprocal relationship between lymphedema and obesity, and whether SHIP2
could bridge these two fields.
5.1: Summary and Significance
5.1.1: Summary
Specifically, in this dissertation the following were accomplished:
1. Using indocyanine green (ICG)-based investigational NIRF lymphatic imaging,
we non-invasively visualized lymphatic architecture and dynamic pumping
function in symptomatic and asymptomatic in human subjects in two families with
varied rare, primary and common, acquired (secondary) diagnoses of
lymphedema.
2. We conducted unbiased WES on the subjects’ collected DNA with the aim of
linking genotypes with the associated abnormal phenotypes. We discovered two
mutations in inositol polyphosphate phosphatase-like 1 (INPPL1) gene that
encodes src homology 2 domain-containing 5’-inositol phosphatase 2 (SHIP2).
We also identified mutations in HGF and VEGFR3, both of which are known to
affect lymphatic development and function. When SHIP2 mutations were
combined with mutations in HGF or VEGFR3, family members suffered more
severe forms of lymphedema, thus forming the basis of our hypothesis: SHIP2 is
a modulator of lymphatic function which could contribute to the varied
expressivity and penetrance seen in lymphatic disorders, including lymphedema.
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3. We investigated the functional role of SHIP2 in lymphatic biology and identified
that SHIP2 is expressed in LECs. Knockdown of SHIP2 using RNA interference
expectedly resulted in activation of PI3K/AKT signaling, a pathway that has been
implicated in lymphatic disease and that SHIP2 is known to inhibit via hydrolysis
of PIP3. Interestingly, we identify that SHIP2 also inhibits MAPK/ERK signaling, a
pathway that has recently been recognized in lymphatic malformations.
Phenotypically, we showed that knockdown of SHIP2 altered all major aspects
of in vitro lymphangiogenesis including LEC proliferation, adhesion, cytoskeletal
reorganization, migration, microtubule morphogenesis and LEC survival, thus
highlighting the importance of this enzymatic adaptor protein in optimal LEC
function.
4. Overexpression of the SHIP2 mutants identified in human subjects in
immortalized LECs revealed aberrant activation of PI3K/AKT and MAPK/ERK
pathways and altered in vitro lymphangiogenesis in LEC, with T180A exhibiting a
complete loss-of-function phenotype and L632I showing a partial loss-of-function
phenotype.
5. Finally, we find that pharmacological inhibition of SHIP2 using AS1949490, a
competitive small molecule inhibitor, resulted in similar loss-of-function in vitro
functional phenotypes and activation of PI3K/AKT and MAPK/ERK pathways
seen in RNAi and mutant SHIP2 LEC studies, further confirming the role of
SHIP2 in LEC biology. Chronic administration of AS1949490 in normal mice
resulted in suppressed in vivo lymphatic contractile function assessed by NIRFLI,
concurrent with upregulation of cytokines previously recognized to impede
lymphatic pumping. Prolonged treatment with AS1949490 also resulted in altered
immune cell profiles in lymph nodes suggesting that SHIP2 is necessary for
normal immunological responses. We find that the normal wound healing
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responses of angiogenesis; lymphangiogenesis and inflammatory cell infiltration
were altered in AS1949490-treated mice. Studies in blood endothelial cells
(BECs) also show that SHIP2 is required for in vitro angiogenesis and regulates
activation of MAPK/ERK, yet does not impact PI3K/AKT activation. In all, these
studies suggest that SHIP2 is intricately involved in blood and lymphatic function,
two circulatory systems that must cooperate in fluid homeostasis, thus could
explain how SHIP2 contributes to lymphatic disease seen in human subjects.
5.1.2 Significance: Improving Cancer Survivorship through NIRF and Gene
Discovery
In the Western world, secondary (or acquired) lymphedema (LE) following cancer
treatment is the most common type of lymphatic disease. While personalized medicine
strategies such as targeted molecular therapies are being developed, surgery and
radiation remain the major treatment options for cancer. Lymph node dissection (LND)
enables regional control of disease and staging to curtail metastases, as majority of
epithelial cancers develop metastatic growth via lymphatic vessels to the tumor draining
LN (TdLN) [198]. Unfortunately, while essential, LND damages and/or obstructs normal
lymphatic flow thus increasing the risk for LE. The exact prevalence of cancer-related
lymphedema (CRL) is unknown due to inconsistent diagnostic methods, which could be
improved by imaging techniques such as NIRFLI. A study estimated that 43%-94% of all
breast cancer survivors developed LE in the arm within 5 years post-surgery [199]. That
such a huge variation exists in estimating BCRL further highlights the lack of consensus
in diagnosing lymphedema. CRL is also prevalent in other cancers. 20% of cervical
cancer survivors; up to 64% of melanoma prostate and bladder cancer survivors and
50% of all head and neck cancer survivors will develop LE as a direct result of their
treatment [67, 200-205]. As of 2012, an estimated 3-5 million of the total 12 million
173

cancer survivors suffer from LE and more are at risk for the incurable disease [206, 207].
With increased cancer survivorship, the incidence of CRL is also expected to rise
accordingly. While primary lymphedema is a rare disease with an estimated incidence of
1/6000 [208], secondary lymphedema is becoming increasingly common given the rise
in cancer survivors. As diagnosis of primary LE is typically based on genetic causes and
no prior trauma or surgery, molecular understanding of the rare primary disease, could
enable our understanding of the more common secondary LE whose etiology is varied.
It remains unknown why some cancer survivors encounter lymphedema after
minimally invasive sentinel LND, while others who have more extensive LNDs and
radiation do not develop LE. Recent evidence suggests that an explanation for this CRL
disparity might be genetically based. We posit that both primary and secondary LE are
diagnoses within the same genetic spectrum, for example primary LE might be caused
by ablative mutations that completely alter genetic function of the encoded proteins,
while secondary LE may be predisposed by genetic variations that do not result in critical
loss of function (first hit) but upon surgery or trauma such as during LND (second hit)
there is onset of LE. Indeed, four clinical studies, summarized in Table 5.1, have thus
far identified various genetic mutations as potential susceptibility genes for breast cancer
related lymphedema (BCRL), lending credence to our hypothesis [63, 70, 209, 210].
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Table 5.1 Identified mutations that increase risk for breast cancer-related lymphedema (BCRL)
Study

Study population

LE Candidate Genes Analyzed

Finegold et al., 2008

Cases: 59 participants with BCRL; 21
participants with LE and intestinal
lymphangiectasia
Controls: 159 unrelated ethnically matched
subjects
Cases: 80 participants with BCRL
Controls: 108 BrCa survivors without LE
Cases: 22 participants who developed LE within
18 months of BrCa diagnosis
Controls: 98 BrCa survivors without LE
Cases: 155 participants with BCRL
Controls: 387 BrCa survivors without LE

VEGFR3, SOX18, FOXC2,
HGF, cMET

Finegold et al., 2012

VEGFR3, FOXC2, HGF, cMET,
GJC2
Newman et al., 2012
VEGFR3, SOX18, VEGFC,
VEGFD, VEGFR2, RORC,
FOXC2, LYVE1, ADM, PROX1
Miaskowski et al., 2013
ANGPT2, FOXC2, HGF, LCP2,
LYVE1, cMET, NRP2, PROX1,
RORC, SOX17, SYK, VCAM1,
VEGFB, VEGFC, VEGFD,
VEGFR2, VEGFR3
LE, Lymphedema; BCRL, Breast cancer related lymphedema; BrCa, breast cancer
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BCRL Susceptibility
Genes
HGF, cMET

GJC2 (Connexin 47)
VEGFR3, VEGFR2,
RORC
LCP2, NRP2, SYK,
VCAM1, FOXC2,
VEGFC

If there is indeed a genetic link between primary and secondary LE, as we
believe, phenotypic characterization using non-invasive NIRF imaging and genetic
techniques such as whole exome sequencing (WES), of cancer survivors and their
family members could provide a method for gene discovery. The identification of
lymphatic biomarkers could affect disease management, for example in a growing
cancer-survivorship population where an unmet clinical need with huge economical
potential and quality-of-life impact exists. For example, identification and biological
validation of a biomarker, such as SHIP2, as a potential therapeutic target to treat and/or
prevent CRL could ultimately influence cancer treatment in the following ways: (i) enable
phenotypic characterization of lymphatic architecture and function prior to start of cancer
treatment using NIRFLI; (ii) enable genetic screening of cancer patients to determine risk
of developing CRL based on their biomarker status; and (iii) ameliorate the risk of LE by
seeking alternate cancer treatment options for those patients who harbor a genetic
predisposition for the disease.
5.2: Future Directions
In the short term, we can address the disparity in lymphedema diagnosis by
improving the lymphatic imaging system; and reclassify lymphedema based on
phenotype-genotype associations by incorporating NIRFLI and WES techniques, rather
than age of onset. In the long term, molecular treatments should be developed that
target the underlying pathology of lymphedema rather than management of symptoms.
5.2.1: Improving NIRF lymphatic imaging
Currently, NIRF imaging makes use of ICG, a fluorescent dye that has been used
safely in humans for over 50 years in vascular and hepatic studies due to its dark green
color and ability to bind serum and albumin proteins in blood [211-214]. ICG is the only
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FDA-approved agent that can be used off-label as a NIR fluorophore used for
interrogating lymphatics. However, ICG has poor fluorescent properties including short
~20-hour half-life once reconstituted and low quantum yield, necessitating development
of brighter and stable NIR dyes. Owing to the poor stability and low quantum yield of
ICG, we have recently developed an enhanced NIR peptide dye, cyclic albumin-binding
domain peptide conjugated to IRDye800 (cABD-IRDye800). cABD-IRDye800 has high
affinity for albumin and has superior optical properties and lymphatic retention compared
to either ICG or IRDye800 alone. cABD-IRDye800 has a half-life of 20 days in solution
and has been found to be 5-fold brighter than ICG in in vivo preclinical studies [215].
Regulatory efforts are currently being made towards translating cABD-IRDye800 for
clinical use.
The use of fluorescent gene reporters in conjunction with ICG (or cABDIRDye800) NIRF imaging is another option in increasing the utility of fluorescent
lymphatic imaging. Gene reporter studies have traditionally involved expression of
shorter wavelength visible fluorescent reporters such as green fluorescent protein (GFP)
under control of lymphatic-specific markers such as Prox1 promoter [216]. A recent
study employed a dual fluorescence-luminescence reporter consisting of EGFP-LUC
under control of Vegfr3, whereby low resolution non-invasive bioluminescence was used
to longitudinally assess lymphatic responses and high resolution fluorescence
microscopy performed at animal endpoint [177]. To our end, we are currently making
use of far-red, longer wavelength fluorescent gene reporters in combination with near
infrared longitudinal lymphatic imaging. For example, in a recent study [217] (Appendix
page 207), we stably transfected infrared fluorescent protein (iRFP) gene reporter in
human inflammatory breast cancer (IBC) cell line (SUM149) which was then inoculated
in mice. Thus, a dual-wavelength analysis could assess tumor growth, progression and
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metastasis using the iRFP spectra (excitation 690nm; emission 710nm) and associated
lymphatic response using ICG spectra (excitation 785nm; emission 830nm). With
development of other far-red fluorescent reporters currently underway, such dual
imaging strategies will offer non-invasive methods to longitudinally monitor lymphatic
response to tumor growth and could be extended to other pre-clinical applications, such
as drug discovery.
5.2.2: Proposed classification of lymphedema based on phenotype-genotype
associations
Historically, primary lymphedema has been classified based on the age of onset
of disease. In 1934, Allen et al. introduced “lymphedema congenita” as primary
lymphedema present at birth and “lymphedema praecox” as disease that presents
shortly thereafter [218]. In 1957, Kinmoth et al. added “lymphedema en tarda” to the
original classification if disease onset is >35yrs [219]. These simplistic classifications of
primary lymphedema have since remained in place, and in 2010 Connell et al. proposed
an algorithm based on clinical phenotype that took into account patient age, affected
sites, and associated features, extent of lymphatic involvement and familial history
[220]. In 2013, these authors updated this algorithm to include causative genes that had
been discovered since 2010 and suggested genetic tests; a tool that has been useful in
clinical diagnosis [221]. However, if this classification scheme were applied to our
studies, subjects would be erroneously classified. For example Subjects #1, 4, 16 and
17 would be classified as having Meige disease with likely mutations in GJC2, which
they do not possess; while Subject #2 would be classified as having Milroy’s disease yet
she does not harbor VEGFR3 nor VEGFC mutations. Concurrent with the Connell 2013
study, Mendola et al. also proposed a scheme for genetic analysis of lymphedema [96].
With the accumulating evidence of a possible genetic link between primary and
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secondary lymphedema, we build on both of these 2013 classification schemes and
propose (i) the addition of accurate phenotyping such as that afforded by NIRF lymphatic
imaging, (ii) inclusion of secondary lymphedema, both CRL and non-CRL such as filaria,
(iii) whole exome analysis and subsequent pathway analysis to help identify potentially
causative, yet currently unknown genes and finally, (iv) biological validation of potential
genetic variants as we have attempted with SHIP2 in this dissertation project. This
proposed classification scheme is shown in Figure 5.1. While we propose the use of
WES, it is likely that as NGS techniques become more affordable, other analyses such
as whole genome sequencing (WGS) that interrogate the entire genome including the
protein-encoding exome and non-encoding intronic regions; and copy number variation
(CNV) analysis that assesses regions that are deleted or amplified within chromosomes
could be performed, which could potentially identify whether epigenetic and somatic
changes have a role in lymphedema.
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Figure 5.1 Proposed scheme for the phenotypic and genotypic analysis of
lymphedema patients.
Adapted and modified from:
Mendola, A., Schlogel, M.J., Ghalamkarpour, A., Irrthum, A., Nguyen, H.L., Fastre, E.,
Bygum, A., van der Vleuten, C., Fagerberg, C., Baselga, E., Quere, I., Mulliken, J.B.,
Boon, L.M., Brouillard, P., and Vikkula, M., Mutations in the VEGFR3 signaling pathway
explain 36% of familial lymphedema. Mol Syndromol, 2013. 4(6): p. 257-66. [96].
Connell, F.C., Gordon, K., Brice, G., Keeley, V., Jeffery, S., Mortimer, P.S., Mansour, S.,
and Ostergaard, P., The classification and diagnostic algorithm for primary lymphatic
dysplasia: an update from 2010 to include molecular findings. Clin Genet, 2013. 84(4): p.
303-14. [221].

180

Figure 5.1 Proposed scheme for the phenotypic and genotypic analysis of lymphedema patients
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5.2.3: Treating Lymphedema: Beyond Manual Lymphatic Drainage (MLD)
Developed in the 1930’s by Dr. Vodder, MLD therapeutic massage techniques
still remain the standard of care for lymphedema treatment [222]. As discussed in
Chapter 1, there are neither pharmacological treatments nor preventive strategies for
lymphedema, and none of the current techniques reverse the underlying lymphatic
pathophysiology of the disease. The basis of the MLD technique is two-fold: stimulation
of lymphatic drainage from the receiving lymph node basins and subsequent stimulation
of contractility of the superficial lymphatic vessels, with treatment outcomes measured
through reduction of limb volume, often with varying success rates [223]. Additionally,
patients are required to wear compression garments, which unfortunately are frequently
uncomfortable and fraught with non-compliance. As a result, while incidence of
lymphedema is rising and now among the most reimbursed therapeutic service by US
Centers for Medicare and Medicaid Services (CMS), medical coverage is threatened as
CMS recently reported that no study has demonstrated direct evidence of benefit of
lymphedema MLD treatment (or lymphedema diagnosis using the current clinical “goldstandard” imaging technique of lymphoscintigraphy for that matter) [224]. Thus negative
coverage decisions could impact the availability of the only clinically accepted treatment
for lymphedema patients, including the growing number of cancer survivors [224].
Nonetheless, the recent identification of molecular regulators of lymphatic development
and function provides an exciting new frontier for development of targeted,
pharmacological therapies for lymphedema.
Lymphangiogenic growth factor therapy is the most promising molecular strategy
in treating damaged or insufficient lymphatic vessels. Stimulation of VEGFR3 using
VEGFC results in growth and survival of LECs and lymphangiogenesis. In mice, VEGFC
therapy has been shown to result in lymphatic capillary growth, remodeling,
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differentiation and maturation into functional vessels [225]. Various preclinical studies of
primary and secondary lymphedema have shown effective reduction in lymphedema
symptoms through VEGFC delivery either through adenoviruses, adeno-associated
viruses, naked plasmids or recombinant protein soluble VEGFC to Chy (Vegfr3 mutant)
mice, rabbits and sheep [24, 226, 227]; (Appendix page 210). Other studies have
included lymph node (LN) transplantation in conjunction with VEGFC therapy resulting in
formation of afferent and efferent vessels around transferred LNs and their connection to
pre-existing lymphatic networks, restoring lymphatic function [225, 228-230]. Ideally,
treating human lymphedema will require long term delivery of VEGFC such as that
afforded by adenoviral transfer, with or without LN transplantation, and following initial,
active lymphangiogenesis, newly formed vessels would mature, with pericytes and
intraluminal valves (Figure 5.2). This treatment strategy could be longitudinally
monitored using NIRF lymphatic imaging.
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Figure 5.2. VEGFC-induced regeneration of lymphatic vessels for treatment of
lymphedema. Lymphedema develops following lymphatic injury such as during cancer
treatment, surgery or infection. Adenoviral VEGFC with or without lymph node (LN)
transfer at diseased site could be used. VEGFC expression increases with maximum
levels at approximately two to three weeks. Following initial capillary sprouting and
lymphangiogenesis, vessels mature, with smooth muscle cells (SMC; pericytes)
development and formation of intraluminal valves, as levels of VEGFC reduce over time.
NIRF lymphatic imaging can be used to noninvasively monitor effectiveness of treatment
as newly-formed vessels become functional.
Modified and reproduced with permission from Zheng, W., Aspelund, A., and Alitalo, K.,
Lymphangiogenic factors, mechanisms, and applications. J Clin Invest, 2014. 124(3): p.
878-87 [231].
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Figure 5.2. VEGFC-induced regeneration of lymphatic vessels for treatment of lymphedema
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However, additional considerations should be made for cancer patients and
cancer-related lymphedema. As most epithelial tumors metastasize via lymphatic
vessels and produce lymphangiogenic growth factors which stimulate vessel growth to
provide new routes for tumor progression, current cancer therapies are targeting tumorinduced lymphangiogenesis. Strategies of inhibiting VEGFR3 signaling include trapping
VEGFC using soluble VEGFR3 (sVEGFR3), blocking ligand-receptor binding, inhibiting
receptor dimerization using blocking antibodies or inhibiting the VEGFR3 tyrosine kinase
activity, all of which have shown success in various tumor models in suppressing
lymphangiogenesis [231]. Additionally, with activation of PI3K/AKT and MAPK/ERK
pathways seen in many tumors, inhibitors of these pathways are successfully being used
to suppress tumor growth. It remains to be seen whether these inhibitors have long-term
anti-lymphangiogenic side effects which could ultimately result in lymphedema.
Nonetheless, periorbital edema (lymphedema of the eye) is a common side effect to
STI571 (imatinib mesylate), a selective inhibitor of the bcr-abl, c-KIT and platelet-derived
growth factor receptor (PDGFR) kinases used in treating chronic myelogenous leukemia
(CML)

and

gastrointestinal

stromal

tumors

(GIST)

[232,

233].

Given

that

lymphangiogenesis is usually active during development and decreases to low levels
during adulthood unless reactivated during pathological conditions such as cancer,
wound repair and inflammation, it is likely that in some patients anti-lymphangiogenic
strategies would be initially used to control tumor growth and metastasis and if they
develop lymphedema, pro-lymphangiogenic treatment such as that outlined in Figure
5.2, could be initiated during remission to treat secondary lymphedema. Additionally, if
warranted by more studies, cytokine treatments such as anti-IL6 and anti-TNF-α can
also be employed to offset lymphedema symptoms as a prophylactic therapy.
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5.3: Lymphedema and Obesity: is SHIP2 the missing link?
An emerging concept in lymphatic research is whether a link exists between
lymphedema and obesity. As lymphedema progresses, increased interstitial fluid
accumulation leads to tissue fibrosis, unresolved inflammation and adipose tissue
deposition. Clinical studies have shown that obesity increases the risk of secondary
lymphedema following lymphatic damage [234]. Specifically, the 5-year incidence of
lymphedema in breast cancer survivors with body mass index (BMI) >29 is 36%, in
comparison to 12% risk of lymphedema in women with lower BMI. On the other hand,
obesity increases the risk of lymphedema even without a preceding lymphatic injury,
suggesting that obesity and lymphedema have a reciprocal relationship. Defects in
lymphatic vasculature have been shown to promote obesity. Mice with heterozygous
deletions in Prox1, the master regulator of lymphatic fate, have defective lymphatic
vessel integrity causing fluid leakage and accumulation in the interstitial space, where
lymph stimulates differentiation and growth of adipose cell precursors resulting in adult
onset obesity [235]. Additionally, patients with Dercum’s Disease, a rare adipose
disorder suspected to be a lymphovascular disease and characterized by painful
subcutaneous adipose tissue depositions, have dilated, sluggish, and tortuous
lymphatics [236]. Given that the lymphatics play a major role in lipid absorption and
cholesterol transport from peripheral tissues to blood vasculature via intestinal lymphatic
vessels known as lacteals (Figure 0.1), aberrant lymphatics leads to accumulation of
cholesterol and obesity-related diseases [23].
As discussed in Chapter 2, genetically modified Ship2 mice exhibit defective lipid
metabolism, with Ship2 knockout mice being resistant to weight gain while conversely,
transgenic mice, that overexpress Ship2 gain weight; and SHIP2 has also been
implicated in human metabolic syndrome, which is characterized by Type 2 diabetes,
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hypertension, obesity, and insulin resistance [108, 125]. While a direct mechanism
linking obesity and lymphedema has not been identified, SHIP2 could provide some
insight. Hypercholesterolemia, the increase in low-density lipoproteins (LDL), commonly
known as “bad cholesterol” is a major risk factor for obesity and cardiovascular disease
(CVD). Mice deficient in the LDL apolipoprotein E (apoE-/-), exhibit defective and leaky
lymphatic vessels [26]. A previous study by DeKroon et al. revealed a novel mechanism
by which apoE4 inhibits high density lipoprotein (HDL; “good cholesterol”)-induced AKT
activation by specifically recruiting and activating SHIP2 to inhibit PI3K/AKT signaling in
endothelial cells, thus increasing risk for obesity and CVD [138]. Additionally, SHIP2
mutations have been recently identified in a rare disorder, opsismodysplasia, in which
some subjects are reported pictorially to have distended abdomens at a young age,
(which is consistent with chylous ascites) and other features suggestive of edema in
lower extremities, although there are no reports in literature that they have chylous
ascites or lymphedema. However, while the lymphatics of these rare subjects have not
been evaluated, Type 2 diabetes patients exhibit increased dermal lymphatic vessels
[25].

Therefore, our research showing SHIP2 having a previously unknown role in

lymphatic dysfunction, could encourage clinical investigators to evaluate whether a
dysfunctional lymphatic component is present in the rare disease of opsismodysplasia.
Finally, as mentioned previously, SHIP2 is overexpressed in breast cancer, worsening
patient prognosis and survival, and obesity is a known risk factor for breast cancer.
Therefore it remains to be studied whether a direct correlation exists between SHIP2
overexpression, obesity, breast cancer incidence and prognosis and breast cancerrelated lymphedema. Future studies will be necessary to explore this potential reciprocal
link between lymphedema and obesity, and whether SHIP2 plays an effector role.
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5.4: Conclusions.
Knowledge of the molecular regulation of the lymphatic system has exponentially
grown in the last 15 years. During this period, gene modifiers of lymphatic function,
lymphatic developmental events during embryogenesis, and lymphatic structural
hierarchy have been identified. We anticipate that the next wave of lymphatic knowledge
will be expanded by techniques such as (i) WES that will help identify new genetic
modifiers of dysfunction, and sensitive imaging modalities such as (ii) NIRFLI that will be
improved to allow for high resolution visualization of lymphatic architecture and function
in real time. This new era of the lymphatic research has challenged the classic view that
the lymphatics are merely passive conduits for fluid and immune cell trafficking, but
actually an active circulatory system that modulates nearly all areas of human disease:
inflammation, autoimmune disease, tumor immune response, transplant rejection,
obesity and cardiovascular disease all have a lymphatic component. Finally, we are
hopeful that by promoting understanding of the genetic basis of lymphatic failure, as we
have aimed to do in this dissertation, we will develop new pharmacological therapies that
address the underlying pathological causes of lymphatic dysfunction and design
strategies that stimulate lymphatic flow, as is necessary in lymphedema and in persons
at risk for lymphedema.
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CHAPTER 6
MATERIALS and METHODS

Portions of this chapter are based on:
“Agollah G.D., Gonzalez-Garay M.L, , Rasmussen JC., Tan I-C., Aldrich M.B., Darne C.,
Fife C.E., Guilliod R., Maus, E.A., King P.D., Sevick-Muraca E.M., “Evidence for SH2
domain-containing 5-inositol phosphatase-2 (SHIP2) contributing to a lymphatic
dysfunction” PLoS ONE (2014) 9(11): e112548. doi:10.1371/journal.pone.0112548 [98].
PLOS applies Creative Commons Attribution License (CCAL) and Open-Access
License, wherein no permission is required from authors or publishers for reprints or
reproduction of published works, except proper citation of original work.
This chapter is also based on a manuscript that is currently under peer review, “Agollah
G.D., Kwon, S., Robinson, H., Sevick-Muraca E.M., “Lymphatic and Vascular
Responses

to

Pharmacological

Inhibition

phosphatase-2 (SHIP2)”.
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of

SH2

domain-containing

5-inositol

Human Lymphatic Imaging. The lymphatic phenotype of each subject was determined
using near-infrared fluorescence lymphatic imaging (NIRFLI). As part of an ongoing,
IRB and FDA-approved study of lymphatic disorders conducted under Food and Drug
Administration IND# 102,827 clinical study and funded by the National Heart Lung and
Blood Institute of the National Institutes of Health (Clinical Trials No. NCT00833599:
“Imaging lymphatic function in normal subjects and in persons with lymphatic disorders,”
www.clinical trials.gov), human subjects were imaged following intradermal injection of
indocyanine green (ICG).

All clinical investigation was conducted according to

Declaration of Helsinki principles. Written informed consent was obtained from all
participants prior to NIRFL imaging.
Each subject received a total of 12 intradermal injections of 25 µg of ICG in 0.1
mL saline, with a total dose of 300 µg, for uptake into the peripheral lymphatics.
Injection sites were consistent between subjects and each limb received two injections
on the dorsum of the foot, one injection on the medial ankle, one injection each on the
lateral and medial calf, and one injection on the anterior thigh (see Figure 2.1A).
Immediately following ICG administration and as described previously [99] each leg,
starting at the foot and working upward, was illuminated by the diffuse output of a 785nm
laser diode, and images of the resultant fluorescent signal emanating from the peripheral
lymphatics were optically filtered and acquired using a custom intensified charge
coupled device (ICCD) camera. Exposure times of 200ms permitted the acquisition of
movies of lymphatic contractile function.

Vital signs were measured for two hours

following injection, and a follow-up phone call was made at 24 hours.

Blood was

obtained from each subject and whole exome sequencing (WES) performed.

No

adverse events were reported. Images were analyzed to assess lymphatic uptake at the
injection site and the presence of abnormal lymphatic architecture such as dense
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networks of lymphatic capillaries with extravascular fluorescence frequently known as
dermal backflow, lymphatic capillaries radiating from the intradermal injection sites, as
well as tortuous and/or dilated lymphatics. The brightness and contrast levels of the
NIRFLI images presented herein were adjusted to increase the overall dynamic range
observable in the image (i.e. to enable the visualization of both the dim and the bright
signals within the lymphatics). The NIRF images are presented in pseudo-color.

Whole Exome Sequencing (WES). DNA was extracted from either blood using
Paxgene Blood DNA Kit (PreAnalytix, Switzerland) or saliva using Promega’s wizard
genomic DNA purification kit according to both vendors’ instructions. At least 2μg of
genomic DNA were submitted to Axeq Technologies for human exome capture
sequencing using TrueSeq 62-Mb target enrichment (Illumina, San Diego, CA).
Approximately 63,000,000 reads of an average size of 107 bp per sample was returned
to us as two fastq files (one file per orientation).

Genetic Sequencing Analysis. Each pair of fastq files was aligned to human genome
(hg19) using Novoalign (Novocraft Technologies; www.novocraft.com), keeping
parameters at the default settings, as recommended by Novocraft Technologies.
Novoalign, SAMtools (http://samtools.sourceforge.net) was used to sort the SAM files,
create

BAM

files,

and

generate

their

index

files.

Picard

(SourceForge;

http://picard.sourceforge.net ) was used to remove all of the PCR duplicates from the
BAM files. For local realignments, base quality recalibration, and variant calling, we
used Genome Analysis Toolkit (GATK) Version 2.2. Finally, for variant annotation, we
used SnpEff (http://snpeff.sourceforge.net/), variant tools and ANNOVAR using multiple
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databases from UCSC Genome bioinformatics. Functional effects of each nonsynonymous coding variant were evaluated using three different functional prediction
algorithms: (1) Polyphen 2.0 Prediction of functional effects of human nsSNPs
(http://genetics.bwh.harvard.edu/pph2),
(www.mutationtaster.org)

using

the

(2)
dbNSFP

SIFT

and

database.

(3)
Filtration

MutationTaster
of

common

polymorphisms was accomplished using frequencies from the NHLBI Exome sequencing
project (ESP) (http://evs.gs.washington.edu/EVS) 1,000 Genomes Project (VCF Version
4;

www.1000genomes.org/wiki/Analysis/Variant%20Call%20Format/vcf-variant-call-

format-version-41 )

Validation of Exome Sequencing Variants through Sanger Sequencing. Primers
were designed using Oligo 7 and Primer3 softwares for exome sequencing variants that
were considered potentially relevant to the lymphedema phenotype. Polymerase chain
reactions (PCRs) were performed using the Kapa HiFi HotStart ReadyMix DNA
Polymerase (KapaBiosystems #KK2602) as per manufacturer’s instruction. To visualize
DNA fragments, 5μL of the PCR product was loaded on a 1% agarose gel (or Lonza
1.2% agarose Flash Gel); ethidium bromide was used for the staining. Purification of the
DNA was done utilizing Qiagen Gel Extraction Kit (#28706) following manufacturer's
instruction.

Purified PCR products were sequenced at the University of Texas MD

Anderson genetic sequencing facility using a 3730XL DNAnalyzer (AppliedBiosystems,
Foster City, California, USA). The following primers were used to validate mutations in
INPPL1 (Protein ID O15357); HGF (Protein ID P14210) and FLT4 (Protein ID P35916):
Gene
INPPL1
INPPL1

Mutation
p.T180A
p.L632I

Forward (5’3’)
GAGGCCTTCTAAGACCCCAC
TACCGCCTGGACATGGATATCCAGG

HGF

p.G315V

TGATCAGAAATCCACCTAGGGAT

193

Reverse (5’3’)
GGTGTAATACATGGGGCTGG
TGCCAGGCATATGTGTCCCG
G
ACATGTGGAGGTAAAATGCAT

FLT4
FLT4

p.D481EQ
p.H890Q

CTTGCAGAACTCCACGATCA
TGCATGTCAGCTTCCTTGTC

TTAA
TACAGCTCACCTGCAACTGG
GGAGTTCGAGACCAGCTGAC

Animals. Sixteen female C57BL/6 mice (Charles River, Wilmington, MA), aged 6-8
weeks, were utilized in this study. Mice were housed and handled in compliance with
the Association for Assessment and Accreditation of Laboratory Animal Care and
protocols approved by The University of Texas Health Science Center at Houston
Animal Welfare Committee (UTHSC-H AWC). 2-mm circular penetrating punch biopsy
wounds were made in the left ear of all mice.
300mg/kg

of

AS1949490

A cohort of mice (N=9) was given

(3-[(4-chlorobenzyl)oxy]-N-[(1S)-1-phenylethyl]-2-

thiophenecarboxamide; R&D/Tocris Biosiences) suspended in 0.5% methylcellulose
(Sigma Aldrich) twice daily by oral gavage.

Seven control mice received 0.5%

methylcellulose. Mice were sacrificed on either Day 3 or Day 7 p.o.
In vivo functional NIRF lymphatic imaging Mice were imaged twice for baseline
assessment prior to beginning AS1949490 treatment (See treatment scheme
Supplementary Fig 1A). Mice were anesthetized with isoflurane and maintained at
37°C on a warming pad. A volume of 10μl of 645μΜ of ICG (Akorn, Inc.) dissolved in
mixture of distilled water and 0.9 % sodium chloride in a volume ratio of 1:9 was injected
intradermally at the base of the tail using 31 gauge needles (BD Ultra-FineTM II Short
Needle, Becton and Dickinson Medical). Fluorescence images were acquired
immediately before and for up to 20 min after i.d. injection using a custom-built NIRF
imaging system as described previously [88].

Lymphatic function analysis. The data was analyzed with ImageJ (National Institutes
of Health). To reveal contractile activity resulting in propulsive lymph flow, the same size
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of fixed regions of interest (ROIs) in fluorescent lymphatic vessels was defined on
fluorescence images. The averaged fluorescence intensity within each ROI in each
fluorescence image was plotted as a function of imaging time. The number of “pulses”
of ICG-laden lymph is an indication of lymphatic contractile activity and termed as
“contractions.”

Cell Culture. Primary human dermal lymphatic endothelial cells (HDLEC) were obtained
from Science Cell (Carlsbad, CA) at passage 2 and cultured in complete endothelial cell
media (ECM) supplemented with 5% fetal bovine serum (FBS), penicillin/streptomycin,
and growth supplements (ECGS), from Science Cell. Human telomerase-immortalized
dermal microvascular endothelial cells (TIME) were obtained from American Type
Culture Collection (ATCC, Mannassas, VA) at passage 25 and cultured in complete
endothelial growth medium, EGM-2MV, from Clonetics-Lonza (Walkersville, MD)
supplemented with 5% FBS, EGF, VEGF, hFGF-B, R3-IGF-1, ascorbic acid,
hydrocortisone and blasticin S HCl. Human umbilical vein/vascular endothelium cells
(HUVEC) were obtained from ATCC at passage 14 and cultured in complete ECM media
used for HDLEC and supplemented with 0.1mg/ml heparin and 10% FBS. Confirmation
of lymphatic and blood endothelial cell lineage was performed using flow cytometry
analysis using anti-human podoplanin and CD31-fluorophore conjugated antibodies
(eBioscience) and FACS data analyzed using FlowJo software (Treestar).

Whole mount staining: Ears were fixed in 4% paraformaldehyde (PFA) overnight at
4°C. Cartilage was removed under a dissecting microscope and tissues washed with
0.3% TritonX-PBS at least 10 times over 4 hours. Samples were blocked with 0.2%
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BSA, 5% goat serum in 0.3% TritonX-PBS for 2 hours at room temperature before
staining with rabbit-anti mouse LYVE1 antibody (1:100; Angiobio); rat anti-mouse
PECAM (CD31; 1:100 Thermo Fisher) at 4°C overnight with shaking. Tissues were
washed for at least 6 hours with 0.3% TritonX-PBS before being incubated at 4°C
overnight with secondary antibody (Alexa-Flour 488nm; goat anti-rabbit; Alexa-Fluor
goat anti-rat; 1:500 in 0.3% TritonX-PBS) with shaking.

Some tissues were further

stained with allophycocyanin- conjugated F4/80 (1:100; eBiosciences). Tissues were
washed at least 10 times over 6 hours with 0.3% TritonX-PBS before 10 min fixation with
4% PFA. Final wash was performed with PBS 5 times over 30 mins before tissues were
mounted with Vectashield (Vector Labs).

Fluorescent images were analyzed using

EVOS FL microscope (Invitrogen). Lymphatic and blood vessel networks were quantified
using AngioTool software (NCI) [178] and F4/80 cell count of x40 images was performed
by CellProfiler cell image analysis software (Broad Institute) [237, 238].

RNAi transfections. Double-stranded ON-TARGET Plus human siRNA SHIP2-specific
sequences (#1-UCAAGGAGCUUACGGAUCU; #2-GUCAGUACGUCCAGUGUGA; #3CCAAGAAAGGGCUCUCAAA; #4-GCACACGUAUCGCAUUCUG and SmartPool of
these 4-(Catalog# L-004152-00-005)) and ON-TARGETplus Non-targeting (NT) Control
(D-001810-01-05) were obtained from Dharmacon-Thermo Fisher (Lafayette, CO).
Transfection was performed using Lipofectin reagent (Invitrogen) according to
manufacturer’s instructions at a final concentration of 100nM siRNA. To confirm
transfection efficiency, Alexa Block-iT oligonucleotide (Invitrogen) was used. Mock
transfection consisted of lipofectin reagent and Alexa Block iT oligonucleuotide only.
Gene expression transcript and protein levels were determined using standard RT-qPCR
and immunoblotting techniques.
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Site-directed mutagenesis. Human INPPL1 TrueORFTM cDNA Myc-DDK clone was
obtained from OriGene. SHIP2 T180A and L632I mutants in pCMV6-Entry-AC-MycDDK
were made using QuickChange® site-directed mutagenesis kit (Stratagene). Single
nucleotides were changed at 71617801 of AG (forward sequence) and TC (reverse)
resulting in T180A and at 71621609 of CA (forward) and GT (reverse), resulting in
L632I. Mutant plasmids were Sanger-sequenced to confirm the introduction of point
mutations before transfection into TIME cells. Stably transfected cells were selected for
neomycin resistance by 400μg/ml Geneticin (G418)

MTS Cell Proliferation Assay. 5x103 cells/well were plated in 96-well plates and
allowed to adhere overnight. For stimulation experiments, cells were starved 4 hours in
1% FBS, before growth factors were added. Cell proliferation was evaluated using
tetrazolium salt colormetric assay (MTS) using CellTiter 96 AQeous One Solution
(Promega) according to manufacturer’s instructions at 24, 48 hr and 72 hrs post plating.

Cell Adhesion Assay. 96-wells plates were coated with 1% BSA, 10μg/cm2 collagen or
10μg/ml bovine plasma fibronectin (Sigma) diluted in calcium/magnesium-free PBS
overnight. Excess collagen and fibronectin was aspirated and all wells were blocked with
1% BSA for 2 hours, and then rinsed with PBS. 2x104 cells/well were plated and allowed
to adhere for 2 hours. Plates were washed 5 times with PBS to remove unattached cells,
and adhered cells were then fixed using 4% paraformaldehyde, followed by
permeabilization with 1% (w/v) Triton-X in PBS. Adhered cells were stained with 0.1%
crystal violet in 2% ethanol and images acquired at 40x magnification.
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Wound-Healing Cell Migration Assay. Cells were plated in either 6-well plates or
rectangular culture plates and when approximately 80-90% confluent and then
perpendicular scratches created using either sterile P1000 pipette tips or cell combs
(Millipore). Cells were rinsed with PBS, and incubated over 48hrs, during which they
were imaged using a Leica DM microscope (Leica Microsystems,) to assess the
migration in closing the wound. Some cells were stained with 1µM CellTracker Green
Fluorescent Probe (Lonza) prior to wounding, and fluorescent microscope images taken
using the GFP filter. Wound area was calculated using ImageJ software (NIH) as
percentage of 0hr coverage at wounding site.

Tubulogenesis Assay. Matrigel matrix (Becton-Dickson) was liquefied overnight on ice
at 4°C. 50μl of the matrix was aliquoted in 96-well plates and incubated at 37°C for 3060 min prior to plating 5x104 cells per well. Cells were cultured for 24hrs and tube
formation monitored by inspection by phase contrast microscopy (Leica Microsystems).
At the end of the 24hr incubation, cells were labeled with 1μM Calcein AM (Trevigen)
and cell viability assessed using a fluorescent inverted microscope with a 485nm
excitation filter. For PI3K inhibition experiments, cells were treated for 2 hours with 50µm
LY294002 before seeding into Matrigel.

Annexin V Apoptosis Assay. Cells were plated in 6-well dishes, subjected to siRNA
transfection for 48hours then serum-starved overnight. Cells were treated with 1µM
staurosporine (Cell Signal) for 3 hours. Cells were harvested, washed in cold PBS,
counted and apoptosis quantified using Alexa Fluor 488 Annexin V/Propidium Iodide
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dead cell kit (Invitrogen) following manufacturer’s instructions. Cells were analyzed by
flow cytometry BD FACS Aria II using FITC and Texas Red filters and 50,000 events
used for each sample. Data was analyzed using FlowJo Software (Treestar) and data
presented as total AnnexinV positive % (sum of AnnexinV population representative of
early apoptotic cells and double positive PI+AnnxV representing late apoptotic cells).
Fluorescence mean intensity of FITC (Annexin V) and phycoerythrin (PE) or PE-Texas
Red (propidium iodide) is also presented.

Proximity Ligation Assay (PLA) and Immunofluorescence. Carefully following
Duolink II instructions, cells were plated in chamber slides, allowed to adhere overnight,
starved for 4 hours and stimulated with appropriate growth factors. Cells were then fixed
using 4% paraformaldehyde (VWR) followed by permeabalization with 1% (w/v) Triton-X
in PBS. Anti-DDK mouse monoclonal antibody (Origene) was combined with either
rabbit polyclonals cMET or VEGFR3 (C28 and C20, SCBT). Following PLA, cells were
counterstained with DAPI and Alexa-Flour Phalloidin. Fluorescence spots were
quantified using ImageJ software (NIH). For immunofluorescence, cells were serumstarved, stimulated, fixed and permeabilized as described above. Immunofluorescence
cytochemistry was done using rabbit anti-SHIP2 antibody (Cell Signal) for determining
expression of SHIP2 in LEC and anti-PIP3 IgG antibody (Echelon Biosciences) to
determine cellular levels of PtdIns(3,4,5)P3. For cytoskeletal reorganization experiments,
cells were starved overnight in 1%FBS media, harvested and plated onto 10µg/cm2
collagen–coated chamber slide for lamellipodia assay for 1 hour prior to stimulation with
VEGFC and stained with Alexa-488 phalloidin. Cells were counterstained with either
Alexa Flour 488 or 594 phalloidin (Invitrogen) to show actin localization and either
DRAQ5 (Biostatus) or DAPI (Invitrogen) to show cell nucleus. Cells were visualized
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using either confocal laser microscope (Leica), epifluorescence inverted microscope
(Leica) or EVOS FL microscope (Invitrogen).

Malachite Green Phosphatase Assay. Cells were serum-starved overnight then lysed
using a nondenaturing buffer (10mM sodium phosphate pH 7.5, 150 mM NaCl, 1 mM
PMSF and 1X Halt Protease and Phosphatase inhibitors cocktail). FLAG antibody was
preabsorbed overnight with Protein A/G sepharose beads (SantaCruz Biotechnology)
and immunocomplexed with precleared 500μg lysates. Immunocomplexes were washed
and FLAG-tagged protein eluted from agarose beads using 2M glycine buffer, pH 2.8,
and protein concentration quantified using BCA assay (Pierce). Eluted SHIP2 (0.05µg)
was combined with 120µM recombinant PI(3,4,5)P3 substrate (P-3908, Echelon
Biosciences) at final concentrations of 0.025µg and 60µM, respectively and catalysis
allowed to occur at 37°C for 30 mins. Reactions were stopped using BIOMOL GREEN
(AK-111, Enzo Biosciences), incubated at room temperature for 15mins while shaking,
and absorbance read at 620 nm. Phosphate standard curve was performed to estimate
the concentration of released phosphate in the experimental samples. 0.05µg
recombinant SHIP2 (Echelon Biosciences) was used as positive control and 120µM
recombinant PIP3 was used as negative control (substrate only, no enzyme).

Immunoblotting, Immunoprecipitation and PIP3 delivery. Cells were grown to
desired confluency and lysed in buffer (20mM Tris pH 9, 137mM NaCl, 5mM EDTA and
0.5% (w/v) SDS containing 1mM phenylmethylsulfonyl fluoride (PMSF) and 1X Halt
Protease and Phosphatase inhibitors cocktail (Thermo Fisher). Protein concentration
was measured using BCA assay kit (Pierce). 50μg total protein was loaded in 4-20%
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TGX SDS-PAGE gels (BioRad), and Western blots probed with appropriate primary
antibodies (goat polyclonal SHIP2 (I-20, SCBT); rabbit antibodies against SHIP2,
DYKDDDDK, pAKT-S473, pAKT-T308, pP44/P42, AKT, P44/P42, COX IV, β-actin and
GAPDH from Cell Signal) . For signaling studies, after 48hr siRNA transfections, cells
were serum-starved for 4hrs and stimulated with 30ng/ml rmHGF or 100 ng/ml rhVEGFC
(R&D Systems) in 1% FBS prior to lysis and immunoblotting. For inhibitor studies, cells
were pretreated with 10μm U0126 for 1 hour or 50μm LY294002 for 2 hours prior to
growth factor stimulations. For AS1949490 SHIP2 inhibitor studies, cells were serumstarved overnight then treated with increasing doses of AS1949490 in starvation media
for 1 hour prior to growth factor stimulations. For immunoprecipitations, cells were serum
starved overnight and stimulated with indicated growth factors and lysed with IP lysis
buffer (25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol
containing 1mM PMSF) followed by centrifugation to remove debris. 1µg IP antibody
was pre-adsorbed with 20µl Protein A/G PLUS agarose beads (Santa Cruz) overnight
and washed with PBS and blocked with 10% BSA. 500µg total lysates were complexed
with pre-adbsorbed antibody-beads for 4 hours at 4°C and immunocomplexes washed
with cold PBS before samples were denatured and subjected to electrophoresis and
immunoblotting. For exogenous PIP3 delivery, cells were treated for 1 hour with
increasing concentrations of recombinant PtdIns(3,4,5)P3 using Shuttle PIP kit (Echelon
Biosciences) following manufacturer’s instructions before proceeding with standard
immunoblotting techniques. All blots were followed by IRDye-labeled secondary
antibodies (LICOR), and blots were viewed using Odyssey Classic fluorescence viewer
(LICOR).
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Boyden Chamber Chemotaxis Assay. Boyden chamber assay was performed using
ThinCerts (3µm pores, Grenier BioOne) precoated with 1ug/ml fibronectin before use.
Cells were starved overnight before seeding into upper chambers (2x105/well) in 1%
FBS and stimulant media added to the bottom wells. Chemotaxis was assessed after
staining with DRAQ5 by measuring fluorescence of cells migrated to the lower chamber
using EVOS FL microscope using filters set at 618/40nm excitation and 692/40nm
emission. Number of migrated cells was quantified using ImageJ (NIH).

Flow cytometry analysis. Single cell suspensions were prepared from axillary lymph
nodes by passing through 70µm nylon cell strainers (BD Falcon) with syringe plungers.
Cells were counted and labeled with fluorophore-conjugated mouse monoclonal
antibodies anti-CD45, anti-CD4, anti-F4/80 (eBioscience), anti-CD8a, anti-CD19, antiCD11c, anti-CD11b, and anti-Gr1/CD38 (BD Biosciences). 300,000 to 500,000 events
were collected and analyzed using BD FACs Aria II (BD Falcon) and data analysis
performed using FlowJo vX.0.7.

Multiplex cytokine profiling. Animals were bled and following room temperature
incubation of the blood, serum was collected. Skin samples were obtained from
euthanized mice and subjected to homogenization using denaturing lysis buffer with
protease and phosphatase inhibitors, centrifuged at 12,000RPM for 30 minutes at 4°C to
remove debris, and supernatants collected and stored at -20°C until analysis. Serum
was diluted 2-fold, and 250ug total protein from skin supernatants was diluted in blocking
buffer and incubated with mouse cytokine 4 target array (Quansys). Subsequent
incubations were performed following manufacturer’s instructions. Fluorescence
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detection was performed using IRDye800-Streptavidin and plates scanned using
Odyssey 262 infrared imaging system (Licor). Fluorescence signal intensities were
quantified using Quansys software, and spots in each blot normalized to positive control
spots followed by comparison of analytes between the treatment groups.

Flexible motion simulations. Elastic network normal mode analysis was carried out
using Elnemo on a one-site-per-residue model of the SHIP2 structure, placing springs
between all sites lying within 12 Angstroms of each other, generating low-frequency
normal mode eigenvectors for modes 7 to 16, the ten lowest-frequency nontrivial
motions. Flexible motion of the all-atom SHIP2 structure along each mode direction was
then explored using template-based geometric simulation with FIRST/FRODA. Key
settings were: a directed step size of 0.01 Angstroms and a hydrogen bond inclusion
energy cutoff of -2 kcal/mol. 1000 frames of motion for each direction were generated
with every 100th frame saved for inspection.

Statistical analysis. Student t-test and one way ANOVA were used to evaluate the
data. Data are expressed as means ± SEM. All in vitro experiments independently
repeated at least 3 times. P values of <0.05 were considered statistically significant.
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APPENDIX
PROJECT SUMMARIES OF SECONDARY PRECLINICAL NIRFLI STUDIES
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Systemically impaired lymphatic function in mice with dextran-sulfate sodiuminduced acute colitis
Agollah G.D., Wu, G., Sevick-Muraca, E.M., Kwon, S., (manuscript under review;
December 2014)

Background and Aim: Recent data suggests that the lymphatic system plays an
important role in the pathogenesis of inflammatory bowel disease (IBD) and extraintestinal manifestations. However, it is unknown if, and how local inflammation in the
gut systemically affects the lymphatics. The aim of our study was to investigate whether
lymphatic function and architecture are systemically altered in dextran sulfate sodium
(DSS)-induced acute colitis.
Methods: Mice were fed 4% DSS in the drinking water for 7 days and monitored
to assess disease activity. Mice were also treated with both DSS and a NOS inhibitor,
NG-nitro-l-arginine methyl ester (L-NAME).

Mesenteric lymphatic vessels were

visualized after oral gavage of a fluorescently-labelled fatty acid analogue.

Dermal

lymphatic contractile function and vessel remodeling were longitudinally characterized
using dynamic near-infrared fluorescence (NIRF) imaging following intradermal injection
of indocyanine green (ICG) prior to, 4, and 7 days after DSS treatment. In addition,
dendritic cell (DC) migration, lymph node (LN) architecture and cytokine expression in
the skin were assessed.
Results: NIRF imaging data demonstrated dilated lymphatic vessels and
reduced lymphatic contractility in the skin of mice with DSS-induced acute colitis. DSScolitis mice with L-NAME treatment showed partial but not complete improvement of
systemic lymphatic pump activity. Additionally, peripheral LNs of mice exposed to DSS
showed altered architecture, and DC migration.
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Conclusions: The lymphatics are locally and systemically altered in acute colitis,
and functional NIRF imaging is useful for noninvasively monitoring of systemic lymphatic
changes during inflammation.

206

“In vivo lymphatic imaging of a human inflammatory breast cancer model”
Agollah G.D., Wu, G., Sevick-Muraca, E.M., Kwon, S., (J Cancer 2014; 5(9):774-783.
doi:10.7150/jca.9835) [217]

Background: Inflammatory breast cancer (IBC) remains the most aggressive
type of breast cancer with the greatest potential for metastasis and as a result, the
highest mortality rate. IBC cells invade and metastasize through dermal lymphatic
vessels; however, it is unknown how lymphatic drainage patterns change during IBC
growth and metastasis. Herein, we non-invasively and longitudinally imaged lymphatics
in an animal model of IBC using near-infrared fluorescence (NIRF) imaging.
Materials and methods: Mice were imaged in vivo prior to, and up to 11 weeks
after subcutaneous or orthotopic inoculation of human IBC SUM149 cells, which were
stably transfected with infrared fluorescence protein (iRFP) gene reporter (SUM149iRFP), following intradermal (i.d.) injection of indocyanine green (ICG).
Results: Fluorescence images showed well-defined lymphatic vessels prior to
SUM149-iRFP inoculation.

However, altered lymphatic drainage patterns including

rerouting of lymphatic drainage were detected in mice with SUM149-iRFP, due to
lymphatic obstruction of normal lymphatic drainages caused by tumor growth.

In

addition, we observed tortuous lymphatic vessels and extravasation of ICG-laden lymph
in mice with SUM149-iRFP.

We also observed increased and dilated fluorescent

lymphatic vessels in the tumor periphery, which was confirmed by ex vivo
immunohistochemical staining of lymphatic vessels.
Conclusions: Our pre-clinical studies demonstrate that non-invasive NIRF
imaging can provide a method to assess changes in lymphatic drainage patterns during
IBC growth and metastasis.
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“Spatio-temporal changes of lymphatic contractility and drainage patterns
following lymphadenectomy in mice”
Kwon, S., Agollah G.D., Wu, G., Chan, W., Sevick-Muraca, E.M., (PLoS ONE 9(8):
e106034.doi:10.1371/journal.pone.0106034 (2014)) [239]

Objective: To investigate the redirection of

lymphatic

drainage post-

lymphadenectomy using non-invasive near-infrared fluorescence (NIRF) imaging, and to
subsequently assess impact on metastasis.
Background: Cancer-acquired lymphedema arises from dysfunctional fluid
transport after lymph node dissection (lymphadenectomy) performed for staging and to
disrupt drainage pathways for regional control of disease. However, little is known about
the normal regenerative processes of the lymphatics in response to lymphadenectomy
and how this response can be accelerated, delayed, or can impact metastasis.
Methods: Changes in lymphatic “pumping” function and drainage patterns were
non-invasively and longitudinally imaged using NIRF lymphatic imaging after popliteal
lymphadenectomy in mice. In a cohort of mice, B16F10 melanoma was inoculated on
the dorsal aspect of the paw 27 days after lymphadenectomy to assess how drainage
patterns impact metastasis.
Results: NIRF imaging demonstrates that, although lymphatic function and
drainage patterns change significantly in early response to popliteal lymph node (PLN)
removal in mice, these changes are transient and regress dramatically due to a high
regenerative capacity of the lymphatics and the co-opting of collateral pathways around
the site of obstruction. Metastases followed the pattern of collateral pathways and could
be detected proximal to the site of lymphadenectomy.
Conclusions: Both lymphatic vessel regeneration and co-opting of contralateral
vessels occur following lymphadenectomy, with contractile function restored within 13
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days, providing a basis for preclinical and clinical investigations to hasten lymphatic
repair and restore contractile lymphatic function after surgery to prevent cancer-acquired
lymphedema.

Patterns of cancer metastasis after lymphadenectomy were altered,

consistent with patterns of re-directed lymphatic drainage.
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“Response to adeno-associated virus VEGF-C therapy in the Chy mouse, a model
of human Nonne-Milroy disease, assessed by near-infrared fluorescence imaging”
Davies-Venn, C.A, Aldrich M.B., Kwon, S., Agollah G.D., Gonzalez-Garay M.L,
Rasmussen JC., Robinson, H., Alitalo K, Sevick-Muraca, E.M. (manuscript under review;
December 2014)
Abstract
Currently, there is no cure for lymphedema, a chronic, debilitating disorder of the
lymphatics that can result from mutations in genes for molecular factors crucial to
lymphangiogenesis, the process of new vessel growth. Emerging therapies that can
provide missing lymphangiogenic factors, such as vascular endothelial growth factor C
(VEGFC), via adeno-associated viral delivery, promise correction of deficient lymph
removal. In this study, we track lymphangiogenesis in response to adeno-associated
virus-expressed VEGFC (vascular endothelial growth factor C) and soluble VEGFC
therapy in a mouse model of lymphatic insufficiency, the Chy mouse, deficient in
VEGFR3, a VEGFC receptor, using near-infrared fluorescence lymphatic imaging
(NIRFLI). We also present lymphatic imaging of corresponding mutations in humans
with VEGFR3 mutations that result in the limb and truncal swelling, cellulitis, and other
symptoms of lymphedema. In the mouse experiments, lymphatic vessel growth was
evident in ears, but not inguinal areas, of approximately half of the AAV-VEGFC- treated
mice. Variation in responses may have occurred due to variable penetrance of the
Flt4/Vegfr3 (Fms-related tyrosine kinase 4/vascular endothelial growth factor receptor 3)
mutation in the Chy mouse model or genetic variations in the background strain.
Despite the nonuniformity of responses in this mouse model, NIRFLI promises
noninvasive, temporal monitoring of lymphangiogenic therapy in mice and potentially in
humans.
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“Direct Visualization of Changes of Lymphatic Function and Drainage Pathways in
Lymph Node Metastasis of B16F10 Melanoma Using Near-infrared Fluorescence
Imaging”
Kwon, S., Agollah G.D., Wu, G., Chan, W., Sevick-Muraca, E.M., (Biomedical Optics
Express, Vol. 4, Issue 6, pp. 967-977 (2013)) [91]
Abstract
The lymphatic system provides an initial route for cancer cell dissemination in
many cancers including melanoma. However, it is largely unknown how the lymphatic
system changes during tumor progression due in part to the lack of imaging techniques
currently available. In this study, we non-invasively imaged changes of lymphatic
function and drainage patterns using near-infrared fluorescence (NIRF) imaging.
Dynamic NIRF imaging following intradermal injection of indocyanine green (ICG) was
conducted in C57BL/6 mice prior to inoculation of B16F10 murine melanoma cells to the
dorsal aspect of the left hindpaw for baseline data or directly to the popliteal lymph node
(PLN) and until 21 days postimplantation (p.i.). A series of acquired fluorescent images
were quantified to measure lymphatic contractile function. Computed tomography (CT)
was also performed to measure the volume of tumor-draining lymph nodes (LNs). We
observed significant reduction of lymphatic contractility from 7 days p.i. until 21 days p.i.
Altered lymphatic drainage patterns were also detected at 21 days p.i. in mice with tumor
in the paw and at 11 days p.i. in mice with tumor in the PLN, due to lymphatic
obstruction of normal lymphatic drainages caused by extensive tumor invasion of
draining LNs. Since lymphatic function and architecture were progressively altered
during tumor growth and metastasis, non-invasive NIRF imaging may provide a new
method to stage disease. In addition, this novel technique can be used as a diagnostic
method to non-invasively assess lymphatic response as mechanism of therapeutic
action.
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“Altered Lymphatic Function and Architecture in Salt-Induced Hypertension
Assessed by Near-Infrared Fluorescence Imaging”
Kwon, S., Agollah, G.D., Chan, W., Sevick-Muraca, E.M., J Biomed Opt. 2012
Aug;17(8):080504-1[90]
Abstract
The lymphatic system plays an important role in maintaining the fluid
homeostasis between the blood vascular and interstitial tissue compartment and there is
recent evidence that its transport capabilities may regulate blood pressure in saltinduced hypertension. Yet, there is little known how the lymphatic contractile function
and architecture responds to dietary salt-intake. Thus, we longitudinally characterized
lymphatic contractile function and vessel remodeling non-invasively using dynamic nearinfrared fluorescence (NIRF) imaging in animal models of salt-induced hypertension.
The lymphatics of mice and rats were imaged following intradermal (i.d.) injection of
indocyanine green (ICG) to the ear tip or the base of the tail before and during two
weeks of either a high salt diet (HSD) or normal chow. Our non-invasive imaging data
demonstrated dilated lymphatic vessels in the skin of mice and rats on a HSD as
compared to their baseline levels. In addition, our dynamic imaging results showed
increased lymphatic contraction frequency in HSD-fed mice and rats.

Lymphatic

contractile function and vessel remodeling occurs in response to salt-induced
hypertension suggesting a possible role for the lymphatics in the regulation of vascular
blood pressure.
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